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Preface 
This dissertation concludes my industrial PhD-project carried out at the Department of 
Chemistry, Physical and Biophysical Chemistry, Technical University of Denmark and 
Haemophilia Biochemistry, Novo Nordisk A/S under the supervision of associate professor 
Günther H. Peters, PhD (DTU) and principal scientist Ole H. Olsen, PhD (Novo Nordisk 
A/S) as an external advisor. The bulk of the presented dissertation is centered at studying 
the two central factor Xase (tenase) complexes of the blood coagulation cascade using 
computational biophysics and, in particular, the molecular dynamics (MD) method.  
 
At the very core of the performed studies lies an attempt to understand function on the 
basis of structure. I.e. if we know the structure of a complex, can we elucidate its 
functional characteristics? The blunt and conservative answer to this question that has 
arisen over time is: sometimes. The reason for this is that many functional properties are in 
many cases a manifestation of dynamical behaviour and, hence, only poorly represented 
static structures. Enter MD. While there are many technical caveats and inherent 
limitations of present implementations of MD, the in silico method has proven itself a 
valuable tool over the last > ~30 years, in particular when used in conjugation with other 
complementary techniques (often wet-lab experimental ones). 
 
The research have been performed primarily at Novo Nordisk A/S and using the affiliated 
supercomputer named “Davinci” to execute the MD simulations. Though, during my stay 
in the spring of 2013 as a visiting scientist with the Tajkhorshid group at the Beckman 
Institute, University of Illinois at Urbana-Champaign, I also exploited local resources for 
our joint study of the membrane-interaction of factor VIIIa. 
 
The dissertation is structured as follows. Starting with a general introduction of the 
biochemical components (Chapter 1) and the applied methodologies (Chapter 2), the major 
parts of this thesis consist of manuscripts of scientific papers (Chapters 3 & 4 contain 
manuscripts (ms.) 1-5, of which ms.2, ms.3, and ms.4 have been submitted and are under 
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peer review) that are rounded-off and complete entities in themselves. Concluding remarks 
are provided in Chapter 5. 
 
Kgs. Lyngby, August 2014 
 
Jesper Jonasson Madsen, M.Sc.Eng. 
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  Structural and functional characterization of protein complexes in the blood coagulation cascade 
Summary 
In this dissertation, components of coagulation factor (F)X-activating (tenase; fXase) 
complexes are studied using computational biophysics and the molecular dynamics (MD) 
method. The main focus is on structure-function relationships of the two central tenase 
complexes with respect to activation processes, complex formation, and platelet membrane 
association.  
 
Both the intrinsic and the extrinsic tenase complex consists of a trypsin-like serine protease 
and auxiliary domains complexed with the appropriate cofactor; FIXa with FVIIIa and 
FVIIa with tissue factor (TF), respectively. 
 
Topics covered will include the structural and dynamical changes upon proteolytic 
activation and TF-induced allosteric activation of FVIIa. In addition, FVIIa variants with 
the 170-loop grafted from trypsin will be looked into and, in particular, the mechanisms 
that enable these variants to have increased activity without TF are explained. Furthermore, 
the inter-domain linker connecting the two epidermal growth factor-like domains of FVIIa 
will be discussed with respect to consequences for its ability to form a productive complex 
with tissue factor. Finally, membrane binding of FVIIIa as mediated by the tandem C2-like 
domains is described using a highly mobile membrane-mimetic model. 
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Dansk resumé 
Denne afhandling omhandler anvendelse af beregningsmæssige biofysiske metoder, 
specielt molekyldynamik, til karakterisering af koagulationsfaktor (F)X-aktiverende 
(FXase; tenase) protein komplekser. Primær fokus vil være på struktur-funktion relationen, 
der gælder for de to centrale tenase-komplekser i forhold til aktiveringsprocesser, 
kompleksdannelse, og interaktionen med blodplademembraner. 
 
Både det intrinsiske og det extrinsiske tenase kompleks består af en trypsin-lignende 
serinprotease med tilhørende domæner, som kræver en passende cofaktor; FIXa med 
FVIIIa og FVIIa med vævsfaktor (TF), respektivt. 
 
Emner, der vil blive berørt i denne afhandling, inkluderer de strukturelle og dynamiske 
ændringer efter proteolytisk aktivering of TF-induceret allosterisk aktivering af FVIIa. 
Derudover kigges der nærmere på FVIIa-varianter hvor 170-løkken fra trypsin er integreret 
og, i særdeleshed, de mekanismer, som giver disse varianter øget aktivitet uden TF. 
Desuden vil interdomæne-linkeren, som forbinder de to epidermal vækstfaktor (EGF)-
lignende domæner i FVIIa blive diskuteret i forbindelse med konsekvenser for dens 
medbestemmende rolle i at tillade en produktiv interaktion med TF. Slutteligt kigger vi 
nærmere på membran-interaktionen af FVIIIa, som er medieret af de to tandem C2-
lignende domæner, ved brug af en mobil membran-mimetisk model.  
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1. General introduction 
1.1 Haemostasis and haemophilia 
In this chapter, we shall introduce the biomolecular components and mechanisms of 
relevance to this dissertation into a broader biological context.  
 
In the blood circulates the molecular apparatus to repair traumatic injury and stop 
bleedings (up until a certain point). Haemostasis is the name for the complex network of 
inter-connected biochemical reactions which occur upon vessel injury and, when 
functioning properly, stop the bleeding. The haemostatic system has many components and 
an exhaustive review of the involved molecular biology is out of scope for the present text. 
An impressively thorough overview of principles in haemostasis and thrombosis can be 
found in the book by Marder et al.(Marder, Aird, Bennett, Schulman, & White, 2012)  
 
For our purpose, however, a relatively brief and idea-driven introductory description of 
haemostasis is going to suffice. The two principal processes of haemostasis are:  
 
1. The adherence of thrombocytes (platelets) to sub-endothelial collagen. 
 
2. Stabilization of the thrombocyte matrix by a dense cross-linked network of fibrin. 
 
The first step involves the glycoprotein-complex receptor GPIb-V-IX, which binds von 
Willebrand Factor (vWF), thereby allowing the platelet adhesion and plug formation at the 
spot where the blood vessel has been injured. The following step stabilizes the 
thrombocyte plug by a highly dense and cross-linked fibrin network. The biochemical 
reactions governing this second step is collectively designated the blood coagulation 
cascade and they involve many biomolecular components (coagulation factors), who 
interact promptly in a complicated yet highly regulated manner (Fig. 1). (MacFarlane, 
1964)(Davie & Ratnoff, 1964) Two pathways, the extravascular (extrinsic) and the 
intravascular (intrinsic) both lead to the activation of the zymogen factor X (FX), which, in 
turn, combines with its enzyme cofactor, factor Va, to form the prothrombinase complex 
responsible for the rapid generation of thrombin. Thrombin is a key player in haemostasis 
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because it is the only one of the haemostatic proteases that is able to covert fibrinogen into 
fibrin, which polymerizes in the presence of FXIIIa to make the clot.  
 
 
 
Figure 1 Schematic depiction of the coagulation cascade reactions leading to fibrin clot formation. 
The membrane is shown with sticks and half-transparent surface (pink). Haemostatic serine proteases 
((pro)thrombin, FVII(a), FIX(a), FX(a), FXI(a), FXII(a)) are indicated by blue boxes and protease protein 
cofactors (TF, FV(a), FVIII(a)) by green boxes. FVIII(a), a transglutaminase, is shown in red. Explicitly 
labelled are the two tenase complexes (TF:FVIIa, the extrinsic tenase complex; FVIIIa:FIXa, the intrinsic 
tenase complex) and the prothrombinase complex (FXa:FVa).(Reconstructed from Fig. 7.1 of (Engelke, 
2010)) 
 
Tissue Factor(TF)-triggered coagulation is initiated by the extrinsic tenase complex 
TF:FVIIa in the presence of Ca
2+
 and phospholipids. The intrinsic pathway involves the 
activated FVIII and FIX, which make up the membrane-bound intrinsic tenase complex 
that is potently capable of activating FX. Complex formation of the tenase complexes on 
the membrane surface provides a mechanism to localize the clotting of blood to the injury 
site. 
 
Fig. 1 is deliberately kept simple and while reality in vivo is considerably more 
complicated, the most important reactions of the coagulation cascade are well represented 
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by the schematic. What is not elaborately shown in Fig. 1, however, is detailed co-factor 
dependence of each individual chemical reaction and in which ways coagulation is 
successively stopped. The latter is achieved mainly through the activated protein C (APC) 
anti-coagulation pathway, where the activation of PC depends on thrombomodulin and 
protein S, but also by the serine protease inhibitors (Serpins) tissue factor pathway 
inhibitor (TFPI) and anti-thrombin (AT). APC inactivates FVa and FVIIIa by proteolytic 
cleavage whereas TFPI inhibits FVIIa and FXa, and AT inhibits FXa and thrombin. A 
recent review of the protein C biology is found in (Mosnier, Zlokovic, & Griffin, 2007). 
 
Individuals suffering from haemophilia A (B) are deficient in FVIII (FIX) and are, as a 
consequence, not able to activate enough FX to get proper amplification of the coagulation 
signal, negatively affecting the bloods ability to clot when needed. Roughly 400,000 males 
around the world suffer from haemophilia of which only ~25 % are currently receiving 
treatment according to (“World Federation of Hemophilia,” 2014). Disease symptoms vary 
and include prolonged bleedings, joint bleedings, muscle and sub-cutaneous bleedings, 
internal bleedings, and intra-cranial bleedings. The typical treatment for haemophiliacs 
involves replacement therapy where the missing coagulation factor is provided. E.g. dosing 
with a recombinant (r)FVIIa, such as NovoSeven®, can provide haemostasis in patients 
with severe haemophilia A or B, offering a safe treatment without significant side-effects 
in most patient cases. 
 
The coupling between structure and function is necessary for basic understanding at the 
molecular level of theory. Furthermore, such insights can lead to the development of 
therapeutic pro- and anti-coagulant treatments to benefit for patients with haemophilic and 
thrombotic disease, respectively.  
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1.2 Molecular structures and mechanisms in coagulation 
1.2.1 Serine proteases and cofactors 
 
Figure 2 Graphical abstract for manuscripts 1-3 regarding the extrinsic tenase complex. 
(A) Crystal structure of the FVII zymogen structure (ms.1). FVII is shown as surface (blue) and TF in wire 
representation (green). The bound Ca
2+
 ions are shown as spheres (purple). (B) The structure of the 
TF:FVIIa tenase complex (PDB entry code 1dan(Banner et al., 1996)) with the TF-binding helix (ms.2) and 
the EGF1-EGF2 inter-domain linker highlighted (ms.3). FVIIa light chain (blue), FVIIa heavy chain (gray) 
is shown as surface and TF in wire representation (green). The bound Ca
2+
 ions are shown as spheres 
(purple). (C) The structure of the TF:FVIIa tenase complex (PDB entry code 1dan(Banner et al., 1996)) 
shown in wire representation including domain nomenclature for FVIIa. 
 
The precursor FVII (Fig. 2A) is produced as a single chain polypeptide molecule(Broze & 
Majerus, 1980). The architecture of FVII is a C-terminally positioned trypsin-like serine 
protease with three auxiliary domains; a vitamin K-dependent membrane-anchoring GLA-
domain, and two epidermal growth factor (EGF)-like domains (Fig. 3). This exact domain 
template is shared among factors VII, IX, X, and protein C.  
 
 
 
Figure 3 Domain architecture of coagulation factors VII, IX, X, and protein C 
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The concept of the C-terminally positioned serine protease is wide-spread with members 
represented begin responsible for maintaining or assisting many physiologically important 
processes including digestion, immune response, blood coagulation, fibrinolysis, and 
reproduction.(Hedstrom, 2002) For instance, other coagulation and fibrinolytic proteins 
with this generalized architecture include FXI, FXII, prothrombin, protein S, plasminogen, 
urokinase plasminogen activator, tissue-type plasminogen activator, and the success of 
such a design suggests a lego-block evolutionary process.(Patthy, 1985) 
 
There is a preferred standard orientation of view for proteases to which we will adhere 
when visualizing molecular structures.(Gomis-Rüth, Botelho, & Bode, 2012) For FVIIa 
(Fig. 4A), this will correspond to aligning the active site cleft horizontally and having the 
non-prime side to the left and prime side to the right. This orientation positions the TF-
binding helix and following 170-loop at the periphery of the SP domain to its left side with 
a top view of said helix (Fig. 4B). 
 
Catalytic competency can be sampled (experimentally) at different levels of complexity 
(Table 1).(Mugherli, Burchak, Chatelain, & Balakirev, 2006)(Butenas, DiLorenzo, & 
Mann, 1997)(Morrissey, 2005) The trend is that for the larger substrates it gets 
increasingly difficult to infer the structural basis of the resulting measured signal. Small 
molecule and peptidic substrates probe the catalytic efficiency of the enzyme locally 
around the active site residues, the oxyanion hole, and the integrity of the S1 pocket, 
whereas the degradation of protein substrates potentially has major contributions from exo-
sites and protein-protein interactions. Clotting assays are the coarsest grained and can be 
complex to interpret or rationalize. In ms.3 and subsequent notes on the 170-loop-swapped 
FVIIa variants, we shall use the amidolytic activity of FVIIa variants to gauge catalytic 
competency with and without TF. 
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Table 1 Protease catalysis assays common for FVIIa and corresponding structural inference 
Substrate Signal Structural inference 
Small molecule substrates, 
e.g. esters 
Colorimetric or 
fluorometric 
Oxyanion hole 
Peptidic substrates 
(amidolytic activity) 
Colorimetric or 
fluorometric 
Oxyanion hole, S1 pocket, 
sub-sites specificity  
Protein substrate 
(proteolytic activity) 
FX activation (indirect) Oxyanion hole, S1 pocket, 
sub-sites specificity, exo-
sites specificity, protein-
protein interactions 
Thrombin assay Thrombin-generation 
(indirect) 
Complex 
Clotting assay Viscosity change Complex 
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Figure 4 The TF:FVIIa tenase complex and protease domain. 
(A) Structure of the TF:FVIIa tenase complex based on PDB entry code 1dan(Banner et al., 1996). TF is 
shown in wire representation (green), the FVIIa light chain domains GLA, EGF1, EGF2 as surface (blue), 
and the FVIIa heavy chain SP domain as surface (gray). Ca
2+
 ions are shown as spheres (purple). (B) The 
FVIIa SP domain in wire representation and standard orientation with certain residues1 explicitly shown as 
sticks (I153, H193, D242, S344, W364). The co-crystallized covalent inhibitor is shown as sticks (cyan). The 
bound Ca
2+
 ion is shown as a sphere (purple). 
 
FVIIa structures. 
A comprehensive list of FVII/FVIIa/TF solved structures is maintained by James H. 
Morrissey.(http://www.tf7.org/) While these are generally well-represented by the by the 
structure of FFR-CMK-inhibited FVIIa (ASIS) with soluble tissue factor (PDB entry code 
1dan, (Banner et al., 1996)) or the truncated EGF2-SP construct of FVIIa inhibited by 
Benzamidine (PDB entry code 1kli(Sichler et al., 2002)), certain structures stand out and 
warrant additional attention (Table 2). In particular, two TF-free structures of FVIIa with a 
visible EGF1 domain exist (PDB entry codes 1qfk(Pike, Brzozowski, Roberts, Olsen, & 
Persson, 1999)and 1dva(Dennis et al., 2000)) (Fig. 5). 
                                                                                                                                                    
1
 Two prevalent numbering schemes for FVII/FVIIa residues exist: Full-length FVII numbering and chymotrypsin-alignment numbering. 
Throughout this dissertation we the former are as standard and without explicit resignation, whereas chymotrypsin-numbering, when 
used, will be followed by ‘c’ in curly brackets, e.g. H193{c57} is the active site histidine-193 {ctr. res. no. 57}.   
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Table 2 Survey of crystal structures of FVIIa with features distinct from the representative PDB entry code 
1dan. 
PDB  Feature Comment Reference 
1qfk Free FVIIa with visible 
EGF1 domain.  
Stabilized by crystal 
contacts. Gla domain 
not visible. 
(Pike et al., 1999) 
1dva Free FVIIa with visible 
EGF1 domain. 
Dimerically ‘curled up’. 
Gla domain not visible. 
(Dennis et al., 2000) 
1klj Uninhibited and free 
FVIIa.  
Truncated construct 
containing EGF2 and 
SP. The co-crystallized 
inhibitor (benzamidine) 
was soaked out.  
(Sichler et al., 2002) 
2f9b Alternative 
W364{c215} 
position/rotamer. 
Bulky heterocyclic 
inhibitor with which 
W364 stacks. 
(Rai et al., 2006) 
2a2q Alternative 
conformation of peptide 
bond Lys192-Gly193 
 (Bajaj, Schmidt, Agah, 
Bajaj, & Padmanabhan, 
2006) 
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Figure 5 Comparison of available structures of free FVIIa with a visible EGF1 domain to the extended 
conformation of FVIIa adopted when complexed with TF.  
Shown in wire-representation are PDB entry codes 1dan(‘H’, heavy chain in gray; ‘L’, light chain in marine 
blue), 1qfk(‘L’, light chain in cyan), 1dva(‘L’, light chain in pink). The three structures have been 
structurally aligned based on their respective SP domains (‘H’, heavy chains). 
 
It is evident that the light chain of free FVIIa is able to co-exist in (at least) several a 
couple of major conformations (Fig. 5). Furthermore, because there is no clashes between 
the light and heavy chain, it seems plausible that the entire span of intermediate 
conformations are equally like to also co-exist in the dynamical ensemble, brining into 
question whether the predominant species of free FVIIa in solution is the extended form 
know from the TF:FVIIa complex. The free FVIIa structures are stabilized by the protein-
protein contacts (1qfk contacts a crystal neighbour and 1dva dimerically ‘curled up’), but 
their mere existence reveals that the observed light chain conformation are not un-physical. 
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FVIIa and sodium. 
There is some evidence that ions besides Ca
2+
 could bind to FVIIa and therefore be 
considered cofactors under certain conditions. In particular, has been proposed that Mg
2+
 
could take the place of three of the seven bound Ca
2+
 ions and, furthermore, that FVIIa 
contains two Zn
2+
 binding sites and a Na
+
 binding site(Bajaj et al., 2006). Na
+
-induced 
allostery is of fundamental importance in for instance thrombin(Gandhi, 2010; Huntington, 
2008) where its stimulating effects and underlying molecular mechanisms of allostery have 
been elucidated(Gandhi, Chen, Mathews, & Di Cera, 2008). However, the crystal 
structures of Bajaj and co-workers were obtained under salt concentrations far above the 
physiological relevant range which, combined with the lack of stimulating effect of Na
+
 in 
FVIIa in the presence of Ca
2+
, brings into question the potential significance of a putative 
role for Na
+
 in FVIIa allostery.  
 
The serine protease hydrolysis mechanism. 
A recent and rather comprehensive review of the serine protease mechanism and 
specificity can be found in (Hedstrom, 2002). 
 
The intermediary structures formed in between enzyme and substrate in the hydrolysis 
mechanism of a serine protease has four principal states: The resting enzyme (Fig. 6), 
(tetrahedral) intermediary I (Fig. 7), the acyl-enzyme complex (Fig. 8), and the 
(tetrahedral) intermediary II (Fig. 9). The enzymatic mechanism proceeds as follows. 
Initially, a nucleophilic attack by the active site serine (195{c}) is performed in the peptide 
carbonyl. The nucleophilic property of said serine is enhanced due to stabilizing 
interactions with the active histidine, which, in turn, is held in a “protein acceptor state” by 
an aspartate (D102{c}).  
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Figure 6 The resting state of the catalytic serine and histidine residues of the serine protease. 
 
The oxygen anion in the tetrahedral intermediary I (and II) is stabilized by hydrogen 
bonding to the NH groups of S195{c} and G193{c} in the enzyme’s so-called oxyanion 
hole (Fig. 10). The next step of catalysis is the reconstruction of the carbonyl double bond 
while releasing the C-terminal peptide leaving group. This is the step at which the peptide 
substrate is cleaved and it results in the acyl-enzyme complex where the N-terminal 
peptide is bound as an ester to S195{c}.  
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Figure 7 The first tetrahedral intermediary structure of the enzymatic mechanism of the serine protease. 
 
The acyl-enzyme complex is hydrolysed in the deacylation reaction and this conversion 
consumes a water molecule to produce the tetrahedral intermediary II, where, as before, the 
oxygen anion is stabilized in the oxyanion hole until the N-terminal peptide is released and 
the enzyme active site is restored to its resting state.  
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Figure 8 The acyl-enzyme complex structure of the enzymatic mechanism of the serine protease. 
 
The organic chemist might wonder if the mentioned tetrahedral intermediates (Figs. 7 & 9) 
indeed are formed or the reaction actually follows the SN2 reaction pattern in a single step, 
which you might expect from alkyl substrates (halides e.g.). Indeed, this topic has been 
controversial in the early years of investigation, however, we now know from molecular 
orbital theory that acyl and alkyl substrates have very different electronic orbital 
constructions. In particular, differences in the lowest unoccupied molecular orbitals 
(LUMOs) of the electrophilic substrates, which accepts nucleophilic attack of the highest 
occupied molecular orbital (HOMO) from S195{c}, satisfactorily explains why the scissile 
peptide bond cannot be broken directly in the enzymatic mechanism. Further structural 
subtleties in the serine protease mechanism has been elucidated recently including a ring-
flip of H57{c}.(Ash et al., 2000) 
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Figure 9 The second tetrahedral intermediary structure of the enzymatic mechanism of the serine protease. 
 
A primary determinant of substrates specificity of serine proteases is the sidechain of the 
residue Rn (using the nomenclature from the above figures; also called position P1) 
because this moiety interacts directly with the enzyme by inserting into a substrate pocket, 
the sub-site S1 (Fig. 10).(Hedstrom, 2002) In FVIIa, that is known to have trypsin-like 
specificity, D189{c} resides in the bottom of the S1 pocket, consistent with its preference 
for R or L at position P1 of the peptide substrate (Fig. 10). By comparison, chymotrypsin 
has a more hydrophobic S1 pocket (incl. S189) and prefers F, Y, or W at position P1. 
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Figure 10 Interaction between FFR-CMK inhibitor and FVIIa in ASIS indicating the position of enzyme sub-
sites S1,S2, and S3, residue positions P1, P2, and P3 of the substrate (non-prime side), as well as the 
oxyanion hole. 
Interaction-figure of inhibitor and enzyme of ASIS (PDB entry code 1dan(Banner et al., 1996)) was 
generated using PoseView(Stierand, Maass, & Rarey, 2006). Residues are numbered according to 
chymotrypsin. 
 
The prothrombinase complex. 
A crucial step in the coagulation cascade reactions is the burst of thrombin produced by the 
prothrombinase complex as noted in the previous section 1.1. The FVa is cofactor to the 
serine protease FXa and on the (endothelial or platelet) membrane surface they assembly 
into the highly potent activator of prothrombin. Prothrombin activation proceeds by 
cleavage at two distinct sites (after R320 and R271) ensuing fibrin clot formation. The 
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prothrombinase complex, while important by itself, is of special interest to the work in this 
dissertation (Fig. 11A; ms.4) due to its homology with the intrinsic tenase complex (Fig. 
11C), whose structure, to this date, has not yet been solved.  
 
 
 
Figure 11 Graphical abstract for manuscripts 4-5 regarding the intrinsic tenase complex. 
(A) Membrane-interaction of FVIIIa discoidin domains (ms.4). (B) Clearance of FVIIIa by LRP1 (ms.5). (C) 
A putative FVIIa:FIXa tenase complex model. 
 
 
Recently, the re-engineered prothrombinase complex made up of proteins from the eastern 
brown snake (pseudonaja textilis) was solved.(Lechtenberg et al., 2013) This is a 
substantial advance toward understanding also the human counterpart and, by homology 
extension, possibly the FVIIIa:FIXa tenase complex. Since this structure will the key 
source in constructing a putative FVIIa:FIXa tenase complex model (Fig. 11C, ms.4), it 
warrants thorough examination.  
 
In the snake venom prothrombinase complex, FXa snuggles in between the A2 and A3 
domains of FVa. Surprisingly, a peptidic segment from FVa extends over the FXa SP 
domain and thereby embracing it. The positioning of FVa and FXa in the complex reveals 
that the FVa and FXa molecules roughly assume the equal relative (to the membrane) 
heights. The predominant role of the A2 the interaction between protease and cofactor 
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
beautifully explains why removal of A2 from FVa by APC leads to dissociation of the 
prothrombinase complex and subsequent cessation of thrombin generation in the negative 
feedback loop (Fig. 1). While the interaction between prothrombin and the prothrombinase 
complex and cleavage of the substrate may not be directly evident, one could speculate on 
the position of prothrombin based on the established fact that prothombin is first cleaved at 
R320 (forming meizothrombin) and subsequently cleaved at R271 to release the mature 
thrombin molecule(Orcutt & Krishnaswamy, 2004), as indeed Lechtenberg, Murray-Rust 
and co-workers have done in their pioneering paper (Fig. 3 of (Lechtenberg et al., 2013)). 
Of further notice for the work presented in this dissertation is the observation that the 
snake venom FVa from the prothrombinase complex (PDB entry code 4bxs) has a 
significantly different relative orientation of FV C1 and FV C2 when compared with other 
(free) FVa structures (e.g. the APC-inactivated bovine FVa, PDB entry code 1sdd(Adams, 
Hockin, Mann, & Everse, 2004)), indicating mobility of the discoidin C2-like domains in 
the cofactor. In the former structure, the two consecutive tryptophan residues positioned in 
the FV C2 spike 1 are translated almost 30 Å in an out-of-plane back-kicking structural 
change relative to their respective positions in the latter structure (Fig. 12). 
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Figure 12 Overlaid FVa molecules with different relative orientations of the tandem discoidin domains.  
Structural alignment of the snake venom prothrombinase complex in wire-representation (FVIa in cyan; FXa 
in green) from PDB entry code 4bxs(Lechtenberg et al., 2013) with the APC-inactivated bovine FVa in wire-
representation (in red) from PDB entry code 1sdd(Adams et al., 2004) in standard orientation, same as Fig. 
11C, (left panel) and a +90 degree rotated view around the z-axis (right panel). Highlited (as sticks) are the 
two adjacent tryptophans residing within the spike 1 of the C2 domains and a bar (length 27.9 Å) indicating 
their translated distance.  
 
FVIII catabolism.  
The clearance of FVIII is known to be mediated by low-density lipoprotein receptor-
related protein (LRP) (Fig. 11B) and glycoproteins, e.g. heparin sulphate proteoglycans 
(HSPGs). It is hypothesized that the initial interaction between the cell membrane and the 
FVIII/vWF complex happens primarily via HSPGs and then, once bound, FVIII can be 
taken up by LRP-mediated endocytosis.(Saenko, Shima, & Sarafanov, 1999) 
 
In the next chapter, we will re-visit fundamental aspects of the molecular dynamics 
methodology. 
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2. Computational biophysics and the molecular 
dynamics method 
The molecular dynamics (MD) method is a powerful technique for generating a dynamical 
ensemble, which with recent year’s advancement in software and hardware capacities 
allows the study of fundamental biological systems and processes at relevant size and time 
scales. Mind you, not all time scales are equally accessible once the level of theory have 
been specified since, obviously, achievable simulation time and degree of detail relate 
inversely for a fixed amount of computational resources.  
 
The time evolution (dynamics) of the modelled system is propagated by solving its 
equation of motion. To the degree that our systems can be well represented by classical 
mechanics, the following equation of motion applies 
 
 ⃗( ⃗  )   
   ⃗
   
   ⃗     
 
where  ⃗ is the net force acting on the particle,  is the mass, and  ⃗ is the acceleration 
vector describing the resulting kinematic motion. This above equation is of course nothing 
other than the familiar Newton’s second law of motion.  
 
The present chapter on MD methodology is not meant to be comprehensive. Instead, the 
interested reader is referred to classical texts such as (McCammon & Harvey, 1988) and 
(Allen & Tildesley, 1989), or modern incarnations hereof(Frenkel & Berend, 
2001)(Rapaport, 2004). 
 
 
2.1 The force field 
Common empirical force fields for simulating biomolecular systems include CHARMM, 
AMBER, OPLS, and GROMOS. These FFs share the same basic structure in that 
contributions of the potential energy function,  , is divided into bonded and non-bonded 
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terms. The former are heuristic descriptions of the potential energy of bonded interactions 
and in CHARMM(MacKerell et al., 1998) they include terms to account for bond 
stretching, angles bending, torsion (or dihedral) rotation, improper (out-of-plane) bending, 
and a Urey-Bradley (UB) component (a cross-term for angle bending using 1,3 non-
bonded interactions). The terms for bonds, angles and dihedrals are intuitive descriptors. 
The purpose of the UB term is to couple atoms which are two covalent bonds apart, and the 
improper term governs planarity of conjugated systems such as aromatic rings. 
Furthermore, a correction term for backbone φ, ψ and side-chain χ(1) and χ(2) dihedral 
angles (CMAP(Best et al., 2012)) is included.  
 
The non-bonded interaction of the FFs are divided into two terms,      and               , 
representing long range dispersion interactions and electrostatic interactions, respectively. 
Of primary relevance to these terms are pairs of atoms not covalently bonded; non-bonded 
terms for these interaction pairs are typically scaled or discarded.  
 
Mathematically, the potential energy function for the CHARMM (with CMAP) all-atom 
MD simulations can therefore be written as 
 
                                                                 
 
where individual terms may be explicitly expressed as 
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The bond-, angle-, UB-, and improper terms are harmonic potentials with force constants   
and equilibrium values for the respective (internal) coordinates denoted by subscript index 
  . The distance between atoms   and   is denoted    , while   and   denote angles defined 
by groups of atoms. The dihedral term is described by a cosine function with phase   and 
number minima  . The van der Waals interaction is approximated by a standard 12-6 
Lennard-Jones potential with well-depth     and collision distance    , which can be 
expressed as     
       
 
 and     √       (Lorentz-Berthelot combination rules). The 
electrostatic interaction is described by a Coulombic potential with partial charges on 
atoms   and   are    and   .    is the vacuum permittivity and    is the relative dielectric 
constant (where the latter is set to unity in all-atom MD simulations because screening 
effects are directly accounted for). The set of parameters { ,    ,    ,  ,  ,   ,    ,  ,  , 
  } are fitted to against experimental thermodynamic properties and quantum mechanical 
calculations. For CHARMM, this fitting is performed in the explicit presence of water to 
optimize the description of aqueous systems (Mulliken procedure; (Mulliken, 1955)).  
 
There are important limitations to this conceptually simple FF description of a physical 
system. Most notable, bonds cannot form or break, meaning that chemical reactions do not 
occur. Furthermore, the partial charges fixed and not reassigned during the simulations, so 
many-body effects such as (electronic) polarization is neglected.  
 
2.2 The numerical integrator 
The time step in the numerical integrator must be chosen to optimize efficiency while 
maintaining precision. On the formal side of the matter, the sampling theorem by Nyquist-
Shannon(Shannon, 1998) tells us that if the highest frequency motion in the simulation is 
W, we should choose a time step of maximally W/2 to adequately sample the motions. 
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Therefore, since our simulations will contain hydrogen atoms which have high-frequency 
bond vibrations(Nibbering et al., 2014), we are typically limited to pick time steps at 
around ~1.0 fs. However, we shall employ an algorithm to rigidify bond lengths, namely 
SHAKE(Ryckaert, Ciccotti, & Berendsen, 1977), by which we can roughly double the time 
step for the velocity Verlet integrator(Verlet, 1967).  
 
2.3 Software 
The MD software employed in the present work is called NAMD(Phillips et al., 2005) and 
based on charm++(Brooks et al., 2009). NAMD is a sophisticated tool and has several 
important features and functionalities aimed at computational accuracy and efficiency. 
However, describing these in details is out of scope for this text. A few include: 
∙ Multiple Time Stepping, allowing long-range interactions to be computed less often 
∙ Electrostatics calculations by the Particle-mesh Ewald algorithm(Essmann et al., 1995) 
∙ Load balancing schemes and parallel scalability. 
 
Visualization of molecular structures throughout this dissertation was made using either 
PyMOL(The PyMOL Molecular Graphics System, Schrödinger, LLC) or 
VMD(Humphrey, Dalke, & Schulten, 1996). Plots were prepared using Grace (xmgrace, 
http://plasma-gate.weizmann.ac.il/Grace). 
 
2.4 Simulating the serine protease 
The successful execution of MD simulations of biomolecular systems involves careful 
preparing of the systems. Of particular concern when simulating serine proteases is that the 
protonation state of the active sites residues (in chymotrypsin numbering H57{c}, 
D102{c}, and S195{c}) should adequately represent their most likely configuration, e.g. 
for physiological conditions the pH value should be ~7.  
 
X-ray resolved crystallographic structures have the major limitation that hydrogen atoms 
cannot be seen. Furthermore, due to common ambiguity, the actual orientation of the 
imidazole ring of (the rotameric state) of the active site histidine is not known. Relevant 
protonation states for histidine include (in CHARMM language) HSE, which is neutral and 
the ε-nitrogen is protonated, HSD, which is also neutral but the δ-nitrogen is protonated 
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and, lastly, HSP, where both the ε-nitrogen and the δ-nitrogen is protonated. Besides the 
chosen protonation, also rotameric states could be considered.  
 
Biochemistry textbooks usually cite the pKa of histidine (the imidazole sidechain) around 
~6.0-6.5.(Stryer, Berg, & Tymoczko, 2002) However, estimates of the empirical tool 
PROPKA(Li, Robertson, & Jensen, 2005) for the FVIIa SP domain (PDB entry code 
1kli(Sichler et al., 2002)) can be seen in Table 1. These results indicate that D102{c} is 
unprotonated (negatively charged) and H57{c} as doubly-protonated (positively charged). 
In addition, it the proton affinity of D189{c}, positioned in the bottom of the S1 specificity 
pocket, is predicted relatively high by PROPKAv.3.0. 
 
Table 3 PROPKA estimates of protonation states of selected residues of the FVIIa serine protease. 
Type Res.No. {ctr.no.} pKa (v.3.0)  pKa (v.3.1) Model-pKa 
His 344{57} 7.31 8.01 6.50 
Asp 242{102} 4.39 3.58 3.80 
Asp 338{189} 7.50 3.78 3.80 
From left to right: Three-letter amino acid code for residue, residue number {chymotrypsin number}, 
PROPKA v.3.0 pKa estimate (protein-only), PROPKA v.3.1 pKa estimate (protein-ligand), reference value 
pKa. FVIIa structure was PDB entry code 1kli(Sichler et al., 2002). 
 
Simulations at the level of theory applied in this dissertation do not allow for alternating 
protonation states, such as QM/MM hybrid methods(Born & Oppenheimer, 1927)(Car & 
Parrinello, 1985) or various heuristic constant pH schemes. Therefore, a single 
representative state must be picked. To represent a (uninhibited) state of the serine protease 
in which the H57{c} serves as the catalytic base in the deacylation step of hydrolysis 
(section 1.2 & Fig. 8), the H57{c} was neutral (CHARMM type HSE) and 
D102{c}+D189{c} were charged (-1 e, standard acidic titration state) though out. This is 
furthermore consistent with neutron diffraction experiments.(Kossiakoff & Spencer, 1981) 
Though, that the protonation states may become inadequate during the time course of the 
simulations, due to strong coupling between protonation and structural conformation, is of 
potential concern.  
 
  
41 
 
3. Extrinsic tenase complex 
3.1 Proteolytic activation of FVII 
3.1.1 Prelude 
The draft manuscript 1 describes structure and dynamics of the FVII zymogen, a molecular 
structure that has remained elusive. The structure was based on a crystal of FVIII-S344A 
(active serine mutated to alanine) in complex with tissue factor which was discovered to be 
twinned. In addition, the solved structure contains relatively large unresolved segments for 
several loops, specifically around activation loops 1, 2, 3, and in the 170-loop.  
 
To shed light in the molecular flexibility of these regions and the dynamics, in general, of 
the FVII zymogen, a homology model was constructed and studied. 
 
Thermodynamics of complex formation. Equilibrium reactions of complex formation 
between FVII and FVIIa with TF are stoichiometric 1:1, i.e.  
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The enthalpic and entropic state functions         are for each state of the molecules 
indicated. By definition,       and      . If it is assumed that the state functions of 
FVIIa are in the same order as those of FVII, the major differences in TF-affinity between 
the activated and zymogen FVII originates from differences in terms              , i.e. 
 
     (     )   (     )  
 
This may seem like a crude approximation, but the zymogen-like property of FVIIa is well 
established on a functional level. The standard procedure used to quantify this (at least 
within the field of haemostasis-related biochemistry) is carbamylation(Hilgartner & Miller, 
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1975), where the N-terminus is chemically modified (by cyanate) to inactivate the enzyme. 
The assay is obviously indirect since the measured signal is residual enzymatic activity, but 
the conclusion holds unambiguously that TF protects the N-terminus of FVIIa from 
chemical modification and, by inference, promotes N-terminal insertion. 
 
The major contributor to the first enthalpic term of the delta-delta Gibbs free energy (above 
equation) is the insertion of the N-terminus into the activation pocket, where it forms a 
stabilizing salt bridge with D242. The (signed) enthalpic gain of the formation of said 
isolated and buried salt bridge stems from favourable hydrogen-bonding and electrostatic 
interaction and amounts to approximately     ( 4.4) kcal/mol for typical salt bridges in 
proteins(Kumar & Nussinov, 1999). Considering that binding affinity of TF to FVIIa is 
some 5-fold enhanced over that to FVII, the lhs. amounts to  
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where   is the gas constant and   is the temperature. Thus, differences in entropic 
contributions (favouring the free form of the FVII zymogen) and enthalpic contributions 
(favouring the TF-complexed form of FVIIa) result in a subtle balancing of contributing 
terms. But they are likely large enough that experimental validation should be achievable, 
e.g. using isothermal titration calorimetry(Zakariassen & Sørlie, 2007). 
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3.1.2 Manuscript 1 (preliminary): Madsen JM, et al, in preparation 
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Introduction 
The solution of the X-ray crystallographic structure of factor (F)VIIa with soluble tissue 
factor (TF) marked a major breakthrough toward understanding the molecular mechanisms 
involved in the initiation of blood clotting(1). Ever since, however, a great desire has been 
to discover the structure of the FVII molecule in its (un-activated) zymogen form in order 
to better understand the activation transition undertaken. The activation of FVII involves 
proteolytic cleavage after position R152, positioned in between the serine protease (SP) 
domain and the epidermal growth factor-like 2 (EGF2) domain, splitting the molecule into 
two chains (heavy chain: SP; light chain: Gla, EGF1, EGF2) still covalently linked 
together by an inter-chain disulfide bridge, C135-C262. 
 
Although the activation transition is, to some extent, analogous to that of trypsinogen-
trypsin, which has been thoroughly studied, there are subtle yet important differences 
between FVII and trypsinogen. The first mechanistic description of the activation transition 
of trypsinogen emerged almost 40 years ago.(2) In trypsinogen, a hexameric peptide is 
removed from the N-terminal region upon activation to trypsin and this cleavage promotes 
the transition from a disordered state (trypsinogen) to an ordered state (trypsin).(3) It is 
well-known that intrinsically disordered peptidic segments of proteins lacking structure can 
carry the capacity to undergo disorder-to-order transitions upon e.g. ligand-binding. (4)(5) 
The defining functional distinction between FVIIa and trysin (as well as other homologous 
proteins) is that FVIIa, even once activated, is enzymatically incompetent and requires its 
biological cofactor, TF, for significant activity. This property is due to the an incomplete 
activation transition (or rigidification) of the activation domain of FVIIa(6)(7), which is 
popularly referred to as still being ‘zymogen-like’. Therefore, the actual nature (and 
structure) of the FVII zymogen is required to elucidate the activation process satisfactorily 
for this pivotal protease.  
 
An eccentric activation mechanism of FVII involving reconfiguration of β-strands has 
previously been hypothesized(8). However, detailed experimental and theoretical 
investigations(9)(10)(11) do not support the reregistration hypothesis and it is not 
discussed further.  
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A further complication is the role of TF in the induction of order to the activation domain 
of FVII/FVIIa. The affinity maturation which occurs is bi-directional; substrate (or 
inhibitor) binding to FVII increases the affinity for TF and, vice versa, the TF:FVII 
complex has increased affinity toward substrates. A consequence hereof is that the rate of 
auto-activation of FVII is likewise increased by the binding of TF(12), but the mechanism 
through which this happens is not clear.  
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Materials and Methods 
Protein production and X-ray crystallography. Crystals of the complex sTF:FVII-S344A 
was obtained by the hanging-drop method similar to previously described(13). Diffraction 
data were collected at beamline I911 MAX-lab, Lund, Sweden.(14) 
 
Structural refinement. 
The structure of TF:FVII-S344A was determined by molecular replacement based on the 
binary complex between FVIIa and TF (PDB entry code 1dan(1)). Automated refinement 
was performed using Refmac(15) and PHENIX(16) to a resolution of 2.7 Å with the twin 
law = h, – k, – l and twin fraction 0.5 (full twinning) for phenix_refine. Cycles of manual 
model building in Coot(17) into the feature-enhanced electron density map (FEM) 
continued as long as confident building into density (down to 0.5σ) with generally good 
geometry could be done. Refinement statistics can be found in Table 1. 
 
Molecular Dynamics Simulations. 
Model building.  
There are several published zymogen structures of proteases with the chymotrypsin fold 
(Table 2). Retrieval of sequences and alignment of S1 peptidase regions/domains was done 
with Uniprot(18) and the clustal Omega algorithm(19). The missing loop segments in the 
FVII crystal structure were modeled using Quanta(Molecular Simulations Inc., San Diego, 
CA) based on trypsinogen resolved at 1.55 Å (PDB entry code 2ptn(20)). All bound Ca2+ 
ions and crystal water molecules were included in the constructed model. 
 
Simulation details. 
For the simulated systems (Table 3), all non-protein moieties present in the PDB files, 
except Ca2+ ions and crystal water molecules, were removed. The potential energy was 
initially minimized by applying the conjugated gradient method for 5,000 steps. At this 
point, the production run of length 100 ns was executed in the NPT ensemble with the 
target P = 1 atm and T = 310 K controlled by the Nosé-Hoover Langevin piston 
barostat(21)(22) and the Langevin thermostat (damping coefficient: 5/ps)(23), respectively. 
Throughout, anisotropic pressure coupling was applied (piston damping coefficient: 5/ps, 
piston period: 100 femtosecond (fs), and piston decay: 50 fs). Long-range electrostatic 
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forces were calculated using the Particle Mesh Ewald method(24)(25) with a grid spacing 
of approximately 1 Å and a fourth-order spline for interpolation. Electrostatic forces were 
updated every 4 fs. Van der Waals interactions were cut off at 12 Å in combination with a 
switching function beginning at 10 Å. Periodic boundary conditions were applied in x-, y-, 
and z-directions. The simulation was performed using the NAMD 2.7 software 
package(26) with the CHARMM27 force field(27), and the TIP3P water model(28). An 
integration time step of 2.0 fs was used for the velocity Verlet algorithm with SHAKE(29). 
All analysis and visualization of molecular structures was done using the Visual Molecular 
Dynamics (VMD) 1.9.1 software package.(30) Plots were prepared using Grace (xmgrace, 
http://plasma-gate.weizmann.ac.il/Grace).  
 
Analysis. 
RMSF. The Root mean square fluctuation (RMSF) of atomic positions for backbone atoms 
were calculated in a window width of 0.5 ns with a step size of 0.1 ns as  
 𝑀  ( )  √
 
 
∑(𝑣  ?̅?) 
𝑇
 = 
 
where T = no. frames 
 
B factors. 
X-ray crystallographic B factors relates to the rms fluctuation via the equation(31) 
𝐵( ) ≝
   
 
< 𝑀  ( ) > 
hence giving a quantitative measure for comparison between experiments and 
computation. 
 
Model simulation fit into density. Cross-correlation coefficient at 5 Å resolution between 
the X-ray crystallographic electron density map and each frame of the FVII homology 
model simulation (SP domain only) were calculated using the MDFF plugin(32) in 
VMD(30). 
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Results and Discussion 
The resulting determined FVII zymogen structure had missing loop segments at residues 
144-156 (part of activation linker region), 286-294 (activation loop 1), 317-321 (part of 
170-loop), 337-340 (part of activation loop 2), 364-373 (activation loop 3) (including the 
mentioned loop flanking residues). Autolysis sites are present in the 170-loop and 
activation loop 1 of FVIIa but no degradation is expected to have occurred because FVIIa-
S344A is catalytically inactive. 
 
No significant density (above noise level) was visible for the activation linker region and 
170-loop residues in the feature-enhanced electron density map (FEM) or maximum-
entropy electron density map (MEM). The flexible nature of the 170-loop is consistent 
with other structures of FVIIa, for instance the structure of a TF-free truncated construct of 
FVIIa containing only EGF2 from the light chain and where the co-crystallized inhibitor 
was soaked out(PDB entry code 1klj(33)). It is surprising, though, that the 170-loop is not 
stabilized (and hence visible in the crystal structure) in the presence of TF. There is no 
evidence of cleavage at R152, nor is I153 found in the activation pocket, confirming that 
the structure presented in this study indeed is the zymogen FVII. Residual density is 
observed in the FEM around the region where the activation loops 2 and 3 are positioned in 
FVIIa is observed. Intriguingly, these weak “tubes” of density (Fig. 5A) align not far from 
the main chain atoms in FVIIa. However, no confident model building based on this 
residual density could be performed with good geometry and the loop segments 
corresponding to activation loops 1,2, and 3 are possible predestined as too flexible in the 
absence of an inhibitor. This view is consistent with the disorder embraced by trypsinogen-
like zymogens and likely further worsened by the extended loops in FVIIa.  
 
 
The multiple sequence alignment guide tree generated by uniprot reveals that nearest 
sequence-based relatives among serine proteases with resolved zymogen structures are (in 
sorted order) FXI, MASP-1, and Thrombin. The structure of FXI(34), however, does not 
provide insight into the region around activation loops 1, 2, and 3, because these are, 
analogously to the present study’s FVII structure, also missing. Furthermore, structurally 
aligning MASP-1 SP domain(from PDB entry code 4igd(35)) with FVII results in a higher 
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overall geometric deviation (based on calculated RMS values) than the alignment of the 
structural ancestor trypsinogen with FVII. The model of the complete FVII zymogen was 
therefore constructed from the X-ray crystallographic structure with missing loops 
modeled based on trypsinogen(PDB entry code 2ptn(20)).  
 
A major aim for the constructed homology model of the FVII zymogen is to approximate 
the structure in protein segments where no confident building could be performed guided 
by the X-ray diffraction data. FVII (and other coagulation serine proteases) circulate the 
blood as inactive zymogens and a hallmark structural modification is facilitated proteolytic 
activation and insertion of the newly formed N-terminus into the activation pocket, 
forming a salt bridge with D194. From a survey of published structures of zymogen 
proteases with the chymotrypsin family, that it is usual for the zymogen to have the same 
fold as the enzyme with the lack of N-terminus insertion, D194 rotamer, and concurrent 
‘kink’ in the backbone on the surrounding residues. We shall analyze the structural and 
dynamical consequences caused by this modification in FVII. 
 
The unrestrained simulated structure (in aqueous environment) drifts away from the X-ray 
crystallographic structure as measured by the decrease of the calculated cross-correlation 
coefficients. This is probably to be expected because of the temperature differences 
between computation and experiment, as well as crystal packing.  
 
The RMSF was calculated for each residue of the protein-aligned trajectory to reveal areas 
of the FVII molecule exhibiting large fluctuations. In the SP domain, flexible areas 
encompass solvent exposed surface loops (activation linker region, 60-loop, calcium loop, 
99-loop, act loop 1, 170-loop, act loop 2, and act loop 3), which is expected considering 
the domain topology. 
 
In the model FVII, corresponding mass-weighted density volumetric maps was computed 
for each frame of the entire simulation trajectory, and combined using averaging. This this 
was done both for the missing parts of activations loop 1, 2, and 3, and all three in 
combination. The results indicate that said loops are indeed very flexible and no clear 
conformity between the electro density maps and the simulated density tracings could be 
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found.   
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Figure- and table texts 
TABLE 1: Statistics on Diffraction Data and Structure Refinement of the FVII zymogen 
 
TABLE 2: Published X-ray crystallographic structures of zymogens with the 
chymotrypsin fold. 
a
 indicates zymogen with enzyme-induced structural features (and 
b
 
vice versa). 
 
TABLE 3: Overview of the simulated systems 
 
FIGURE 1: (A) X-ray crystallographic structure of the FVII zymogen shown in wire 
representation. There are two complexes in the unit cell, TF1:FVII1 (in green and gray, 
respectively)  and TF1:FVII1 (, red and blue ,respectively). (B) Close-up of the SP domain 
of the TF1:FVII1 monomer of the crystal structure in wire representation. The missing loop 
regions of the 170-loop, activation loops 2+3, and activation loop 1 are encircles and 
labeled. (C) Structural alignment of the FVII crystal structure (gray), the FVIIa from PDB 
entry code 1dan(1) (orange), and trypsinogen from PDB entry code 2ptn(20). 
 
FIGURE 2: Crystallographic B factors (rescaled by 
 
   
) vs. residue for the FVII zymogen 
Cα atoms. 
 
FIGURE 3: RMSF vs. residue for the simulated FVII model. Errorbars indicating the 
standard deviation are drawn as dotted lines. Highlighted above the panel are named 
regions of the SP domain of the FVII zymogen (brown bars). 
 
FIGURE 4: Cross-correlation coefficient between the X-ray crystallographic electron 
density map and each frame of the FVII homology model simulation (SP domain only). 
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FIGURE 5: Comparison of residual density around the missing loop segments in the 
feature-enhanced crystal density map (FEM) and calculated volumetric maps of the density 
tracing based in the simulated FVII model. (A) Residual density around activation loops 2 
and 3 in the electron density (FEM) maps (top, at      ; bottom, at      ). The 
protein Cα’s are traced out in pink wire and density maps are shown as blue mesh (proteins 
are oriented similarly). The white arrows indicate density which is likely due to either 
activation loops 1, 2, 3, or a combination. (B) Calculated density tracing of the activation 
loop 1 isolated (top left, in pink). Calculated density tracing of the activation loop 2 
isolated (top right, in blue). Calculated density tracing of the activation loop 3 isolated 
(bottom left, in red).  Calculated density tracing of the activation loops 1+2+3 combined 
(bottom right, in black). Molecular structures are shown in wire representation with the SP 
domain of the FVII model in gray and TF in green. Shown in sticks are the catalytic triad 
residues (D242, H193, and S344) as well as W364. The loop segments corresponding to 
the missing parts from the crystal structure have been colored (act loop 1 in pink; act loop 
2 in blue; act loop 3 in red) 
 
FIGURE 6: Scatter-plot showing the structural integrity of the catalytic triad residues in 
FVII as determined by interatomic Cβ-Cβ distance of H193 to S344 and H193 to D242 for 
FVII. The blue arrow indicates the drift (in time.) 
 
FIGURE S1: RMSF vs. residue for the reference simulations of trypsin (top, PDB entry 
code 1j8a(36)) and trypsinogen (bottom, PDB entry code 2ptn(20)). 
 
FIGURE S2: Scatter-plot showing the structural integrity of the catalytic triad residues for 
the reference simulations of trypsin (PDB entry code 1j8a(36)) and trypsinogen (PDB entry 
code 2ptn(20)) as determined by interatomic Cβ-Cβ distance of H57{c} to S195{c} and 
H57{c} to D102{c}.  
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FIGURE S3: PROPKA(v.3) pKa value estimates for the active site histidine (residue 
H193) during the FVII simulation. 
 
FIGURE S4: Assignment (by STRIDE(37)) of secondary structure during FVII 
simulation. Chain F is FVII zymogen (residues 1-406), chain T is tissue factor. The one-
letter secondary structure codes are: H, α-helix; G, 310-helix; I, PI-helix; E, extended 
conformation (sheet); B, isolated bridge; T, turn; C, random coil (none of the previous). 
(10 frames = 1 ns simulation) 
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Tables 
Collected Crystal Data Data 
Resolution (Å) ∞ – 2.700 
Space group P43 
Unit cell parameters a = b = 150.530 Å, c = 92.060 Å 
α = β = γ = 90o 
No. of unique reflections 56562 
Completeness (%) 99.85 
Refinement  
   Resolution (Å) 29,521 – 2.700 
   Rfree (%) 27.68 
RMSDs  
   Bond lengths (Å) 0.019 
   Bond angles (deg) 0.788 
TABLE 1 
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Serine 
endopeptidase 
zymogen  
PDB entry 
code 
Resolution 
[Å] 
Uniprot entry 
code for S1 
peptidase 
region 
Comments 
α-Lytic protease  4pro 2.40  Complex with pro-
region 
Chymotrypsinogen 2cga 
1pyt 
1.80 
2.35 
sp|P17538 Native 
+proproteinase E 
Complement 
protease C1r 
1md7,1md8 
1gpz 
3.20, 2.80 
2.90 
sp|P00736|464-
702 
 
Catalytic domain 
only 
Complement 
protease C1s 
4j1y 2.66 sp|P09871|438-
680 
 
Factor VII 1jbu 
 
(this study) 
2.00 
 
2.7 
sp|P08709|213-
452 
Re-registration has 
been refuted 
AL1,2,3, 170-loop 
not resolved 
Factor XI 2f83 2.87 sp|P03951|388-
623 
AL1,2,3 not 
resolved 
MASP-1 4igd 2.50 sp|P48740|449-
696 
 
MASP-2 1zjk 2.18 sp|O00187|445-
684 
 
Plasminogen 1qrz 2.00 sp|P00747|581-
808 
Proenzyme domain 
only 
Prethrombin-1 3nxp 2.20 sp|P00734|364-
618 
 
Prethrombin-2 1hag 
1mkx (K) 
3sqe, 3sqh 
1nu7
a
 
2.00 
2.20 
1.90, 2.20 
2.20 
sp|P00734|364-
618 
+hirugen 
+α-thrombin (H) 
S195A, open form  
+Staphylocoagulase 
Profactor B 3hrz (D), 3hs0 
(D,I) 
2.20 sp|P81187|477-
754 
+cobra venom factor 
Profactor D 1fdp 2.10 sp|P00746|26-253  
Progranzyme K 1mza,1mzd 2.23, 2.90 sp|P49863|27-259  
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Prokallikrein 6 1gvl 1.80 sp|Q92876|22-
242 
 
Proproteinase E 1fon 
1pyt 
1.70 
2.35 
 Truncated 
+chymotrypsinogen 
Tissue-type 
Plasminogen 
Activator 
1bda 3.35 sp|P00750|311-
561 
Single chain 
+synthetic inhibitor 
Trypsinogen 2tgt 
1tgn, 2ptn, 
+… 
1.70 
1.65, 1.55 
tr|Q5NV56  
Urokinase-type 
Plasminogen 
Activator 
4dw2
b
 2.97  uPA in complex with 
zymogenizing 
inhibitory antibody 
Fab 
TABLE 2 
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Serine 
(pro)protease  
Bound 
cofactor(s) 
PDB entry 
code source 
Simulated 
time [ns] 
No. of 
atoms 
Human FVII Tissue factor, 
Ca2+ 
X-tal structure 
(this study); 
2ptn 
100 ~93,000 
 
Human FVII Ca
2+
 X-tal structure 
(this study); 
2ptn 
pending ~87,000 
Bovine trypsin Ca
2+
 1j8a 200 ~16,000 
Bovine 
trypsinogen 
Ca2+ 2ptn 150 ~15,000 
TABLE 3 
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Figures 
 
FIGURE 1 
  
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
 
FIGURE 2 
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FIGURE 3 
  
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
 
FIGURE 4 
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FIGURE 5 
  
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
 
FIGURE 6 
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FIGURE S1 
  
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
 
FIGURE S2  
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FIGURE S3 
  
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
 
FIGURE S4 
 
 
  
FVII 
TF 
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3.2 Allosteric activation of FVIIa 
3.2.1 Prelude 
Manuscript 2 entitled “Tissue factor activates allosteric networks in factor VIIa through 
structural and dynamical changes” by Jesper J. Madsen, Egon Persson and Ole H. Olsen 
describes the application of MD simulations to elaborate how tissue factor activates 
coagulation factor VIIa through an allosteric mechanism. Our results elegantly 
complements previous MD studies of the TF:FVIIa complex(Chang Jun Lee, Wu, 
Bartolotti, & Pedersen, 2012; Y Z Ohkubo, Morrissey, & Tajkhorshid, 2010) which have 
focused solely on the enzyme-substrate colocalization, but not described how the protease 
domain of FVIIa is stimulated by TF. 
 
The work presented in the subsequent notes follows up on the intriguing observation that 
FVIIa with the 170-loop grafted from trypsin has increased catalytic activity in the absence 
of TF.(Soejima et al., 2001a) In the following, said FVIIa variant is named FVIIa-311. 
Several point mutations have been made on top of this FVIIa-311 scaffold to investigate 
the cause of the increased activity. Particularly promising is the observation modifying the 
tyrosine residue which harboured by the trypsin 170-loop (to either F for FVIIa-860 or S 
for FVIIa-313) seems to abrogate the increased activity of these variants (without TF), 
which, in addition, are not stimulated significantly by TF either. The performed MD 
simulations of variants FVIIa-311, FVIIa-313, and FVIIa-860 in the absence of TF indicate 
that the stabilizing effect of the grafted 170-loop is indeed only observed for FVIIa-311, in 
excellent agreement with the experimental results.  
 
Jointly, manuscripts 2 and the subsequent notes suggest the hypothetical common 
mechanism of stimulation for TF-activated FVIIa and FVIIa-311 that involves the 
stabilization of residues 364-368 and a tryptophan-gate via W364.  
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3.2.2 Manuscript 2: Madsen JM, et al, submitted 
Tissue factor activates allosteric networks in factor VIIa through structural 
and dynamical changes 
 
Jesper J. Madsen1,2, Egon Persson3, Ole H. Olsen1 
 
1 Haemophilia Biochemistry and 3 Haemophilia Biology, Novo Nordisk A/S, Måløv, 
Denmark. 
2 DTU Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark. 
 
Correspondence: Ole H. Olsen, Haemophilia Biochemistry, Novo Nordisk A/S, Novo 
Nordisk Park, F5.1.29, DK-2760 Måløv, Denmark. 
Tel.: +45 3075 4511 
E-mail: oho@novonordisk.com 
 
Running Title: Tissue factor-induced allostery in factor VIIa 
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Summary 
Background. Tissue factor (TF) is known to promote colocalization of enzyme (factor 
(F)VIIa) and substrate (FX or FIX) and to stabilise the active conformation of FVIIa. 
Details on how the interaction with TF induces structural and dynamical changes in the 
catalytic domain of FVIIa to enhance its efficiency remain elusive.  
Objective. To elucidate the activation of allosteric networks in the catalytic domain of the 
FVIIa protease when bound to TF. 
Methods. Long-timescale molecular dynamics simulations of FVIIa, free and in complex 
with TF, have been executed and analysed by dynamical network analysis. 
Results. Allosteric paths of correlated motion from the TF contact point, M306, in FVIIa to 
the active site triad can be described and quantified. In particular, shortest paths from 
M306 to S344 and H193 are 16% and 8% longer in free FVIIa as compared with 
TF:FVIIa. Furthermore, paths from M306 to I153 (N-terminus) and W364, both 
representing hallmark residues of allostery, are 7% and 37% longer, respectively, in free 
FVIIa. There is a significantly weaker coupling between the TF contact point and key 
residues in the catalytic domain of FVIIa which causes the active site triad to disintegrate 
when TF is not present. 
Conclusions. These findings complement the current understanding on how the protease 
FVIIa is stimulated by TF. In addition to the allosteric paths previously identified by 
mutagenesis of FVIIa, we demonstrate allosteric networks in the catalytic domain that are 
activated by TF and help making FVIIa an efficient catalyst of FIX and FX activation. 
 
Keywords: Allosteric Regulation; Coagulation Factor VIIa; fXase; Molecular Dynamics 
Simulations; Tissue Factor 
 
Introduction 
Factor (F)VIIa is the initiating protease in tissue factor (TF)-triggered blood coagulation. 
Upon trauma in the form of blood vessel injury, circulating FVIIa encounters its cofactor, 
TF, to assemble a highly potent complex which launches the molecular cascade that 
eventually leads to a burst of thrombin and ensuing fibrin clot formation. The details of the 
allosteric mechanism by which TF transforms FVIIa to an efficient catalyst of FIX and FX 
activation remain elusive and warrant further investigation. 
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A major breakthrough toward understanding the initiation of coagulation on the molecular 
level was provided with the solution of the X-ray crystallographic structure of the binary 
complex between FVIIa and soluble TF[1]. To this date, most of our structural knowledge 
on TF-induced changes and allostery in FVIIa is rationalized on the basis of the structure 
of the TF:FVIIa complex or inferred from the comparison of this structure with free FVIIa 
structures[2]. Within the last decade, accumulating experimental evidence in the form of 
mutagenesis studies combined with biophysical and functional characterization have laid 
the foundation for two distinct TF-induced allosteric pathways in FVIIa[2]. Path I consists 
of the stabilization of the TF-binding helix (residues 307{c165}-312{c170}) that 
propagates through the 170-loop (residues 313{c107A}-321{c170I}) to activation loop 3 
(residue 372{c223}) causing a maturation of substrate-binding subsites S1-S3. In an 
orthogonal path (path II), the favorable interaction between L305{c163} and F374{c225} 
induced by TF binding changes the conformation of activation loop 3 (residues 
364{c215}-372{c223}) , affecting the activation pocket and the S1 subsite. This in turn 
encourages N-terminal insertion and the formation of a salt bridge with D343{c194}. It is 
well noteworthy that there exists variants of FVIIa, e.g. FVIIaDVQ[3], known to have the N-
terminus protected from chemical modification (presumably inserted into the activation 
pocket) which are still significantly activated by TF. This observation would suggest that 
TF-induced allostery is present in both populations (protease-like and zymogen-like) of the 
FVIIa ensemble, and furthermore that the allosteric signal is accentuated for molecular 
states of FVIIa where the N-terminus is not properly inserted into the activation pocket. 
Common to path I and II is that M306{c164} is the main origin of TF-induced effects on 
the conformation and activity of FVIIa[4].  
 
There is no structure available for native (free and uninhibited) FVIIa. This is unfortunate 
because inhibitors, covalent or not, invariably stabilize the active conformation of the 
FVIIa protease domain by inducing structural changes similar to those mediated by TF. In 
addition, X-ray crystallographic structures are static snapshots and reveal little or nothing 
about dynamic properties. One tool to extend and add to this picture a dynamical 
dimension with atomic level detail is provided by computational biophysics and the 
molecular dynamics (MD) method.  
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Recently, an intriguing study[5] showed that it is possible to interpret MD simulations 
using dynamical network analysis[6]. In doing so, the authors demonstrated qualitatively 
how a subtle redistribution of the dynamical ensemble of thrombin could separate the 
behavior of the protease domain upon performing two diametrically opposed biological 
activities regulated by cofactor binding. For FVIIa, in particular one computational 
study[7] has explained in detail how TF manages to restrain FVIIa in a conformation 
which enhances catalytic activity by enzyme-substrate alignment and colocalization. 
Similar results have been reported for the binary complex between FVIIa and TF in the 
presence of the TF transmembrane domain[8]. However, these investigations do not 
address the mode of action of the allosteric switch originating from the primary TF contact 
point, M306{c164} [4][9]. Furthermore, the decisive role of TF on the structure of the 
FVIIa protease domain, the enforcement of N-terminal insertion, is not well understood. 
Hence, at present, a comprehensive mechanistic picture of the ways TF stimulate FVIIa is 
still missing.  
 
Materials and methods 
We have adopted an approach where the dynamical analysis of Luthey-Schulten and co-
workers[6] is performed in a sliding window to analyze long-timescale molecular 
dynamics (MD) simulations of the free FVIIa protease (PDB entry code 1kli, ~1.0 µs 
simulation) and the TF:FVIIa complex (based on PDB entry code 1dan, ~0.45 µs 
simulation) in order to produce novel rationalizations on the allosteric communication 
networks in FVIIa without and with TF.  
 
Preparation of systems. The coordinates for the TF:FVIIa complex were built as described 
by Ohkubo et al. [7] and were graciously provided by the authors. Briefly, the complex 
was modeled on the basis of PDB entry code 1dan with missing loop segments modeled 
from PDB entry codes 1boy and 2hft for TF and PDB entry codes 1qfk and 2h9e for FVIIa. 
To facilitate simulation of long-timescale dynamics, the free FVIIa structure was based on 
PDB entry code 1kli which is a truncated construct with the heavy chain and only the 
EGF2 domain of the light chain. For all structures, the co-crystallized inhibitor was 
removed. All bound calcium ions were included in the simulations. The resulting systems 
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of TF:FVIIa and free FVIIa were solvated using the Solvate in VMD[10] and ionized to a 
salt concentration of 0.15 M with Na
+
 and Cl
-
 ions. 
 
Simulation details. Conventional molecular dynamics simulations were performed using 
the NAMD2[11] software, the CHARMM27 forcefield[12] and the TIP3P water 
model[13]. An integration time step of 1.0 femtosecond (fs) was used for the velocity 
Verlet algorithm. Simulations were carried out at constant pressure (P = 1 atm), and 
constant temperature (T = 310 K) controlled by the Nosé-Hoover Langevin piston 
barostat[14] and the Langevin thermostat (damping coefficient: 5/ps), respectively. 
Throughout, anisotropic pressure coupling was applied for the barostat using a piston 
period of 100 fs and piston decay of 50 fs. Long-range electrostatic forces were calculated 
using the Particle Mesh Ewald method[15] using a grid spacing of approximately 1 Å and 
a fourth-order spline for interpolation. Electrostatic forces were updated every fourth fs. 
Van der Waals interactions were cut off at 12 Å in combination with a switching function 
beginning at 10 Å. Periodic boundary conditions were applied in x-, y-, and z-directions. 
The potential energy in all prepared systems was initially minimized using 5,000 steps of 
the conjugated gradient method. 
 
Dynamical network analysis.  
The dynamical network analysis was performed using the NetworkView plugin of 
VMD[10] which utilizes Carma[16] to calculate covariance matrices. The NetworkView 
plugin creates a graph of the protein structure by the following rules: Each Cα atom is 
assigned a node and nodes are inter-connected by an edge if and only if they are within 5 Å 
at least 75 % of the trajectory window (excluding main chain-neighboring Cα atoms). A 
weight,    , is calculated for each edge based on the atomic displacement covariance 
coefficient (correlation value,    ) by the formula 
        (     ), 
which allows the weights to be interpreted as ‘lengths’ or ‘distances’ because a higher 
(numerical) correlation gets mapped onto a shorter distance. Following this nomenclature, 
the distance of an allosteric path,    , is simply found by summation, 
    ∑       . 
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Sliding window analysis.  
A sliding window approach was applied to sample the long-timescale molecular dynamics 
trajectories. The optimal path from M306 to residues of interest (I153, H193, S344, W364) 
was found in a 10-ns window whose starting point was incremented by +2 ns in each step 
to slide over the entire simulated trajectory. The relative observed frequencies were 
normalized by the number of occurrences of the most frequent (primary) path during the 
whole simulation trajectory. The average length of the specified paths was calculated by 
averaging its length in the individual windows where it was found.  
 
Results and discussion 
Our main results, sketched in Figure 1, elucidate how the long-range allosteric signal 
propagates from the TF contact point (M306{c164}) through the protease domain to the 
catalytic residues of the active site (Figure 1A) causing the triad to be stabilized (Figure 
1B). Of particular interest to the propagation of the allostery are structural changes 
enabling the transmission of the signal through the complexed FVIIa, and the actual 
residues within which the signal itself travels via correlated motions and fluctuations. In 
the language of dynamical network analysis, the former affects the residue-residue contact 
maps describing allowed connectivities in the protein, while the latter defines the strength 
of these pair-wise interactions. In the TF:FVIIa complex, the predominant pathway of 
communication (from the source M306{c164}) to the active site residue targets 
S344{c195} and H193{c57} is ~47 % and 35 % more frequent than the second-most 
observed path, respectively. Actual optimal paths traveled by the allosteric signal are 
M306{c164}-C329{c182}-V376{c227}-T378{c229}-D242{c102}-H193{c57} and 
M306{c164}-C329{c182}-Y377{c228}-V362{c213}-S344{c195}. Comprehensive 
statistics for lesser traveled paths (less frequent optimal paths and suboptimal paths) is 
available from the authors upon request. Interestingly, in the absence of TF, the same 
shortest source-to-target paths M306{c164}-S344{c195} and M306{c164}-H193{c57} 
are, on average, 16 % and 8 % (based on the full length trajectory) longer and, hence, 
result in a significantly weaker coupling for free FVIIa than for TF:FVIIa (similar results 
have been observed upon performing the analysis on the trajectories from Ohkubo et al.[7] 
of TF:FVIIa bound to a membrane patch). Furthermore, the experimentally determined 
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pathways of allostery summarized above, path I and II, are 37 % and 7 % longer in free 
FVIIa when represented by the connection between M306{c164}-W364{c215} and 
M306{c164}-I153{c16}, respectively. The strongest paths of correlated motions, however, 
do not align with the mechanistic picture suggested by the experimental data[2]. These 
findings illustrate how TF can induce an allosteric effect within the FVIIa protease domain 
and, furthermore, suggest through which residues the allosteric signal is most likely to 
travel on its way from the primary enzyme-cofactor contact point to the catalytic apparatus. 
As a consequence, the active site is stabilized in the potent, canonical trypsin-like 
configuration (Figure 1B). While there is significant variance in the distances between the 
catalytic residues in our dynamical simulation, TF clearly induces structural preservation 
of the active site triad with gaussian variation around the 1dan reference point. In the 
simulation of free FVIIa, however, a complete loss of the canonical triad geometry is 
observed as indicated by the drift of the critical Cβ-Cβ distances from H193{c57} to 
S344{c195} and, in particular, to D242{c102} (Figure 1B). In addition, salt bridge 
between the N-terminal I153{c16} and D343{c194} is significantly destabilized for free 
FVIIa as gauged by the inter-atomic distance between the γ-carbon (CG) of D343{c194} 
and the amino group nitrogen (N) of I153{c16}, which is 3.25 ± 0.13 Å for TF:FVIIa and 
3.50 ± 0.48 Å for free FVIIa during the course of the simulations. A further structural 
stabilization is seen in the residues following the ‘E2’ β-strand leading into activation loop 
3. 
 
A dynamical picture is emerging from the molecular dynamics simulations of how TF 
stimulates the productivity of FVIIa in the complex by, in addition to alignment and 
colocalization of enzyme (FVIIa) and substrate (FIX/FX) as previously described (5)(6), 
induction of a direct, long-range allosteric effect in the protease domain originating from a 
contact point at the N-terminal part of the TF-binding helix. This induced effect, in turn, 
stabilizes the active site catalytic triad as well as encourages N-terminal insertion. The 
allosteric network illuminated in this study would most likely not be deducible by 
mutagenesis studies, partly due to the disruptive nature of mutations introduced in the 
protein core, but also because signal-carrying motions include those of backbone amide 
and carbonyl groups. Vice versa, the experimentally derived allosteric pathways I and II 
and inferred mechanisms are not evident from the results of the dynamical network 
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analysis. However, paths of correlated motions exist between the TF contact point and key 
structural points representing path I and II which are strengthened in the presence of TF. 
We are very excited that experimental data supporting the proposed allosteric network are 
emerging from studies using hydrogen-deuterium exchange mass 
spectrometry[17](Hongjian Song & Kasper D Rand, personal communication).  
 
Figure text 
Figure 1: (A) Primary allosteric paths from the TF-contact point to the active site 
H193{c57} and S344{c195} residues. TF (green), FVIIa light chain (tan) and heavy chain 
(cyan) are shown in wire-representation. The catalytic triad residues of the FVIIa protease 
domain are shown in sticks. Bound Ca
2+
 are shown as spheres (yellow). Cα atoms of the 
residues of the proposed allosteric paths from M306 to H193 and S344, respectively, are 
highlighted by spheres (purple) and labeled according to amino acid type and residue 
numbers (full-length FVIIa numbering). (B) Geometry of the active site triad residues 
D242{c102}, H193{c57}, and S344{c195} in TF:FVIIa (green dots) and free FVIIa (black 
dots). Reference values from PDB entry code 1dan[1] are H57:CB/D102:CB = 5.5 Å and 
H57:CB/S195:CB = 6.5 Å and shown by a red triangle. Top left insert shows the structure 
of the canonical catalytic triad from PDB entry code 1dan[1] with the catalytic residues 
shown in sticks with the Cβ atoms highlighted as purple spheres. 
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Materials and Methods 
Salt bridge interactions. 
Salt bridges with one interacting partner in both FVIIa and TF were detected by applying a 
geometric distance cut-off equal to 3.2 Å between any of the sidechain oxygen atoms of 
acidic residues and nitrogen atoms of the basic residues. Resulting salt bridges were 
divided into four groups: those present persistently, present transiently, formed, or broken. 
 
Results and Discussion 
In this SI document further analysis and the raw data upon which the distance of each 
allosteric path is calculated in the free FVIIa and TF:FVIIa simulations. The covariance 
matrix of the TF:FVIIa simulation supports the experimentally derived fact of M306 being 
the primary point entry for TF in FVIIa (Fig. S1). The region enclosed the green box, 
representing M306 in FVIIa and its contact partners (W45 & Y94) in TF, elaborates that 
the residue-residue correlated motion is very high. 
 
Fig. S2 shows the distance between Cγ atom of D242 and the amino group nitrogen atom 
of the N-terminus I153, and such indicates the stability of the N-terminally formed salt 
bridge. Violent fluctuations are evident in the simulations of free FVIIa, wheresas these are 
effectively truncated by the presence of TF. Furthermore, no significant slip or drift in the 
interface between FVIIa and TF is observed over the course of the TF:FVIIa simulation. 
However, not all inter-protein salt bridges are rigidly formed (Figs. S3-S6). The 
dampening effect of TF on the FVIIa SP domain is gauged by finding the shortest paths 
from M306 to any other residue of the SP domain (Fig S7). Surpricingly, the ‘dampening’ 
effects of TF, by which it likely enhances the inter-residue correlated motions in the SP 
domain of FVIIa is not found for all regions. In particular, the 170-loop seems to be 
decoupled in the free FVIIa but not in TF:FVIIa.  
  
Tables S1-S5 contain the raw data for the calculated lengths of allosteric paths of interest 
based on our MD simulations. 
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Figures and Tables 
 
 
 
 
Figure S1: Variance-covariance matrix. Residues 1-406 represent FVIIa and residues 407-
619 belong to TF. Highlighted is the region around the primary TF contact in FVIIa, 
M306{c164}, and its corresponding interaction-partner in TF.  
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Figure S2: Distance between the Cγ atom of D242 and the amino group nitrogen atom of 
the N-terminus I153 plotted for the long-timescale simulations of free FVIIa (top) and the 
binary complex between TF and FVIIa (bottom). 
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Figure S3: Persistent salt bridges between TF and FVIIa in the simulation of the tenase 
complex. 
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Figure S4: Transient salt bridges between TF and FVIIa in the simulation of the tenase 
complex. 
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Figure S5: Newly formed salt bridges between TF and FVIIa in the simulation of the 
tenase complex. 
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Figure S6: Broken salt bridges between TF and FVIIa in the simulation of the tenase 
complex. 
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Figure S7: Trajectory-average distance of (shortest) allosteric paths from M306 to each 
other residue in the FVIIa protease domain. Plottet value reflects the difference between 
the free FVIIa and TF:FVIIa. 
 
Path TF Relative 
Frequency 
Length  
[mean ± 
std.dev.] 
193-242-378-376-329-306 - 1 504.21 ± 
56.6228  
193-363-377-329-306 - 0.782609 513.824 ± 
59.693  
193-242-378-327-329-306 - 0.695652 509.219 ± 
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57.1741  
193-242-378-327-323-306 - 0.413043 504.439 ± 
54.3949  
193-191-361-377-329-306 - 0.369565 483.353 ± 
53.3934  
193-363-376-329-306 - 0.333333 475.609 ± 
68.6191  
193-362-377-329-306 - 0.318841 526.364 ± 
60.9985  
193-363-378-376-329-306 - 0.304348 518.667 ± 
53.6837  
193-242-327-329-306 - 0.289855 499.675 ± 
61.85  
193-242-326-323-306 - 0.275362 499.711 ± 
66.8139  
193-242-378-376-329-306 + 1 466.537 ± 
55.952  
193-363-377-329-306 + 0.744681 445.6 ± 
57.211  
193-363-376-329-306 + 0.56383 436.717 ± 
49.1933  
193-242-327-329-306 + 0.510638 454.583 ± 
62.1238  
193-242-378-327-329-306 + 0.5 468.894 ± 
54.5591  
193-242-378-328-306 + 0.297872 446.517 ± 
59.1594  
193-242-240-327-329-306 + 0.265957 500.16 ± 
59.7339  
193-364-376-329-306 + 0.255319 460.75 ± 
65.1967  
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193-242-240-326-328-306 + 0.212766 481.7 ± 
58.6985  
193-242-327-323-306 + 0.191489 497.778 ± 
54.7332  
Table S1: Observed frequencies and calculated average lengths of the shortest allosteric 
paths between H193 and M306 elucidated by the sliding window analysis of the molecular 
dynamics trajectories with (+) and without (-) TF present. Top 10 most frequent paths are 
listed.  
 
 
 
Path TF Relative 
Frequency 
Length  
[mean ± 
std.dev.] 
306-329-377-362-344 - 1 453.32 ± 
62.3571  
306-329-377-363-344 - 0.299595 471.351 ± 
60.3862  
306-329-376-378-362-344 - 0.242915 471.183 ± 
53.1992  
306-310-329-377-362-344 - 0.226721 482.464 ± 
66.2309  
306-323-327-378-362-344 - 0.153846 483.105 ± 
54.9199  
306-329-327-378-362-344 - 0.1417 475.943 ± 
52.4437  
306-323-327-377-362-344 - 0.117409 489.759 ± 
44.9188  
306-329-377-361-346-344 - 0.11336 481.179 ± 
64.7512  
306-329-376-363-344 - 0.11336 450.036 ± 
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66.7969  
306-329-376-362-344 - 0.105263 436.654 ± 
69.2503  
306-329-377-362-344 + 1 391.764 ± 
48.3909  
306-329-377-363-344 + 0.68125 392.339 ± 
62.14  
306-329-376-363-344 + 0.51875 384.181 ± 
62.7698  
306-329-376-364-344 + 0.3125 395.56 ± 
43.3839  
306-328-377-362-344 + 0.2375 383.421 ± 
51.39  
306-328-378-362-344 + 0.2 382.375 ± 
43.0521  
306-310-329-377-362-344 + 0.2 429.625 ± 
47.8433  
306-329-376-378-362-344 + 0.13125 432.143 ± 
48.9424  
306-329-376-362-344 + 0.125 388 ± 
25.3791  
306-329-327-363-344 + 0.10625 398.647 ± 
78.8035  
Table S2: Observed frequencies and calculated average lengths of the shortest allosteric 
paths between M306 and S344 elucidated by the sliding window analysis of the molecular 
dynamics trajectories with (+) and without (-) TF present. Top 10 most frequent paths are 
listed.  
 
Path TF Relative 
Frequency 
Length  
[mean ± 
std.dev.] 
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153-300-302-304-306 - 1 422.871 ± 
52.7176  
153-338-375-329-306 - 0.451613 434.822 ± 
57.5339  
153-339-375-329-306 - 0.435484 440.709 ± 
56.8498  
153-338-331-304-306 - 0.41129 422.112 ± 
61.5784  
153-281-302-304-306 - 0.41129 454.474 ± 
49.1653  
153-338-374-329-306 - 0.354839 386.692 ± 
68.0321  
153-340-366-376-329-306 - 0.274194 437.96 ± 
43.481  
153-338-374-310-306 - 0.25 471.8 ± 
54.3831  
153-339-377-329-306 - 0.233871 440.889 ± 
74.6934  
153-339-366-376-329-306 - 0.233871 412.077 ± 
33.5432  
153-300-302-304-306 + 1 395.121 ± 
43.4256  
153-281-302-304-306 + 0.99005 386.053 ± 
47.8504  
153-302-304-306 + 0.58209 384.759 ± 
45.2953  
153-377-329-306 + 0.487562 387.686 ± 
52.6712  
153-281-279-304-306 + 0.383085 395.484 ± 
52.0853  
153-377-327-323-306 + 0.129353 399.409 ± 
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49.6869  
153-335-375-329-306 + 0.124378 404.795 ± 
43.8238  
153-283-281-302-304-306 + 0.124378 404.258 ± 
40.0266  
153-377-329-310-306 + 0.0895522 405.414 ± 
43.6076  
153-281-279-302-304-306 + 0.0646766 406.062 ± 
46.1986  
Table S3: Observed frequencies and calculated average lengths of the shortest allosteric 
paths between I153 and M306 elucidated by the sliding window analysis of the molecular 
dynamics trajectories with (+) and without (-) TF present. Top 10 most frequent paths are 
listed.  
 
Path TF Relative 
Frequency 
Length  
[mean ± 
std.dev.] 
306-323-321 - 1 247.481 ± 
61.804 
306-311-321 - 0.677249 242.734 ± 
57.3958 
306-309-311-321 - 0.518519 250.602 ± 
54.1262 
306-308-311-321 - 0.486772 247.239 ± 
59.4945 
306-309-313-315-317-319-321 - 0.470899 291.393 ± 
52.8648 
306-309-312-314-317-319-321 - 0.460317 295.333 ± 
48.1785 
306-311-317-319-321 - 0.439153 299.41 ± 
48.8474 
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306-310-314-317-319-321 - 0.439153 299.771 ± 
46.6583 
306-310-317-319-321 - 0.428571 306.481 ± 
49.4229 
306-309-314-317-319-321 - 0.402116 296.592 ± 
48.72 
306-310-323-321 + 1 295.75 ± 
44.6161  
306-323-321 + 0.953125 246.213 ± 
41.0298  
306-311-321 + 0.9375 242.583 ± 
47.7854  
306-329-323-321 + 0.90625 288.914 ± 
43.4493  
306-309-311-321 + 0.765625 250.816 ± 
52.6683  
306-308-311-321 + 0.765625 244.265 ± 
50.6709  
306-329-327-321 + 0.640625 278.415 ± 
37.3735  
306-329-376-321 + 0.46875 275.6 ± 
43.0439  
306-329-327-323-321 + 0.40625 295.038 ± 
49.8355  
306-310-307-323-321 + 0.359375 313.957 ± 
46.285  
Table S4: Observed frequencies and calculated average lengths of the shortest allosteric 
paths between M306 and P321 elucidated by the sliding window analysis of the molecular 
dynamics trajectories with (+) and without (-) TF present. Top 10 most frequent paths are 
listed.  
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Path TF Relative 
Frequency 
Length  
[mean ± 
std.dev.] 
306-329-377-362-364 - 1 435.315 ± 
49.4386  
306-329-376-366-364 - 0.75 418.556 ± 
53.6645  
306-310-317-366-364 - 0.694444 383.8 ± 
64.9896  
306-329-376-364 - 0.675926 326.644 ± 
58.5092  
306-311-317-366-364 - 0.62963 392.574 ± 
62.9835  
306-309-313-315-317-366-364 - 0.37963 417.829 ± 
59.0349  
306-310-314-317-366-364 - 0.37037 391.225 ± 
63.8985  
306-329-376-378-364 - 0.361111 440.308 ± 
34.7195  
306-309-312-314-317-366-364 - 0.351852 391 ± 
66.8069  
306-308-311-317-366-364 - 0.342593 394.081 ± 
69.0532  
306-329-376-364 + 1 318.489 ± 
55.0759  
306-329-376-366-364 + 0.369318 363.6 ± 
46.7809  
306-329-375-366-364 + 0.221591 372.231 ± 
51.3172  
306-310-329-376-364 + 0.221591 362.308 ± 
54.5138  
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306-329-327-364 + 0.198864 377.286 ± 
52.2721  
306-329-377-362-364 + 0.142045 399.16 ± 
50.2201  
306-328-376-364 + 0.119318 333.238 ± 
48.3075  
306-329-377-364 + 0.0965909 345.647 ± 
65.2046  
306-310-376-364 + 0.0909091 348.688 ± 
49.2211  
306-310-374-366-364 + 0.0738636 371.154 ± 
33.9158  
Table S5: Observed frequencies and calculated average lengths of the shortest allosteric 
paths between M306 and W364 elucidated by the sliding window analysis of the molecular 
dynamics trajectories with (+) and without (-) TF present. Top 10 most frequent paths are 
listed.  
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3.2.3 Notes: Trypsin 170-loop-swapped FVIIa variants 
Introduction 
In these notes, an activity-governing loop segment from the structural ancestor, trypsin, is 
integrated into FVIIa to engineer a protease that is independent of its biological cofactor, 
tissue factor (TF). Structural and functional characterization of the designed FVIIa variants 
is employed to yield novel insights into the underlying allosteric mechanisms inherent to 
the scaffold of this important protease.  
 
Several of the trypsin-like proteases are poor enzymes after proteolytic activation and 
require cofactors to be significantly active. This fundamental theme enables the high 
degree of regulation as required in for instance emergency responses; typical examples 
include common coagulation factors (VIIa, IXa) and complement factors (B, C2, and 
D).(Gohara & Di Cera, 2011) Also the ubiquitous thrombin, albeit somewhat active after 
final processing of prothrombin, is further stimulated by cofactors. These observations 
suggest that (activated) trypsin-like proteases coexist in molecular states which can be 
either active or inactive and, furthermore, that the trypsin-fold is capable of supporting 
enzymatic allostery. Capturing these mechanisms, however, is a major challenge because 
native states (wild-type, free and uninhibited) are difficult to crystallize.  
 
The 170-loop of FVIIa is peculiar in that is five residues longer in FVIIa than in the 
ancestral trypsin and also related proteases from the coagulation system (thrombin, FIXa, 
FXa, PC). A multiple sequence alignment show that this characteristic encompasses the 
largest inserted region (disregarding the C-ternimally positioned residues) of the SP 
domain of FVIIa. This observation is interesting since the primary point of origin for TF-
induced allostery in FVIIa is likely M306(Persson, Nielsen, & Olsen, 2001)(Rand et al., 
2008), positioned at the N-terminal part of the TF-binding helix and directly leading into 
the 170-loop. Accumulating evidence based on mutagenesis studies have elaborated two 
principal allosteric pathways in FVIIa originating from the TF-binding helix.(Persson & 
Olsen, 2011) The associated mechanistic pictures are rationalized on the basis of X-ray 
crystallographic structures. One signal of allostery (path I) travels up through the 170-loop 
of FVIIa, which is stabilized in the binary complex with TF, and the P321 ‘clamps’ down 
on the W364, assisting the maturation of substrate-binding subsites. In an orthogonal 
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direction, the conformation of activation loop 3 is altered in a manner which facilitates 
appropriate N-terminal insertion into the activation pocket, forming the hallmark salt 
bridge interaction with D242{c194} (path II). Interestingly, grafting the 170-loop from 
trypsin seems to short-circuit both pathway and modify the behavior of FVIIa as to become 
constitutively active in the absence of TF.(Soejima et al., 2001b)  
 
Conversely, certain functionalities from arguably more complicated trypsin-like proteases 
have been successfully integrated back into trypsin, e.g. Na
+
 allostery based on insertion of 
thrombin fragments(Page & Di Cera, 2010) and the modulation of inhibitor specificity 
taken from FXa(Rauh, Klebe, & Stubbs, 2004).  
 
In the present notes, we demonstrate that it is the flexible nature of FVIIa that requires it to 
be tamed by its cofactor. However, the shortening of the 170-loop alone does not 
accomplish this; a key residue interaction is formed by Y314{c170B} cause the segment 
flanking the active site (residues 364{c215}-368{c219}) to be stabilized. These findings 
are, to the best of our knowledge, the first indication that tryptophan-gated allosteric 
mechanisms are present in FVIIa. 
 
Experimental  
Preliminary experimental data (the following two tables) for reference and comparison of 
the presented FVIIa variants was graciously provided by Anders B. Sørensen (to be 
published).  
 
Table 4 sTF binding to the FVIIa variants using surface plasmon resonance (SPR). 
 
Func. Kd [nM] 
Steady-State 
SPR Kd [nM] 
SPR kon [1/Ms] SPR koff [1/s] 
FVIIa-
WT 1.2 (0.3) 6.1 (1.4) 448971 0.0027 (0.0004) 
FVIIa-311 101.6 (4.1) 140.7 (8.3) 213057 0.030 (0.0023) 
FVIIa-313 34.2 (2.0) 38.0 (1.6) 293848 0.011 (0.0001) 
FVIIa-860 231.1 (22.8) 248.7 (18.2) 180048 0.045 (0.0024) 
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Table 5 Kinetic parameters for the hydrolysis of S2288, pABA inhibition values and carbamylation halftimes 
as means with calculated SEM, N=2. 
 
S2288 Km 
[mM] 
S2288 Vmax 
[mAu/min] 
xWT
a 
pABA Ki  
[uM] 
KNCO T½ 
[min] 
-sTF      
FVIIa-WT 8.9 (0.4) 135.5 (3.2) 1.0 1485 (87.7) 43.9 (1.0) 
FVIIa-311 4.0 (0.1) 535.3 (8.5) 8.8 97.6 (10.1) 40.8 (0.5) 
FVIIa-313 5.3 (0.2) 341.2 (5.1) 4.2 190.4 (13.1) 43.8 (0.6) 
FVIIa-860 15.4 (1.3) 120.2 (6.4) 0.5 490.3 (46.3) 32.4 (0.7) 
+sTF      
FVIIa-WT 1.2 (0.03) 610.5 (3.8) 32.7 49.3 (1.8) 536.2 (39.6) 
FVIIa-311 1.2 (0.02) 735.1 (4.0) 40.0 24.7 (1.2) 56.7 (0.9) 
FVIIa-313 3.0 (0.06) 653.3 (5.5) 14.6 41.7 (1.3) 159.0 (4.8) 
FVIIa-860 5.6 (0.1) 381.5 (4.4) 4.5 69.5 (3.7) 37.1 (0.7) 
a 
FVIIa-WT Vmax/Km arbitrarily set to one and all other values calculated as relative 
efficiency 
 
Materials and Methods 
Model construction of FVIIa variants. 
The FVIIa 170-loop variants were constructed using the X-ray crystallographic structure of 
the 311-FVIIa variant as a template (to be published, L. A. Svensson). For the 313- and 
860-variants, the tyrosine 314{c170B} was mutated to serine and phenylalanine 
respectively while preserving the sidechain rotamer from the template. WT-FVIIa was 
based on a representative structure of benzamidine-inhibited FVIIa ((Sichler et al., 2002), 
PDB entry code 1kli). The complete complex of soluble Tissue Factor (residues 1-213) and 
FVIIa was constructed starting from PDB entry code 1dan as described in ((Y Z Ohkubo et 
al., 2010), and graciously provided by the authors) where the absent loops were taken from 
other PDB entries (see also ms.2). For all structures, the co-crystallized inhibitor was 
removed. 
 
Simulation details. 
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Conventional molecular dynamics (MD) simulations of the WT-FVIIa:sTF complex, WT-
FVIIa, and the three FVIIa variants with the trypsin 170-loops were performed using the 
NAMD 2.7 software package(Phillips et al., 2005) with the CHARMM27 force 
field(MacKerell et al., 1998) and the TIP3P water model(Jorgensen, Chandrasekhar, 
Madura, Impey, & Klein, 1983) similarly to as described in ms.1 and ms.2 previously.  
 
Multiple Sequence Alignment.  
Retrieval and alignment of the 170-loop sequences for trypsin and FVIIa was done using 
UniProt(The Uniprot Consortium, 2013) and the Clustal Omega algorithm(Sievers et al., 
2011). 
 
Structural modeling of 170-loop conformations of the 311-, 313-, and 860-FVIIa variants.   
Conformations of the 170-loop in the scaffold of the X-ray crystallographic structure: 
Sampling of the loop conformational space was done using the Rosetta modeling 
suite(Leaver-Fay et al., 2011). Scores (pseudo-energies) of the generated decoy models are 
evaluated under the standard score12 scorefunction unless otherwise stated. A scaffold for 
examining the loop conformations of the 311-, 313-, and 860-FVIIa variants was created 
by removing the 7 variant-specific residues EASXPGK (Fig. 13) in the X-ray 
crystallographic structure resolved for the 311-variant (to be published, L. A. Svensson). 
This scaffold was processed by a high-resolution protein structure refinement protocol with 
backbone perturbations and sidechain repacking (Fast Relax protocol, unpublished). 1,200 
decoys were generated and the best scoring decoy was chosen as a representative model for 
further modeling. On this scaffold, the 170-loop was reconstructed and refined for each of 
the three loop sequences for 311-FVIIa, 313-FVIIa, and 860-FVIIa, respectively, by the 
kinematic closure (KIC) protocol in Rosetta(Mandell, Coutsias, & Kortemme, 2009). 
>20,000 loops were modeled for each 170-loop variants and the best scoring (top 10 %) 
formed the representative ensemble of accessible loop conformations, and were grouped by 
structural clustering. 
 
Results and Discussion 
The N-terminus salt bridge between the amino group of I153{c16} and D343{c194} is 
formed throughout the entire duration of all simulated FVIIa variants; The trajectory 
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averaged distance between the N atom of the amino group and the Cγ atom of the 
carboxylic acid was 3.21-3.29 Å, indicating a stable salt bridge. Since carbamylation is the 
default assay for distinction between the zymogen-like FVIIa and the functionally active 
FVIIa population, we here adopt the notion, that the correctly inserted N-terminus is the 
structurally defining marker for the enzyme, and thus, any activity regulating 
conformational changes distinguish between the active enzyme (E) and the inactive 
enzyme (E*). Sequence alignment of the stidued FVIIa variants with WT-FVIIa and 
trypsin can be seen in the figure below (Fig. 13). 
 
 
Figure 13 Multiple sequence alignment of the 170-loops of the loop-swapped FVIIa variants. 
 
Dynamics Simulations of the FVIIa variants. 
Tryptophan-364{c215} is located in between activation loops 2 and 3 of the SP domain of 
FVIIa (Fig. 4B). In the X-ray crystallographic structures of inhibited FVIIa, well 
represented by PDB entry code 1kli(Sichler et al., 2002), W364{c215} hydrogen bonds 
with V376{c227} as part of a beta-sheet of three juxtaposed beta-strands forming one side 
of the twin beta-barrel domain topology. Furthermore, the amino acid residues surrounding 
W364{c215} constitutes one rim of the S1 substrate specificity pocket. The β-barrel region 
of the SP domain of FVIIa which harbors activation loop 1, activation loop 2, activation 
loop 3, and the 170-loop is more disordered than the opposing half of the domain. In our 
molecular dynamics simulations all three activation loops undergoes significant structural 
changes, and of particular interest, so does the region following the E2 strand sheet which 
harbors W364{c215}. This is expected of surface exposed loops, but the difference in 
flexibility between WT-FVIIa and the sTF:WT-FVIIa binary complex is astounding. The 
re-arrangements of loops is most pronounced in WT-FVIIa where W364{c215} not only 
releases from the aryl binding pocket S3/S4 (Fig. 14B), but the S1 pocket collapses 
entirely, as indicated by the short distance between the Tryptophan and the S344{c195} 
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(Fig. 14C). The molecular dynamics simulations clearly show that TF effectively tame the 
dynamics of WT-FVIIa, keeping it in the productive “open” (E) conformation which is 
structurally and dynamically similar to the active-site inhibited FVIIa.   
 
 
Figure 14 Representative structural conformations of Tryptophan 215{c} relative to the catalytic triad and 
scatter plots of the distances between W215{c} and the active H57{c}/S195{c} in the molecular dynamic 
simulations of the FVIIa variants.  
Snap-shots were taken from the simulation of WT-FVIIa. (A) crystal structure and “open” (E) conformation. 
(B) E* conformation of W215{c}. (C) E* conformation of W215{c} and collapsed S1 pocket.  
 
Most remarkably, this conformational transition to an unproductive (E*) population is 
likewise absent in the trypsin 170-loop variant of FVIIa without Tissue Factor, but is re-
introduced in the 313- and 860-FVIIa variants by modifying a single key stabilizing polar 
interaction of the hydroxyl group of the trypsin 170-loop Y314{c170B} (Fig. 15). The fact 
that the Y314F mutation of 860-FVIIa in the trypsin 170-loop scaffold has such a dramatic 
reversing effect reveals that stacking alone of the bulky hydrophobic sidechains is not 
sufficient to significantly bias W364{c215} toward the “open” (E) conformation. 
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Figure 15 Scatter-plots of W215{c} and the active H57{c}/S195{c} distances calculated every 1 ns during 
the 100 ns-simulations. 
 
170-Loop Conformational Sampling. 
Visual inspection and comparison of crystal structures for WT-FVIIa and 311-FVIIa 
suggests that the P315{c170C} in the trypsin 170-loop variants may restrain the motion of 
the W364{c215} by lidding off the indole group and keeping it in the “open” 
conformation. The 170-loop conformational search for the FVIIa variants 311, 313, and 
860 can be seen in Fig. 16, where the pseudo-energy of the best scoring loop decoys are 
plotted against their geometric distance (RMSD) to the native 311-FVIIa 170-loop. For 
each of these three variants, 5-6 major populations of loop conformations are observed. 
Surprisingly, though, pseudo-energy landscapes looks indistinguishable between 311- and 
860-FVIIa variants, whereas 313-FVIIa is notably different. 
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Figure 16 pseudo-Energy vs geometric distance of the generated 170-loop decoys for the 311-, 313-, and 
860-FVIIa variants on the 311-FVIIa scaffold. 
 
Concluding remarks 
The position of the W364{c215} is crucial for the structural integrity of the aryl-binding 
site of the substrate binding cleft in FVIIa. In the vast majority of published x-ray 
crystallographic structures of inhibited FVIIa, W364{c215} is aligned to a single 
conformation, well represented by PDB entry code 1kli(Sichler et al., 2002). Tryptophans 
which can exist in various structural conformations are known to be important in allosteric 
regulation pathways in other trypsin-like serine proteases, e.g. Thrombin(Gandhi, 2010). 
The conformational transition seen in our simulations has been reported previously for the 
homologous factor Xa in a computational study (Wang, Hao, & Li, 2011). There is strong 
evidence that the Tryptophan 215 {364} conformational change observed in our molecular 
dynamics for the preferentially “open” FVIIa variants is indeed physically attainable ((Rai 
et al., 2006),PDB entry code 2f9b). Though, to the best of our knowledge, the present 
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study is the first indication of the critical role of W364{c215} in FVIIa allostery both upon 
TF-binding and general activity modulation in the trypsin 170-loop-swapped variants. 
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3.3 TF:FVIIa complex formation 
3.3.1 Prelude 
Manuscript 3 describes a functional and structural characterization of FVIIa variants with 
truncations of increasing length (one to four residues) in the inter-domain linker between 
the two EGF-like domains. Said linker has a defining role in the ability of FVIIa to interact 
with TF because it works as a conformational hinge that can accommodate rotated light 
chain conformations (Fig. 5). It is intriguing to note that this functionality is apparently 
preserved even when one or two residues are removed (starting at position residue 86 and 
deleting toward the N-terminus), still allowing a productive interaction with TF to be 
formed. However, truncation by three or four residues completely abolished TF-
mediadated stabilization and, consequently, TF-induced activity enhancement.   
 
Simulations of the free FVIIa linker variants substantiate that no important structural 
elements are destroyed by the linker truncations up till 3 residues toward the N-terminus 
from position 86. Furthermore, enforcing the FVIIa linker variants to complex with TF 
shows that this interaction becomes energetically un-favourable when exactly three (or 
four) residues are removed, but not when only one or two residues are removed. These 
results are in excellent agreement with experimental data. 
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3.3.2 Manuscript 3: Persson E, et al., submitted 
The Length of the Linker between the Epidermal Growth Factor-like 
Domains in Factor VIIa Is Critical for a Productive Interaction with 
Tissue Factor 
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2 
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Running title: FVIIa linker determines tissue factor complementarity 
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ABSTRACT: Formation of the factor VIIa (FVIIa)-tissue factor (TF) complex triggers the 
blood coagulation cascade. Using a structure-based rationale, we investigated how the 
length of the linker region between the two epidermal growth factor (EGF)-like domains in 
FVIIa influences TF binding and the allosteric activity enhancement, as well as the 
interplay between the γ-carboxyglutamic acid (Gla)-containing and protease domains. 
Removal of two residues from the native linker was compatible with normal cofactor 
binding and accompanying stimulation of the enzymatic activity, as was extension by two 
(Gly-Ser) residues. In sharp contrast, truncation by three or four residues abolished the TF-
mediated stabilization of the active conformation of FVIIa and abrogated TF-induced 
activity enhancement. In addition, FVIIa variants with short linkers associated 80-fold 
slower with soluble TF (sTF) compared with wild-type FVIIa, resulting in a corresponding 
increase in the equilibrium dissociation constant. Molecular modeling suggested that the 
shortest FVIIa variants would have to be forced into a tense and energetically unfavorable 
conformation in order to be able to interact productively with TF, explaining our 
experimental observations. We also found a correlation between linker length and the 
residual intrinsic enzymatic activity of Ca
2+
-free FVIIa; stepwise truncation resulting in 
gradually higher activity with des(83-86)-FVIIa reaching the level of Gla-domainless 
FVIIa. The linker appears to determine the average distance between the negatively 
charged Gla domain and a structural element in the protease domain, presumably of 
opposite charge, and proximity has a negative impact on apo-FVIIa activity. 
 
Keywords: Factor VIIa; tissue factor; allostery; structural complementarity; linker region 
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Statement for the broader audience: A linker region connects the N- and C-terminal 
domain pairs in factor VIIa (FVIIa) and other coagulation factors. FVIIa tolerates a 
deletion of only two amino acid residues before the complementarity with tissue factor 
(TF) is lost and cofactor function is abolished. This illustrates the pivotal spacer function 
of a linker region, an optimal length being crucial for a productive, high-affinity 
interaction. Linker regions dictate the distance between components of composite, multi-
domain binding interfaces and presumably play important roles in numerous protein-
protein interactions. 
 
 
 
Abbreviations: FVII(a), (activated) coagulation factor VII; TF, tissue factor; sTF, soluble TF 
(residue 1-219); EGF, epidermal growth factor; Gla, γ-carboxyglutamic acid. 
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Coagulation factor VIIa (FVIIa)
3
 is a serine protease of pivotal importance to the blood coagulation 
cascade, forming the initiating complex with its cognate cofactor, tissue factor (TF) (1). The 
precursor FVII is synthesized as a single-chain, inactive zymogen, and FVIIa results from 
activation by endoproteolytic cleavage after Arg-152. Trace amounts FVIIa patrol the vasculature 
and respond instantly to the exposure of TF as a sign of vascular damage. Free FVIIa is an enzyme 
in a quiescent state lacking significant biological activity, but upon association with TF it becomes 
an efficient catalyst capable of rapidly initiating the blood coagulation cascade by converting more 
FVII to FVIIa and by activating factors IX and X (1). The TF-interactive interface on FVIIa (2) can 
be divided into two parts, the first involving the light chain and providing the majority of the 
binding energy (3) and the second primarily being composed of contact points on the protease 
domain, including Met-306 which is the origin of the allosteric effect on FVIIa (4). FVIIa is 
homologous to other vitamin K-dependent coagulation factors and contains the same four domains 
as, for instance, factors IX and X, namely a γ-carboxyglutamic acid (Gla)-containing domain, two 
epidermal growth factor (EGF)-like domains and a serine protease domain (5). The first three 
domains make up the light chain, whereas the protease domain constitutes the heavy chain. The last 
Cys residue of the first EGF-like domain and the first Cys residue of the second EGF-like domain 
are separated by a 9-residue linker sequence. The linker comprises a hinge region (one residue in 
particular) which permits different relative orientations of the domain pairs on each side (Gla plus 
first EGF-like domains and second EGF-like plus protease domains, respectively) (6). In the 
complex with TF, FVIIa has an extended conformation with a stretched linker region dictated by 
the interactions with the protein cofactor (2). 
     Even though the amino acid sequence of the linker in FVII(a) is not conserved between species 
(7, 8), its length and flank regions, including the most pronounced hinge residue Gln-88, are. This 
suggests that interdomain distance and flexibility are of functional importance. Factors IX(a) and 
X(a) on the other hand have a shorter linker consisting of five and seven amino acid residues, 
respectively. Only the first glutamic acid residue is conserved between the three human factors (9, 
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10). Rather than directly participating in protein-protein interactions, the linker regions may serve 
to define the distance between distant parts of the proteins and allow them to interact optimally 
with for instance protein cofactors and substrates. 
    In this study, we execute a structure-based truncation strategy to demonstrate that the length of 
the linker between the EGF-like domains in FVIIa is crucial for the optimal physical interaction 
with TF. This is in turn necessary for stabilization of the active conformation of FVIIa and a 
productive outcome in terms of enhanced enzymatic activity. Too short a linker cannot, at least not 
in any low-energy conformation with allowed backbone dihedral angles, support an appropriate 
distance between the two EGF-like domains nor between distant patches of the TF-interactive 
interface on FVIIa. We also propose that the linker length governs the spatial distance between the 
Gla domain and an element in the protease domain and thereby influences the residual enzymatic 
activity of the apo form of free FVIIa. 
 
 
RESULTS 
Molecular design rationale behind linker truncations 
Alignment of FVIIa sequences from a wide range of mammals reveals that linker residues Glu-82, 
Gln-88, Leu-89, and Ile-90 are invariably conserved, whereas positions 83-87 are promiscuous 
with respect to amino acid occupancy. This strongly suggests that deletions within residues 83-87 
will affect the linker length without disrupting important secondary structural elements. Compared 
with the X-ray crystal structure of FVIIa bound to TF (2), structures of free FVIIa with visible 
EGF-like domains (6, 26; PDB entry codes 1qfk and 1dva) confirm the presence of the short β-
strand at residues Thr-83 to His-84, but reveal no consensus on the position of the helical fragment 
observed. This suggests that the flexible nature of the linker allows the formation of half or full 
turns but only transiently, consistent with previous computational studies of free and TF-bound 
FVIIa (27). We conclude that only the length of the linker is likely to be affected in the des86- and 
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des(85-86)-FVIIa variants, whereas in des(84-86)-FVIIa, Asp-87 will move to the position 
occupied by the native residue 84. This creates a sequence (Glu-82, Thr-83, Asp-84) present in 
bovine and canine FVIIa making retention of the β-sheet in free des(84-86)-FVIIa plausible. 
However, in the structural minimizations of the des(84-86)-FVIIa-TF complex, no β-sheet is 
observed. This is not due to the relative β-sheet propensity of aspartic acid, but because the linker 
length no longer allows it. The β-sheet might be entirely missing in free des(83-86)-FVIIa. In order 
to evaluate the physical extension of various linker lengths, molecular dynamics simulations were 
performed on native FVIIa and the four truncated variants. Representative snapshots from the 
simulations are shown in Fig. 1. The distance between the last disulfide in the first EGF-like 
domain and the first disulfide of the second EGF-like domain decreases with the number of 
residues truncated while, indeed, the helical element observed in the X-ray crystal structure of 
FVIIa-TF (2) is missing in all the simulated free FVIIa variants and, instead, residues 85-91 are 
engaged in varying degrees of intermittent turn/coil transitioning (Fig. 1). In addition, the short β-
sheet in which strand residues Thr-83 and His-84 participate is preserved in the simulation of 
FVIIa. The strand property is retained in simulations of the truncated des86-, des(85-86)-, and 
des(84-86)-FVIIa variants, but is absent in des(83-86)-FVIIa. These results suggest that the linker 
region in all the free FVIIa variants is devoid of helical elements and that a short strand is present 
when up to three residues are removed. Hence truncation of the linker, at least by up to three 
residues, affects its length but not secondary structural content. 
 
Effects of sTF on activity and conformational stability of FVIIa linker variants 
One purpose of this study was to investigate whether the length of the linker between the two EGF-
like domains in FVIIa is critical for the interaction with, and cofactor-induced effects of, TF. In the 
initial characterization, all the FVIIa variants, both those with an extended and those with a 
truncated linker, were found to possess virtually the same intrinsic amidolytic and proteolytic 
activity as wild-type FVIIa (data not shown). The latter was measured using FX as the substrate 
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
both in the presence and absence of phospholipids. In the next step, the amidolytic activities were 
measured in sTF titration experiments. The FVIIa variants with the smallest truncations, lacking 
one (des86-FVIIa) or two residues (des(85-86)-FVIIa) in the linker, responded normally to sTF 
with a fold activity enhancement at saturating concentrations of sTF and an EC50 value 
indistinguishable from those of wild-type FVIIa (Fig. 2A). In sharp contrast, those with longer 
truncations, i.e. des(84-86)- and des(83-86)-FVIIa, were virtually non-responsive to sTF (even at 5 
µM cofactor). An increased incubation time with sTF did not help to activate the two shortest 
FVIIa variants (data not shown).The variants containing extensions of the linker, 86G87- and 
86GS87-FVIIa, behaved like FVIIa (Fig. 2B). 
    Carbamylation, a chemical modification of the N-terminal amino group of the protease domain 
and a measure of its accessibility to solvent (28), results in loss of enzymatic activity. It was used to 
investigate whether the ability (or inability) of sTF to enhance the activity of a particular FVIIa 
variant was reflected in an increased (or unaltered) degree of burial of the N-terminus in the 
presence of the cofactor. In the absence of sTF, all the studied FVIIa variants, whether truncated or 
extended in the linker, Gla-domainless or full-length, were modified at indistinguishable rates and 
lost 13-14% activity per 10 minutes. When bound to sTF, FVIIa, 86G87-FVIIa, 86GS87-FVIIa, 
des86-FVIIa and des(85-86)-FVIIa were all modified at a significantly slower rate (2-3%/10 min). 
In sharp contrast, the rates of carbamylation of des(84-86)- and des(83-86)-FVIIa were not affected 
by complex formation with sTF. Thus there appears to be an absolute correlation amongst the 
FVIIa linker variants between sTF-induced activity stimulation and burial of the N-terminus into 
the activation pocket. 
 
Binding of FVIIa linker variants to sTF 
The physical binding of FVIIa variants to sTF was examined with the main purpose to investigate 
whether the failure of sTF to stimulate certain FVIIa variants (those with the largest truncations of 
the linker region) was due to an abolished interaction. The kinetics of sTF binding were very 
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similar for FVIIa, 86GS87-FVIIa, des86-FVIIa and des(85-86)-FVIIa, albeit with slightly slower 
association rate and faster dissociation rate for des(85-86)-FVIIa (Fig. 3 and Table 1). These FVIIa 
variants also exhibited indistinguishable degrees of sTF-induced activity enhancement. In contrast, 
des(83-86)- and des(84-86)-FVIIa bound sTF with dramatically different kinetics due to the 
association rates being approximately 80 times slower than those of the longer variants. However, 
once bound, the complexes of des(83-86)- and des(84-86)-FVIIa with sTF were virtually as stable 
as those of the FVIIa variants with a longer linker region. This suggest that an interactive interface 
is eventually formed which provides the same binding energy (affinity) but without a concurrent 
stimulation of the catalytic machinery located in the protease domain. 
 
Modeling of FVIIa linker variants in complex with TF 
For a functional FVIIa-TF complex to be formed, FVIIa must attain a conformation which is 
complementary to TF and accommodate specific exosite interactions with TF. Our striking 
experimental finding that the entire change of the functional properties of FVIIa occurred upon 
removal of the third residue from the linker asked for a plausible explanation. In order to 
investigate how the length of the linker connecting the EGF-like domains in FVIIa affects the 
ability of the molecule to form a fully functional complex, the linker was gradually truncated by 
one to four residues and an attempt to structurally explain the slow, non-productive TF binding of 
des(83-86)- and des(84-86)-FVIIa was made by generating structural ensembles for all of the Ca
2+
-
loaded FVIIa variants in the TF-bound form. The nature of the linker in the X-ray crystallographic 
structure of FVIIa bound to TF (2) encompasses both a β-sheet, pairing the two-residue β-strand 
composed of Thr-83 and His-84 with Phe-76 and Glu-77, and a short 310 helical fragment from 
Lys-85 to Asp-87. This suggests that partial unfolding of the helical element may make it possible 
for the FVIIa-TF complex to tolerate small deletions in the linker region with retained 
functionality, which is indeed what was experimentally observed. 
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    The structural characterization of the phenomenon was done in two manners. Firstly, the strain in 
the X-ray crystal structure introduced by truncations in the linker was gauged. For this purpose, an 
ensemble of possible linker conformations were initially generated using Rosetta's loop modeling 
application on the otherwise fixed structure of the FVIIa-TF complex. This approach revealed that 
in the case of a four-residue deletion, no combination of allowed backbone dihedral angles and 
atomic bond lengths could yield a linker conformation connecting the two flanking Cys residues 
without a chain break (not shown). For this simple reason, we conclude that it is very unlikely that 
one can truncate the linker by four residues and retain the interactions with TF (at least those seen 
in the crystal structure) required for a functional FVIIa-TF complex. Therefore, a second approach 
to evaluate the consequences of linker truncation on the tertiary structure of the FVIIa-TF complex 
by forcing ideal geometry (and hence loop closure) was employed. If four residues were deleted 
and the bond lengths idealized, the FVIIa-TF complex adopts a warped conformation in which 
FVIIa clamps TF causing it to bend significantly and deviate from the known structure. 
Interestingly, the structural ensembles using the native linker or a linker after deletion of one or two 
residues scored virtually identically (Fig. 4). Inspection of representative structures selected by 
clustering methods showed that for a one- or two-residue deletion the loop straightens to some 
extent and the characteristic helical fragment of the linker indeed unfolds, but it does so without 
greatly penalizing the overall score of the complex or the linker region. On the other hand, 
structures for the three- and four-residue deletions were energetically punished, in part, by their 
unfavorable backbone dihedral angles which could be confirmed by Ramachandran plots for the 
linker residues (Fig. 4). 
 
Influence of linker length and Gla domain on the activity of apo-FVIIa 
In the presence of 5 mM Ca
2+
, FVIIa and des(1-44)-FVIIa (Gla-domainless FVIIa) had similar 
amidolytic activities (Km and kcat) as measured with the substrate S-2288 (data not shown). NaCl in 
the range 0.1-0.3 M had a slightly stimulatory effect on the activity of both forms of FVIIa, an 
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effect which gradually decreased with increasing concentration (no net effect at 0.5 M) and turned 
inhibitory at higher concentrations (29). 
     In the absence of Ca
2+
, full-length and des(1-44)-FVIIa exhibited much lower amidolytic 
activity, but des(1-44)-FVIIa retained significantly higher activity than FVIIa as published (30). 
The residual activities of the apo (Ca
2+
-free) forms of FVIIa and des(1-44)-FVIIa were higher when 
the ionic strength was maintained with sodium chloride than with choline chloride (Fig. 5). 
Moreover, increasing the NaCl concentration (at least up to 0.6 M) gradually enhanced the activity 
of full-length and des(1-44)-FVIIa in the absence of Ca
2+
 (data not shown), whereas increasing the 
choline concentration had a marginal effect. This suggests that NaCl shields the charged Gla 
domain and further stimulates the amidolytic activity of FVIIa by saturation of a putative sodium 
site in the protease domain (31, 32). 
     With this background knowledge about the effects of various ions on and the properties of full-
length and Gla-domainless FVIIa in the absence of Ca
2+
, we studied the influence of the linker 
length. FVIIa retained about 7% amidolytic activity upon removal of Ca
2+
 from assay buffer 
containing 0.1 M choline chloride (Fig. 5). Similar residual activity was measured with 86GS87- 
and 86G87-FVIIa. As the linker length decreased, the FVIIa variants gradually retained more 
activity and des(83-86)-FVIIa possessed the same residual activity as des(1-44)-FVIIa (17-18%). 
The pattern was very similar when using NaCl as the salt, but the level of residual activity was 
generally twice as high and ranged from 13 to 35%, conceivably because of Na
+
-specific 
stimulation (Fig. 5). 
     Carbamylation, even when using a relatively low concentration of potassium cyanate (50 mM) 
to achieve a decreased but still measurable rate of activity loss with FVIIa in the presence of Ca
2+
, 
can apparently not distinguish between the degrees of N-terminus exposure in Ca
2+
-loaded and -
free FVIIa (data not shown). 
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DISCUSSION 
     Complex formation with TF is energetically driven by interactions involving the light chain of 
FVIIa, whereas establishment of the interactions involving the protease domain leads to allosteric 
stabilization of the active conformation of FVIIa (2-4). Together, this shapes a high-affinity, 
enzymatically active complex with FVIIa positioned for efficient substrate processing. In free 
FVIIa, the linker between the EGF-like domains in the light chain appears to be a hinge for 
interdomain flexibility (6, 27, 33). FVIIa bound to TF is motionally restricted and adopts an 
extended conformation which intuitively does not permit much reduction in linker length if the 
tight and productive interaction with TF, with participation of the light chain and protease domain, 
is to be maintained (2, 27, 33). Measurement of FVIIa amidolytic activity enhancement provides an 
unambiguous assessment of the stimulatory effect of TF looking exclusively at the catalytic 
machinery and the state of the S1 and proximal subsites without influence from exosites. We 
reduced the length of the linker by truncations at positions which, according to molecular dynamics 
simulations, minimally affected secondary structural elements. Importantly, the simulations of free 
FVIIa variants showed that the helical structure observed in FVIIa-TF is missing throughout. We 
were able to show that the TF-induced stimulation of FVIIa activity was abrogated when three 
amino acid residues are removed from the linker, whereas truncation of two residues, or an 
extension, were perfectly tolerated. The same, very dramatic pattern was observed for the physical 
interaction between FVIIa and sTF. Binding kinetics and affinity were indistinguishable from those 
of native FVIIa unless at least three residues were removed from the linker, in which case the 
association rate plummeted. These observations clearly demonstrated that a linker lacking three 
residues does not allow the physical separation of the light chain and protease domain parts of the 
TF-interactive interface to render allosteric activity enhancement and native affinity possible. The 
weakest part of the interface, that between the protease domain and TF, apparently capitulated and 
this resulted in loss of TF-induced activity increase. Finally, we found that a truncation of the linker 
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by four residues eliminated the negative impact of the Gla domain on the intrinsic activity of FVIIa 
in the absence of Ca
2+
. 
 
    The slower sTF association rates of des(83-86)- and des(84-86)-FVIIa might be explained by 
their preferential existence in energetically favorable conformations encompassing allowed 
dihedral angles. However, because of the relatively short linkers in these variants, these 
conformations do not allow a productive interaction with sTF and establishment of the contacts 
seen in the crystal structure of the complex. The conformations which would fit to TF and form all 
the interactions known from the structure are, if at all possible, extremely unfavorable and scarce. 
This would represent a particular problem if FVIIa initially docks with the protease domain, in 
itself a low-affinity interaction with sTF. In this case, an imminent clash or a suboptimal distance 
between the two parts of the TF-interactive interface on FVIIa (protease domain and Gla/first EGF-
like domains) would prevent the ensuing tethering of the complex by the contacts between the light 
chain of FVIIa and TF. This binding pathway has been inferred from transition state analysis and 
association rate studies of the FVIIa:sTF complex formation (34, 35). There is evidence in support 
of the notion that Gln-88 acts as hinge residue in the linker between the EGF-like domains in FVIIa 
(6). The first EGF-like domain has been resolved by X-ray crystallography in several structures of 
FVIIa in complex with TF with a similar domain configuration, well represented by the structure of 
Banner et al. (2). To our knowledge, only two structures are available of the free form of FVIIa 
with the first EGF-like domain resolved (6, 26). The first EGF-like domains, as represented in the 
structures of TF-bound and free FVIIa, cannot be overlaid without a clash between TF and the 
protease domain of FVIIa when oriented as in free FVIIa. An overlay of the protease domain 
structures does not cause a corresponding clash of the first EGF-like domain with TF. To further 
substantiate this interesting observation, we explored the configurational space around Gln-88. We 
found that the population of models which does not clash with TF is larger when the protease 
domain interacts with TF than when the light chain does (Figs. S1 and S2). This would indicate that 
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it is entropically favorable for the FVIIa protease domain to initiate complex formation with TF 
and be in agreement with the experimentally supported binding pathway (34, 35). 
 
     Of the two parts of the TF-interactive interface on FVIIa located on opposite sides of the linker 
region, the one involving the light chain contributes the majority of the binding energy (3). The 
virtually normal rate of dissociation of the established complex between sTF and des(83-86)- or 
des(84-86)-FVIIa, combined with the inability of sTF to stimulate the activity of these variants, 
thus suggests that the light chain is engaged in its native interactions with sTF with retained affinity 
and that the protease domain simultaneously interacts with sTF in an alternative, non-native mode 
which is capable of maintaining the normal affinity but not forming the allosterically important 
contacts between enzyme and cofactor. These crucial contacts are retained in the complexes 
between sTF and FVIIa variants lacking only one or two residues in the linker. The slow rate of 
association between des(83-86)- or des(84-86)-FVIIa and sTF suggests that a large proportion of 
the docking events mediated by the protease domain does not result in the formation of a stable 
complex because the suboptimal linker length forces the protease domain to slide relative to sTF to 
allow the light chain to bind. This is compatible with and a consequence of the mentioned 
preference of the FVIIa variants to exist in an energetically favorable conformation. At some stage 
during the transition process from encounter to stable complex, neither the initial nor the final 
interactions between FVIIa and sTF are established making the complex vulnerable and prone to 
dissociation. An alternative explanation for the binding kinetics (slow association and normal 
dissociation) of for instance des(84-86)-FVIIa could be that only a small fraction of the molecules 
are in a conformation which is at all compatible with sTF binding but do form the complex as we 
know it. However, this situation is less plausible due to the lack of detectable stimulation by sTF. 
Interestingly, the interaction of the isolated light chain of FVIIa with sTF, which like those of 
des(83-86)- and des(84-86)-FVIIa is of considerably lower affinity than that involving FVIIa, is 
primarily characterized by a much faster dissociation rate with a marginally affected association 
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rate (3). Altogether, the experimental and molecular modeling data obtained with the FVIIa 
variants with the shortest linkers support the hypothesis that FVIIa forms an encounter complex 
with sTF involving interactions between the protease domain and the cofactor, after which the light 
chain engages in binding to tether the proteins to each other. Our findings regarding FVIIa binding 
to TF are almost certainly pertinent also for the binding of FVII and for its ensuing activation. 
Enzyme and zymogen employ the same interactive interfaces on both sides of the linker in their 
very similar, perhaps identical, set of contacts with TF (36). 
 
     The linker region between the two EGF-like domains varies in length and sequence between the 
homologous factors VII(a), IX(a) and X(a). This may represent adaption to their respective cofactor 
(TF, factor VIIIa and factor Va, respectively) and serve as one of several players in the 
optimization of the intermolecular interplay. Factor IXa has the shortest linker and an extension has 
been shown to result in a diminished activity enhancement upon assembly with factor VIIIa (37). 
We have shown that the linker length is critical also in FVIIa and that a limited truncation results in 
a TF binding defect and lack of activity enhancement upon TF association. An extension will, at 
some point, most likely also become unfavorable and have functional consequences. Thus the 
linker length appears to be important for an optimal interaction, plausibly serving a spacer function 
between key cofactor-interactive interfaces on the enzyme surface. Moreover, data with factor Xa 
indicate that the linker sequence becomes more exposed and available for protein-protein 
interactions upon activation of the zymogen (38). This could be part of the explanation for the 
higher affinity of factor Va for factor Xa compared with X (39), definitely also involving 
rearrangements in the protease domain ensuing zymogen cleavage. An optimal combination of 
linker length and availability might be an important interaction determinant in this family of 
coagulation factors. 
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MATERIALS AND METHODS 
Proteins and reagents 
FVIIa, des(1-44)-FVIIa and sTF were prepared as previously described (11-13). Their 
concentrations were determined by absorbance measurements at 280 nm using absorption 
coefficients of 1.32, 1.26 and 1.5, respectively,  for a 1-mg/ml solution and molecular masses of 50, 
46 and 25 kDa, respectively. Biotin-E219C-sTF, a variant of sTF biotinylated on the introduced 
unpaired Cys residue, was a gift from Dr. Henrik Østergaard, Haemophilia Biochemistry, Novo 
Nordisk A/S. Human factor X (FX) was purchased from Enzyme Research Laboratories (South 
Bend, IN). The chromogenic substrates S-2288 and S-2765 were from Chromogenix (Milan, Italy), 
phospholipid-TGT from Rossix (Mölndal, Sweden), and potassium cyanate from Fluka. 
 
Mutagenesis, expression and purification of FVIIa variants 
Residues in FVII were deleted or inserted using the QuikChange kit (Stratagene, La Jolla, CA) and 
the human FVII expression plasmid pLN174 (14). The following sense (and complementary 
reverse) primers were used to generate the FVIIa linker variants: des86-FVIIa, 5’-
CGGAACTGTGAGACGCACAAGGACCAGCTGATCTGTGTG-3’; des(85-86)-FVIIa, 5’-
CGGAACTGTGAGACGCACGACCAGCTGATCTGTGTG-3’; des(84-86)-FVIIa, 5’-
CGGAACTGTGAGACGGACCAGCTGATCTGTGTG-3’; des(83-86)-FVIIa, 5’-
GGCCGGAACTGTGAGGACCAGCTGATCTGTGTGAACG-3’; 86G87-FVIIa, 5’-
GAGACGCACAAGGATGGCGACCAGCTGATCTGTGTG-3’; 86GS87-FVIIa, 5’-
GAGACGCACAAGGATGGCAGCGACCAGCTGATCTGTG-3’. The insertions between wild-
type residues 86 and 87 in the two latter variants are underlined. Plasmids were prepared using a 
QIAfilter plasmid midi kit (Qiagen, Valencia, CA) and the introductions of the desired changes 
confirmed by sequencing. Baby hamster kidney cell transfection and selection, as well as protein 
expression, purification and autoactivation were performed as described (4, 15). 
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FVIIa activity assays 
All assays were routinely performed at ambient temperature in 50 mM Hepes, pH 7.4, containing 
0.1 M NaCl, 5 mM CaCl2, 0.1% (w/v) PEG 8000 and 0.01% (v/v) Tween 80 (assay buffer). The 
amidolytic activity was measured using 300 nM FVIIa, des(1-44)-FVIIa or FVIIa linker variants in 
assay buffer. When studying the Ca
2+
 dependence of the activity, 2 mM EDTA replaced CaCl2 in 
the assay buffer. Either fixed (1 mM) or varying (0.2-12.8 mM) concentration of S-2288 was used. 
The amidolytic activity dependence on ionic strength and Na
+
 was also measured using 1 mM S-
2288 in 50 mM Hepes, pH 7.4, containing 5 mM CaCl2 or 2 mM EDTA, 0.1% (w/v) PEG 8000 and 
0.01% (v/v) Tween 80, by including NaCl or choline chloride at concentrations ranging from 0.1 to 
0.6 M. The effect of the cofactor TF on the amidolytic activity was assessed by mixing 10 nM 
FVIIa variant, no or 2-200 nM sTF, and 1 mM S-2288. Those FVIIa variants that were not 
stimulated at an [sTF] of 200 nM were also tested at 2 and 5 µM sTF. For proteolytic activity 
assessment, 1 µM FX was incubated with 50 nM FVIIa variant in a total volume of 100 µl for 20 
minutes, whereafter FX activation was terminated by the addition of 50 µl assay buffer containing 
20 mM EDTA instead of CaCl2. The formed FXa was measured by the addition of S-2765 
substrate (final concentration 0.5 mM). Alternatively, FX was used at a concentration of 150 nM in 
the presence of 25 µM phospholipids. Enzymatic activities were continuously monitored for 20 
min (FVIIa or FVIIa:sTF amidolytic activity) or 5 min (FXa amidolytic activity) using a 
SpectraMax 190 kinetic microplate reader (Molecular  Devices, Sunnyvale, CA). 
 
Carbamylation 
The FVIIa variants alone (2 µM) or FVIIa variants (0.5 µM) in the presence of 10 µM sTF were 
incubated with 0.2 M potassium cyanate in 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM 
CaCl2, 0.1% (w/v) PEG 8000 and 0.01% (v/v) Tween 80. At time zero and after 20 and 60 minutes, 
20-µl samples were transferred to a well containing 160 µl buffer and the amidolytic FVIIa activity 
was measured after the addition of 20 µl S-2288 substrate (final concentration 1 mM). 
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Surface plasmon resonance analyses 
Biotin-E219C-sTF was injected at a concentration of 150 nM (in the assay buffer described above) 
and a flow rate of 20 µl/min for 100 s over a streptavidin (SA) chip (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden), resulting in an immobilization level of 90-120 resonance units. FVIIa, 
des86-FVIIa, des(85-86)-FVIIa and 86GS87-FVIIa were injected in two-fold dilutions in assay 
buffer from 64 to 4 nM, whereas des(84-86)- and des(83-86)-FVIIa were injected in 2-fold 
dilutions from 640 to 40 nM, all at a flow rate of 20 µl/min. Association and dissociation phases 
lasted for 4 and 10 minutes, respectively. Regeneration between runs was done with a 30-s pulse of 
50 mM EDTA, pH 7.4, at 20 µl/min. All experiments were conducted using a Biacore 3000 
instrument and evaluated using a 1:1 model in Biaevaluation 4.1 supplied by the manufacturer. 
 
Molecular dynamics simulations 
Free FVIIa and variants thereof with a deleted linker region between the EGF-like domains were 
analyzed by molecular dynamics. The models were based on the crystal structure of FVIIa in the 
FVIIa-TF complex (2, PDB entry code 1dan) after removal of the co-crystallized, covalently bound 
active-site inhibitor and TF. In FVIIa, the last 11 amino acid residues of the light chain are missing, 
but no attempts have been made to model the missing part to avoid perturbation of the X-ray data. 
The truncated structures were generated by deleting linker residues and rebuilding the remaining 
linker region. A final relaxation was conducted using 250 steps of conjugated gradient (CONJ) 
energy minimization in CHARMm (Accelrys Inc., San Diego, CA) using the CHARMM27 force 
field (16). 
Molecular dynamics simulations were then performed using the program NAMD 2.5 (17) and the 
CHARMM27 force field for protein. The 9 calcium ions embedded in the X-ray crystal structure 
were preserved. The proteins were solvated (with TIP3P water molecules) in a periodic, truncated 
octahedron with box boundaries at least 6 Å from any given protein atom, and water molecules 
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were treated as rigid. Sodium and chloride ions were added to obtain an ionic strength of 
approximately 0.15. The resulting systems were composed of ~16,000 water molecules, ~ 42 
sodium ions,  ~ 43 chloride ions, and 9 calcium ions (in total approximately 54,000 atoms). A cut-
off of 12 Å (switching function starting at 10 Å) for van der Waals interactions was applied. The 
particle mesh Ewald (PME) method was used to compute long-range electrostatic forces in all 
simulations (18). An integration time step of 1 fs was used. Langevin dynamics was applied to 
enforce constant temperature (T = 300 K) conditions. The Langevin dampening coefficient was set 
to 5 ps
-1
. The pressure was maintained at 1 atm using the hybrid Nosé-Hoover Langevin piston 
method with a decay period of 100 ps and a dampening time constant of 50 ps (19, 20). Each 
system was equilibrated in the constant number, pressure and temperature (NpT) ensemble and 
simulated for at least 100 ns. The secondary structure of the linker was assigned using STRIDE 
(21) and the corresponding logos were generated by WebLogo (22). 
 
Molecular modeling 
The X-ray crystallographic structure of the FVIIa-TF complex (2, PDB entry code 1dan) was 
subject to structural modeling using the Rosetta modeling suite (23). It was processed by a Rosetta 
high-resolution protein structure refinement protocol consisting of three steps. First, stripping the 
structure of non-protein matter and patching the γ-carboxylated glutamic acid residues, then 
idealization of the geometry by IdealizeMover, and, finally, structural refinement with backbone 
perturbations and sidechain repacking by FastRelaxMover. This protocol was set up via the 
RosettaScripts interface (24). Using this protocol, 1,000 decoy models were generated for the wild-
type FVIIa-TF complex and each of the complexes between TF and FVIIa with a truncated linker 
(des86-, des(85-86)-, des(84-86)-, and des(83-86)-FVIIa, respectively). The decoy models which 
scored best (lowest 10% evaluated by the Rosetta score 12 energy function) were chosen as the 
representative ensemble of the most probable structures. In this way, possible linker conformations 
were sampled while allowing for some flexibility in other parts of the structure including, of 
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particular interest, the interface between FVIIa and TF. Finally, the generated decoy complexes 
were structurally analyzed with attention on the FVIIa-TF interface (using InterfaceAnalyzer (25)) 
and the linker residues in FVIIa (the sequence flanked by the last Cys residue of the first EGF-like 
domain and the first Cys residue of the second EGF-like domain). 
   The configurational (φ,ψ)-space of backbone dihedral angles around the hinge residue Gln-88 
was sampled in the X-ray crystallographic structure of FVIIa-TF (2) to quantify the available 
freedom of motion in FVIIa not causing a clash with TF. Two scenarios were investigated; one 
with the FVIIa protease domain aligned with TF as in the crystal structure and the FVIIa light chain 
rotated (roaming), and another with the FVIIa light chain aligned with TF and the protease domain 
roaming. The (φ,ψ)-space was exhaustively searched using 2 degree increments and all 32,400 
generated decoys were scored without any further processing by the full-atom force field in Rosetta 
(score12). 
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Table I. Kinetic parameters of the binding of FVIIa and FVIIa linker variants to sTF 
measured by surface plasmon resonance. Biotinylated sTF was captured on a 
streptavidin-coated chip and the binding of serial dilutions of the FVIIa variants was 
measured. The kinetic parameters (mean ± SEM) were determined using the Biacore 3000 
evaluation software (Biaevaluation 4.1) and a model based on 1:1 binding stoichiometry. 
 
Ligand  kon (x 10
5
M
-1
s
-1
) koff (x 10
-3
s
-1
) Kd (nM) 
86GS87-FVIIa 3.7±0.3  1.2±0.1  3.3±0.3 
FVIIa  4.5±0.3  1.3±0.2  3.0±0.4 
des86-FVIIa  3.7±0.2  1.2±0.0  3.3±0.1 
des(85-86)-FVIIa 2.7±0.4  1.8±0.1  6.8±0.6 
des(84-86)-FVIIa 0.054±0.003  1.7±0.2  310±30 
des(83-86)-FVIIa 0.052±0.003  1.4±0.0  270±10 
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FIGURE LEGENDS 
 
Figure 1. Structures and secondary structure assignments of the linker region in free FVIIa 
variants based on molecular dynamics simulations. Top, representative structures (30-ns 
snapshots) showing the distance in Å (illustrated by a grey line) between the C atoms of Cys-81 
and Cys-91 (full-length numbering). The backbone traces start at residue Phe-71 in the first EGF-
like domain and the sidechains are shown for all residues present in the linker region and the 
flanking Cys residues. Bottom, secondary structure assignments of the linker region based on the 
simulations shown as weblogos (22). The one-letter secondary structure codes are: H, -helix; G, 
310-helix; I, PI-helix; E, extended conformation (sheet); B, isolated bridge; T, turn; C, random coil 
(none of the previous). 
 
Figure 2. Functional response of FVIIa linker variants upon sTF association. A, 10 nM FVIIa 
(green circles), des86-FVIIa (□), des(85-86)-FVIIa (■), des(84-86)-FVIIa (○) or des(83-86)-FVIIa 
(●) was incubated with the indicated concentrations of sTF and 1 mM S-2288. The ratio of the 
amidolytic activities of a FVIIa variant in the presence and absence of sTF is shown as a function 
of [sTF]. The results obtained with des(83-86)- and des(84-86)-FVIIa are virtually identical and the 
data points representing des(84-86)-FVIIa (the open circles) are therefore not visible. B, the 
corresponding data shown for 86G87-FVIIa () and 86GS87-FVIIa (▲) with the FVIIa data from 
A included for comparison. The data shown are from a representative experiment (n = 4). 
 
Figure 3. Kinetics of the binding of FVIIa linker variants to sTF measured by surface 
plasmon resonance. Corrected sensorgrams are shown for the interactions between sTF and 
des(84-86)-FVIIa (A), des(85-86)-FVIIa (B), FVIIa (C), and 86GS87-FVIIa (D). Des(84-86)-FVIIa 
was injected in a 2-fold dilution series in concentrations from 40-640 nM (represented by the 
curves from bottom to top), whereas the other three variants were injected in a 2-fold dilution series 
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in concentrations from 4-64 nM. Experimental data are in black and fitted data in red. Binding 
curves for des(83-86)-FVIIa and des86-FVIIa are not shown here, but the derived constants are 
included in Table 1.  
 
Figure 4. Molecular modeling of FVIIa-TF complexes. Average scores and standard deviations 
in negative Rosetta energy units (REUs) of the best scoring 10% of the models of complexes 
between FVIIa linker variants and TF are shown. The Ramachandran plots visualize the backbone 
dihedral angles (phi, psi) of the amino acid residues in the linker region in these complexes. wt, 
wild-type FVIIa; desX-FVIIa, FVIIa variant with residue(s) X deleted. 
 
Figure 5. Residual amidolytic activity of the apo (Ca
2+
-free) forms of FVIIa linker variants. 
The residual activity after the removal of Ca
2+
 from FVIIa, FVIIa linker variants and des(1-44)-
FVIIa was measured in the presence of 0.1 M NaCl (black bars) or choline chloride (red bars). All 
data are mean ± S.D., n = 3. 
 
Figure S1. Contour-plot of the clash score (in Rosetta Energy Units) upon perturbation of Gln-88 
backbone dihedral angles when the LC of FVIIa is “roaming”. The contour level corresponding to a 
reasonable cut off clash score (zero) is drawn with thick lines. The circle (orange) shows the native 
dihedral angles observed in the crystal structure. 
 
Figure S2. Contour-plot of the clash score (in Rosetta Energy Units) upon perturbation of Gln-88 
backbone dihedral angles when the HC of FVIIa is “roaming”. The contour level corresponding to 
a reasonable cut off clash score (zero) is drawn with thick lines. The circle (orange) shows the 
native dihedral angles observed in the crystal structure. 
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Figure S1 
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Figure S2 
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4. Intrinsic tenase complex 
4.1 Trauma-site directed cofactor function of FVIIIa 
4.1.1 Prelude 
Manuscript 4 described a study of the membrane-interaction of the two C-terminally 
positioned tandem discoidin domains of FVIIIa, FVIII C1 and FVIII C2. Parallel 
simulation trajectories of spontaneous membrane-binding of achieved for each domain 
through the use of a recent membrane-mimetic model(Y Zenmei Ohkubo, Pogorelov, 
Arcario, Christensen, & Tajkhorshid, 2012). The FVIII C1 and FVIII C2 share ~40 % 
sequence identity and the domains cut-out from the crystal structure of FVIII (PDB entry 
code 3cdz(Ngo, Huang, Roth, Furie, & Furie, 2008)) structurally align with sub-Ångstrøm 
RMS. Considering these similarities, our results are unexpected and surprising. 
 
The actual mechanism of protein binding to membranes is often complex because it is a 
combination of several important components. One important aspect in this context is the 
hydrophobic partitioning where parts of the protein enter the membrane to be shielded 
from water. This (partial) insertion of hydrophobic residues or loops follows the initial 
attraction and contact with the membrane, which is governed by electrostatics, likely the 
most important long-range interaction leading to protein-membrane binding.(Bardelle, 
Furie, Furie, & Gilbert, 1993) At the continuum level of theory, Poisson-Boltzmann theory 
can be used to understand the interfacial region between the membrane and water. 
However, inherent limitations of such descriptions does not account for local variation via 
e.g. membrane-composition and specific interactions that can lead to accumulation of 
lipids near the binding region. Furthermore, the conformation of the protein plays a critical 
role for the membrane-binding. In the case of FVIII, intriguingly, the non-activated and the 
activated molecules exhibit distinct binding-dependencies of the PS component of the 
membrane even though there are no cleavage sites within the membrane-anchoring 
modules (FVIII C1 and FVIII C2).(Engelke, Lippok, Dorn, Netz, & Rädler, 2011) 
 
Our simulation results reveal that both FVIII C2 and FVIII C1 insert peripherally via 
extruding β-hairpin loops (the spikes, S1-S4), but whereas FVIII C2 stands almost normal 
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
to the membrane plane, FVIII C1 can adopt several moderately to highly tilted 
orientations, possibly enabling the full-length cofactor (FVIII) to accommodate an 
appropriate interaction in the tenase complex, FVIIIa:FIXa, and in the ternary complex 
FVIIIa:FIXa:FX. 
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Abstract  
A recently developed membrane-mimetic model was applied to study the membrane-
interaction of the two anchoring C2-like discoidin domains of human coagulation factor 
(F)VIIIa. Both individual domains, FVIII C1 and FVIII C2, were observed to enter the 
phospholipid membrane unguided by partial or full insertion of the extruding loops (the 
spikes). FVIII C1 and FVIII C2 adopted different molecular orientations in the membrane-
bound state; FVIII C2 roughly positioned normal to the membrane plane while FVIII C1 
displayed a multitude of tilted orientations. The results indicate that FVIII C1 may be 
important in modulating the orientation of the FVIIIa molecule to accommodate the 
interaction with FIXa, which is anchored to the membrane via its γ-carboxyglutamic acid-
rich (Gla)-domain. Additionally, a structural change was observed in FVIII C1 in the coiled 
main chain leading into the first spike. A tight interaction with one lipid per domain, 
similarly to what have been suggested for the homologous FVa C2, is characterized. 
Finally, we rationalize known FVIII antibody epitopes and the scarcity of documented 
hemophilic missense mutations related to improper membrane binding of FVIIIa based on 
the prevalent non-specificity of ionic interactions in the simulated membrane-bound states 
of FVIII C1 and FVIII C2.  
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Introduction 
Using theoretical and computational modeling, a detailed characterization of the individual 
C2-like discoidin domains from human coagulation factor (F)VIIIa in the membrane-
bound state with respect to lipid specificity, molecular orientation and flexibility is 
presented. These are properties of fundamental importance for the cofactor activity of 
FVIIIa in the intrinsic tenase (FX activating) complex. The molecular dynamics (MD) 
simulation technique provides spatial and temporal resolution fine enough for generating 
detailed information on the atomic level of the membrane binding and lipid interaction of 
the FVIIIa C2-like domains. In order to expedite the dynamics of membrane lipids, the use 
of a Highly Mobile Membrane-mimetic Model (HMMM)(1) is adopted. This enables the 
generation of multiple independent parallel trajectories and hence, a statistical 
representation of the dynamics becomes feasible.  
 
The biochemical processes governing blood clotting is classically represented by a 
‘waterfall’ or ‘cascade’ model(2)(3). Two distinct pathways (intrinsic vs extrinsic) funnel 
into a common amplification phase where activated FX (FXa) is generated which, together 
with its cofactor FVa, is responsible for the burst of thrombin that subsequently leads to 
fibrin clot formation. The biomolecular components FVIII and FIX are circulating the 
bloodstream as the inactive precursors that, upon activation, assemble on a phospholipid 
surface into the highly potent tenase complex. Hemophilia A is characterised by deficiency 
of FVIII observed as low levels or dysfunction of the protein procofactor or the presence of 
inhibitory antibodies and is by far the most common bleeding disease.(4)  
 
A pivotal aspect of the coagulation cascade is the ability of restricting blood clotting to the 
injury site. The platform for this spatial localization is provided by the activated platelet 
membrane surfaces, which attract and stimulate activity by means of both membrane 
composition and the presence of elevated levels of certain cofactors to the coagulation 
enzymes. The tenase components FVIIIa and FIXa have the ability to selectively recognize 
this platform, and once properly bound and the binary complex formed, catalytic efficiency 
of FIXa is up-regulated by approximately five orders of magnitude(5). Their membrane 
binding modes, however, are quite different; FIXa is anchored to the membrane by its 
vitamin K-dependent γ-carboxyglutamic acid-rich (Gla)-domain while the membrane-
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targeting modules of FVIIIa are the two C2-like discoidin domains, C1 and C2, which 
recognize phosphatidylserine (PS)-containing platelet or endothelial cell membranes in a 
Ca2+-independent manner(6). Since either domain alone, FVIII C1 or FVIII C2, by itself 
seemingly has the ability to recruit the entire cofactor molecule to phospholipid 
membranes(7), optimal biological activity most certainly requires both.  
 
The active cofactor molecule, FVIIIa, is a trimer and consists of five major domains (A1, 
A2 and the light chain A3-C1-C2) with a total of >1,200 amino acid residues. The 
structural topology of the homologous C2-like domains is that of lectin and commonly 
known as a jelly-roll β-barrel (Fig. 1A); eight anti-parallel β-strands are arranged in two 
major β-sheets, wrapped to form the barrel and then flattened to a sandwich-like shape.(8) 
Connecting the β-strands at the bottom of the barrel are four hairpin loops also called the 
spikes (S1-S4) or fatty feet(9), the latter designation being due to the presence of multiple 
solvent exposed hydrophobic residues. These spikes are of particular importance for 
platelet membrane-aided functionalities because S1-S4 are hypothesized to insert into the 
hydrophobic core of the phospholipid membrane(10)(11). For this reason, much attention 
has been dedicated in the literature to elucidate how affinity and specificity of the FVIIIa 
molecule (and FVIII C2 on its own) toward phospholipid membranes is facilitated by the 
residues in these spikes (alanine mutagenesis(12), motif mutagenesis(13) and loop-
swaps(9)). The primary membrane-anchoring domain of FVIIIa is conventionally thought 
to be the C2 domain. Recently, however, several studies have emphasized the important 
role of the C1 domain in the membrane-mediated cofactor function of 
FVIIIa.(14)(7)(15)(16)  
 
Previous studies on the molecular orientation of FVIIIa suggest a crystal structure-like 
domain configuration with a membrane-bound configuration in which the molecule is 
close to perpendicular (or slightly tilted) and both FVIII C1 and FVIII C2 are peripherally 
inserted in the membrane.(17)(18)(19) A fundamentally different interaction, requiring 
large scale domain rearrangements to accommodate a binding mode where solely FVIII C2 
interacts with the membrane and is deeply inserted, has been suggested based on the cryo-
electron microscopy technique in conjugation with a membrane model consisting of lipids 
assembled on nanotubes.(20)(21)(22)  
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The article is structured as follows. The protein-lipid interaction of each of the two 
membrane-anchoring discoidin domains from human FVIIIa (FVIII C2 and FVIII C1) is 
characterized, and a PS-binding motif is described. The achieved membrane-bound states 
are discussed in relation to haemophilic disease mutations, antibody binding epitopes, and 
a putative tenase complex model. 
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Materials and Methods 
Molecular Dynamics Simulations. 
Structures and Setup of the HMMM. 
The starting structures of the discoidin C2-like domains were taken from the crystallized 
B-domainless human FVIII with PDB entry code 3cdz(17) (residues 2021-2172 for FVIII 
C1; residues 2173-2332 for FVIII C2). It can be assumed that there is no structural 
distinction between said domains in FVIII and FVIIIa neither in the context of the full-
length (pro)cofactor nor cut-out on their own. pKa calculations were done using 
PROPKA(23) to verify that the standard protonation states appropriately represent a pH 
value of 7; arginines and lysines are positively charged, aspartic and glutamic acids are 
negatively charged, and histidines are neutral.  
 
To assemble the HMMM surface patch(1), short-tailed (st-)lipid molecules truncated at the 
C5 carbon atom containing a PS headgroup were packed to sandwich a layer of 1,1-
dichloroethane (DCLE) solvent molecules with the headgroups facing the water phase and 
acyl chains against the DCLE phase using Packmol(24). 
 
The individual C2-like domains (Fig. 1A) were then hand placed such that the β-barrel 
central axis (the third principal axis of inertia) was oriented approximately perpendicular (θ 
=~ 0; Fig. 1B) to the membrane plane and with the hydrophobic membrane-anchoring 
spikes (S1 is residues 2043-2046 for FVIII C1 and 2196-2203 for FVIII C2; S2 is residues 
2056-2059 for FVIII C1 and 2213-2217 for FVIII C2; S3 is residues 2089-2096 for FVIII 
C1 and 2248-2255 for FVIII C2; S4 is residues 2156-2159 for FVIII C1 and 2313-2316 for 
FVIII C2) of the domain facing the membrane (Fig. 1B). The resulting systems (denoted 
C2/HMMM and C1/HMMM) which contained an HMMM patch and a C2-like domain 
were solvated using the Solvate functionality in VMD(25) and neutralized with sodium 
(Na+) ions. Water molecules placed by Solvate in the organic solvent phase of the 
membrane (due to relatively large gaps) were removed. A reference system was prepared in 
a similar fashion and contained only FVIII C2 in bulk water (C2/Soln) at physiological 
0.15 M NaCl. Detailed overview and component count of the prepared systems can be seen 
in Table 1.  
  
  
153 
 
Simulation details. 
The prepared systems (C2/HMMM and C1/HMMM) were treated in the following manner. 
The potential energy was initially minimized by applying the conjugated gradient method 
for 5,000 steps. Then the systems were subjected to a short (100 picosecond (ps)) 
simulation in the NPT ensemble with constant membrane plane (x/y) aspect ratio to resolve 
imperfect packing of DCLE molecules, and hence equilibrate the membrane thickness. 
During this phase, the area per lipid in the systems was free to change and resulting values 
ranged from 85.0 Å to 88.5 Å (prior to protein insertion), corresponding to reasonable 
values for fluid phase lipid bilayers(26). Once the thickness had adjusted, a mild harmonic 
constraint with force constant 0.01 kcal/mol was applied on the C2 carbon atoms of all st-
lipids to restrain them toward the average position of all C2 atoms in their respective 
membrane leaflet. This was done to gently reduce vertical diffusion (along the z-axis) of 
the st-lipids and to discourage lipid inversion. After this point, the production MD 
simulations was performed 5 times independently of each system in the NPzAT ensemble 
with the target P = 1 atm and T = 310 K controlled by the Nosé-Hoover Langevin piston 
barostat(27)(28) and the Langevin thermostat (damping coefficient: 5/ps)(29), respectively. 
Throughout, pressure coupling was applied along the z-axis (piston damping coefficient: 
5/ps, piston period: 100 femtosecond (fs), and piston decay: 50 fs). Long-range 
electrostatic forces were calculated using the Particle Mesh Ewald (PME) method(30)(31) 
with a grid spacing of approximately 1 Å and a fourth-order spline for interpolation. 
Electrostatic forces were updated every 4 fs. Van der Waals interactions were cut off at 12 
Å in combination with a switching function beginning at 10 Å. Periodic boundary 
conditions were applied in x-, y-, and z-directions. All MD simulations were performed 
using the NAMD 2.9 software package(32) with the CHARMM36 force field(33), CMAP 
correction(34) and the TIP3P water model(35). An integration time step of 2.0 fs was used 
for the velocity Verlet algorithm with SHAKE(36). All analysis and visualization of 
molecular structures was done using the Visual Molecular Dynamics (VMD) 1.9.1 
software package(25); calculation of van der Waals and electrostatic interaction energies 
between protein and the HMMM was done using the NAMDEnergy plugin without the 
PME. Plots were prepared using Grace (xmgrace, http://plasma-
gate.weizmann.ac.il/Grace).  
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Calculation of Order Parameters for Backbone amide (C-N) vectors 
The amide vector was defined for each individual amino acid residue as the normalized 
vector pointing from the backbone carbonyl carbon C (atom) to the backbone amide 
nitrogen N. The protein was aligned over the trajectory by a root mean square deviation-
based structural alignment on heavy atoms. Following this, nematic order parameters were 
calculated as(37) 
 
  
  
 
 
〈?̂?   ̂ 〉
  
 
 
 
 
where   
  is the order parameter for the i’th residue,  ̂  is a unit vector describing the 
trajectory-averaged C-N direction, and ?̂?  is the instantaneous atomic unit vector. The 
brackets imply averaging over the trajectory. The frame rate for the analysis was 10 frames 
per ns. The order parameters assume values from 0 to 1 and they are a measure of how 
much the atomic amide vectors fluctuate around their respective trajectory-averaged 
directions, indicating the flexibility of the backbone at that given position in the structure. 
 
Construction of a putative model of the FVIIIa:FIXa tenase complex 
A putative model of the FVIIIa:FIXa tenase complex was constructed on the basis of the 
recently published X-ray crystallographic structure of the FVa:FXa prothrombinase 
complex from the venom of the eastern brown snake(38). The light chain of FIXa in the 
constructed tenase complex was modeled in a FVIIa-like extended conformation(39), 
instead of an arched conformation adopted by procine FIXa with a partially disordered 
Gla-domain(L chain of PDB entry code 1pfx(40)). Homologous molecules (FVa versus 
FVIIIa and FIXa versus FXa) were aligned and the building of missing loops was done 
with the molecular modeling package Quanta(Molecular Simulations Inc., San Diego, CA). 
The atomic coordinates of the model are available upon request to the authors. 
 
Results and Discussion 
The positively charged C2-like domain is attracted to the negatively charged phospholipid 
membrane due to favorable electrostatic interactions, shown by the calculated non-bonded 
interaction energies between the domain and the membrane (Figs. 2, bottom & S1, in the 
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Supporting Material). As we describe in the following, the five parallel FVIII C2 
trajectories converged into a stable membrane-bound state with comparable spike insertion 
depths and domain tilt angles (Fig. 1C). Interestingly, while FVIII C1 carries a larger net 
positive charge, +9 e for FVIII C1 and +4 e for FVIII C2, respectively, it is FVIII C2 that is 
the stronger electric dipole with 450.1 D compared with 421.8 D (based on the X-ray 
crystallographic structure; differences are further accentuated during the course of the 
simulations, data not shown). The amino acid residues directly involved in the membrane-
binding process and their specific sequence of interaction varied depending on the 
orientation of the studied FVIIIa domain upon membrane contact. In the membrane-bound 
state of FVIII C2, a snug PS-specific interaction via either R2220 or R2320 (Fig. 3) was 
achieved. The same result was not observed for the four membrane binding FVIII C1 
trajectories (one trajectory did not result in spontaneous binding and was discarded from 
further analysis) which instead displayed a broad range of domain tilt angles and 
significant structural modulations. Furthermore, the characteristic tight PS-specific 
interaction with the corresponding arginine R2320-counterpart in FVIII C1, R2163, was 
only established in a single trajectory. The observed tightly bound lipid is further stabilized 
by polar interactions of the amino and phosphate groups with residues of the protein, but 
these depended on the lipid orientation at the PS specificity pocket(10) counterpart in 
FVIII C1 or FVIII C2. These findings show that either domain can achieve a protein-lipid 
interaction that is specific to PS. However, the observed propensities are surprising 
considering experimental reports, which show that the FVIII C2 binding to vesicles is not 
specific to PS.(41) 
 
 FVIII C2 adopts a perpendicular membrane-bound configuration and achieves a PS-
specific interaction. 
The converged molecular orientation is characterized by the domain tilt angle (Fig. 1B), 
which exhibited shallow angles of 20-40 degrees (Fig. 4, top) and hence is consistent with 
the previously proposed perpendicular (or slightly tilted) mode of interaction(17)(18) and 
also entry in the Orientation of Proteins in Membranes (OPM) database(42) for FVIII 
(PDB entry code 2r7e(43)). Regions of FVIII C2 in contact with the membrane were 
largely confined to the spikes (Fig. 5, top). No significant structural modulations are 
observed for FVIII C2 as indicated by the calculated order parameters both for the 
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membrane-bound simulations, C2/HMMM, (Fig. 5, top) and for the FVIII C2 placed in 
bulk water, C2/Soln (Fig. S2), albeit a mild overall stabilization is observed and consistent 
with a recently published study of FVIII C2 by hydrogen-deuterium exchange mass 
spectrometry(44). The extruding hydrophobic spikes (Fig. 1A) are inserted peripherally 
into the membrane as the relative height of the domain tends to decreases over time until 
convergence is achieved (Fig. 2, left). The membrane-contacting surface is confined to 
about one third of the whole domain that mostly includes S1-S4 (Fig. 1C). The basic 
residues of this region of the FVIII C2 domain interact with the acidic PS lipids (either 
<PO4
-> or <COO-> functional group) in a mainly transient and non-specific way with two 
exceptions, R2220 and R2320. It is the unique combination of a soft funnel-like geometry 
of the loops in the membrane-interacting part of the domain and a centrally positioned 
arginine (either R2320 or R2220 depending on the domain tilt angle) that interacts 
selectively with the carboxylic acid group of the lipid that defines the PS-specific 
interaction (Fig. 3). This binding motif is further stabilized by polar interactions of the 
phosphate group of the lipid with surrounding amino acid residues of the protein. It is 
interesting to note that while PS-specific FVIII C2-lipid interactions do occur, 
occasionally, via both R2320 and R2200, they seem to be mutually exclusive; in domain 
orientations that enable R2220 to be selectively engaged with the <COO-> group of a PS 
lipid, R2320 cannot (and vice versa). Furthermore, the PS-specific interactions are 
observed less frequent than for FVa C2 studied previously(45). In the present study, for 
FVIII C2, the key interaction of R2220 is found in two of the five trajectories (#3 and #4) 
and present in about ~80 % of the time in these two cases. The R2320 key interaction is 
also found in two other trajectories, #5 and #3, but only ~33 % and ~10 % of the time, 
respectively. A direct comparison with FVa C2 is complicated by subtle yet important 
differences in amino acid sequences and, in particular, by the fact that FVa C2 carries a 
higher net positive charge than FVIII C2 (as determined by a surplus of basic K and R 
residues over acidic D and E residues of +12 e for FV C2 and +6 e for FVIII C2, 
respectively), differences that necessarily affect membrane affinity and association 
kinetics. While binding free energies can, in principle, be calculated from a long 
equilibrium simulation where many binding-unbinding events occur, spontaneous protein-
phospholipid membrane unbinding events are not observed in this study and have, to our 
knowledge, not been reported in the literature.  
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FVIII C1 exhibits structural flexibility and has multimodal orientations in the membrane-
bound state. 
While the lipid interaction of FVIII C2 resembles that of FVa C2(45), FVIII C1 is 
markedly different in two ways: the trajectories do not converge to a well-defined 
unimodal binding orientation (Fig. 4, bottom), and FVIII C1 in the bound state is 
characterized by shape modulations and disorder in the coiled main chain leading to spike 
1 (Fig. 5, bottom). There are two major contributions to the retardation of the binding motif 
that allow the FVIII C1 domain to adopt a variety of moderately to highly tilted molecular 
orientations in the membrane-bound state: 1) the loss of local structural integrity (Fig. S3) 
and 2) the fact that S1 in FVIII C1 is four residues shorter than in FVIII C2, making it 
extrude significantly less (Fig. 1A). The domain tilt angle is in general steeper for FVIII 
C2 than for FVIII C1; the averages of the angles for 4 individual C1/HMMM trajectories 
range between 30 and 65 degrees (Fig. 4, bottom).  
 
Physically, the structural change in C1 is facilitated by the breaking of the main chain H-
bonds between Q2036 and K2072, which in the X-ray crystallographic structure clamp the 
surrounding loop region to the body of the domain (Fig. S3). Upon release, the main chain 
of the region centered around residue 2030 adheres to the membrane bilayer (Fig. 5, 
bottom) and interacts favorably in a non-specific manner. Such a structural mechanism or 
conformational change could explain, in part, why a complex multiphase binding 
mechanism is observed for FVIII.(46) The general trend of the calculated order parameters 
clearly show that FVIII C1 is more flexible than FVIII C2 (Fig. 5), in particular at regions 
that are in contact with the membrane (including the spikes, and the loop region leading to 
spike 1). Surprisingly, FVIII C1 also exhibits increased flexibility in a loop (residues 2115-
2123), which is never observed to interact with the membrane. The fact that FVIII C1 is 
relatively disordered (for such a β-rich domain) could further, apart from a historical 
interest in FVIII C2, be involved in causing the scarcity of FVIII C1 domain structures 
available in the Protein Data Bank (PDB)(47). There is supporting experimental evidence 
that the protein segment in FVIII C1 involved in the above described structural change is 
indeed very flexible in the form of the crystallographic temperature factors (PDB entry 
codes 3cdz(17) and 4bdv(48)). From our simulations it is not possible to dismiss the 
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possibility that FVIII C2 undergoes a similar structural change under much larger time 
scales.  
 
A search of PS-specific interactions in C1/HMMM reveals that (Fig. S4) on the 
corresponding key positions, R2163 (the counterpart to R2320 in C2; Fig. 3) is only 
observed to interact with the carboxylic acid group of the lipids in a single trajectory and 
R2220 in FVIII C2 has no counterpart in FVIII C1 (K2065 is the closest basic residue in 
alignment positioned two residues downstream and it interacts only non-specifically with 
either negatively charged functional group of the lipids). 
  
Dynamical interpretation of hemophilic missense mutations and antibody epitopes related 
to membrane-binding.  
Our results offer a dynamical interpretation of the available hemophilia A disease 
genotypes related to dysfunctional membrane association and binding of FVIIIa via its dual 
discoidin domains (described in the previous section), a novel approach made accessible 
by the use of the HMMM. Previous analyses have inferred on the functional-structural 
causation of hemophilic missense mutations based upon either homology models(49)(50) 
and/or X-ray crystallographic structures(51), both of which are static representations of 
protein structure in the absence of a membrane. Mutations of special interest are those 
positioned at the membrane interacting surface of the C2-like domains and include the 
following basic residues: R2052, R2090, R2159, R2163 (in C1), and R2320 (in C2). 
Caution must be taken when interpreting mutations. Potential pitfalls include not only 
usual statistical fallacies but also unknown interactions with other biochemical 
components. With these precautions we here adopt the palatable concept that a hemophilic 
disease missense mutation located in the membrane-interacting surface patch of FVIII C1 
or FVIII C2 is potentially caused by improper membrane binding. As has been noted 
previously(51), it is remarkable that only few of the documented hemophilic missense 
mutations are positioned in the membrane-interacting patch (including the spikes) of the 
discoidin domains of FVIII (Fig. 5) and, specifically, only two mutants (V2223M, 
positioned in between spikes 2 and 3, and A2201P located in spike 1) was proposed to 
disrupt membrane binding. This could suggests that the major components necessary for 
sufficient membrane interaction for FVIIIa in vivo are non-specific contributions, such as 
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hydrophobic partitioning and electrostatics, consistent with the performed simulations from 
this study. In addition to this general observation, our results further implicate residues 
R2163 (in C1), R2220, and R2320 (in C2) as potentially critical in that they are the only 
basic residues capable of forming the structurally PS-specific interactions with the PS-type 
lipids. Of these three, R2163 and R2320 are known to give rise to hemophilic conditions 
upon mutation. (HAMSTeRs database; http://hadb.org.uk/) 
 
Antibodies KM33 and ESH-4 are known to modulate FVIII cellular uptake and 
binding.(16)(52)(53)(54) KM33 abrogates the interaction between FVIII and phospholipid 
by binding to residue regions 2092-2093 (within S3 of FVIII C1) and 2158-2159 (within 
S4 of FVIII C1).(55) Analogously, ESH-4 binding epitopes have been narrowed down to 
residue regions 2192-2196 (N-terminal side of S1 of FVIII C2), 2210-2125 (containing S2 
of FVIII C2), and 2313-2316 (S4 of FVIII C2).(56) A (third) FVIII antibody ESH-8 binds 
residue regions 2234-2238 (in between S2 and S3 of FVIII C2) and 2267-2270 (in between 
S3 and S4 of FVIII C2) and does not interfere with phospholipid binding. Our results show 
excellent agreement with the binding epitopes of antibodies KM33, ESH-4, and ESH-8 in 
that the two former have epitopes located entirely within the membrane-contacting surface 
patch of FVIII C1 or FVIII C2, while the latter binds solely to regions not in contact with 
the membrane (Fig. 5). 
 
Proposed mechanism of membrane-interaction for the full-length FVIII and implications 
for a putative FVIIIa:FIXa tenase complex 
Based on our results for the membrane-bound states of FVIII C1 and FVIII C2, putative 
membrane-bound configurations of the intrinsic tenase complex is proposed. Overlaying 
the putative model of the FVIIIa:FIXa teanse complex (Fig. 6A) with the converged final 
membrane-bound orientations of the C2/HMMM simulations (Fig. 6B, top) we find that, in 
all cases, preferential positioning of the C2 domain gives rise to tenase complex models 
without any clashes with the membrane. C1 domain of FVIII, however, is not in contact 
with the membrane, nor is the Gla-domain at (around) its -loop, as proposed for highly 
homologous Gla-domains of prothrombin(57) or FVIIa(58). On the contrary, when FVIII is 
overlaid the final FVIII C1 domain orientations from the C1/HMMM simulations (Fig. 6B, 
bottom), two of the resulting orientations causes significant clashes between FVIII C2 and 
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the membrane (trajectories #3 and #5). Trajectories #2 and #4 of the C1/HMMMs 
correspond to reasonable binding modes between the membrane and the tenase complex in 
which FVIII C1, FVIII C2 and FIXa Gla domains are anchored in the membrane (#2 looks 
intuitive where the entire complex is positioned normal to the membrane plane while #4 is 
very similar to highly tilted orientation suggested by FRET measurements(19)). 
Collectively, these considerations indicate that optimal interaction between FVIII C2 and 
the membrane can be achieved without major domain rearrangements in FVIII, whereas 
FVIII C1 membrane interactions might induce domain rearrangements in FVIII. Since it is 
known that the FVIII binding to membranes involves a complex mechanism(46), and 
considering the coiled nature of the four-residue FVIII C1-C2 inter-domain linker (residues 
2170-2173), domain rearrangements are plausible. In any case, our simulations clearly 
indicate that FVIII C1 (not FVIII C2) plays an important role in modulating the orientation 
of the FVIII molecule to accommodate the interaction with FIXa in the membrane-bound 
state. The inter-domain flexibility of the full-length FVIIIa is unknown and, in particular, 
whether and how the membrane selects for or induces certain relative domain 
configurations. Furthermore, there appear to be non-trivial differences in PS-specificity for 
membrane-binding of FVIII and FVIIIa.(59) However, preliminary results of simulations 
of the crystal structure FVIII light chain bound to HMMM suggest that only minor relative 
domain rearrangements occur, supporting the validity of the presented rigid body putative 
tenase complex model (data not shown). These concepts are intriguing and subject for 
further studies.  
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Conclusion 
The presented simulations show that peripheral tight binding and insertion of the domain 
extruding spikes occur spontaneously and converge to a domain orientation for human 
FVIII C2 that is nearly membrane-perpendicular. Human FVIII C1, however, undergoes a 
structural change and is orientationally promiscuous in that it can adopt one of several 
tilted orientations in the membrane-bound state. For both discoidin C2-like domains of 
FVIIIa, the mode of interaction with the phospholipid membrane is characterized by initial 
non-specific attractive electrostatic interactions and hydrophobic partitioning. The 
insertion of the membrane-anchoring domain is followed by the maturation of a tight PS-
specific interaction where a lipid enters the PS pocket, which is observed more frequently 
for FVIII C2 than for FVIII C1. Deep embedding of large parts of either discoidin C2-like 
domain, as has been suggested for FVIII C2 based on cryo-electron microscopy, is not 
observed.  
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Figure- and table legends 
FIGURE 1: (A) Structural alignment of the domains C1 (wire representation, pink) and C2 
(wire representation, cyan) from FVIII based on PDB entry code 3cdz(17). The spikes S1-
S4 are highlighted in red for FVIII C1 and in blue for FVIII C2. (B) Initial domain 
orientation of the C2-like domain and the membrane patch in the simulation setup. 
Depicted is FVIII C2 (in wire representation) and the HMMM patch (half-transparent). The 
vectors (yellow) show the principal axes of inertia of the FVIII C2 domain. The domain tilt 
angle, θ, is defined as the angle between the third principal axis of inertia and the 
membrane normal, z. (C) Converged FVIII C2 (trajectory #2) in the membrane-bound state 
with inserted spikes. The vectors (yellow) show the principal axes of inertia of the FVIII 
C2 domain. 
 
FIGURE 2: (Left) Insertion depth of spikes 1-3 of the FVIII C2 domain and interaction 
energy with the HMMM as function of simulation time for the five trajectories, #1-#5. 
Each spike depth is represented by a single α-carbon atom. The chosen residues are G2044 
(Spike 1), S2058 (Spike 2), and F2093 (Spike 3). Gray-shaded is the layer below the 
average z-position of the phosphorus atoms of st-lipids, corresponding to the membrane 
region. The reference point (i.e., z=0) is set at the membrane center, which is defined in 
each trajectory frame as the center of mass of DCLE molecules. Calculated non-bonded 
interaction energy is divided into van der Waals (vdW, in green) and electrostatic (Elec, in 
blue) components. (Right) Insertion depth of spikes 1-3 of the FVIII C1 domain and 
interaction energy with the HMMM as function of simulation time for the four binding 
trajectories, #2-#5, (black) and the non-binding trajectory, #1 (red). Each spike depth is 
represented by a single α-carbon atom. The chosen residues are M2199 (Spike 1), R2215 
(Spike 2), and L2252 (Spike 3). Gray-shaded is the layer below the average z-position of 
the phosphorus atoms of st-lipids, corresponding to the membrane region. The reference 
point (i.e., z=0) is set at the membrane center, which is defined in each trajectory frame as 
the center of mass of DCLE molecules. Calculated non-bonded interaction energy is 
divided into van der Waals (vdW, in green) and electrostatic (Elec, in blue) components. 
 
FIGURE 3: (Left) Position of the R2220 and R2320 of FVIII C2 (cyan wire 
representation, spikes highlighted in blue). (Right) A cross section view of the FVIII C2 
  Structural and functional characterization of protein complexes in the blood coagulation cascade 
(cyan wire representation, spikes highlighted in blue, and black half-transparent surface) 
with a tightly bound st-lipid interacting with the R2320 of the characteristic soft ‘funnel’ 
PS pocket. The view point is 90 degree rotated towards right from the left panel. Snapshot 
was taken from trajectory #5 at t = 21 ns. 
 
FIGURE 4: Distribution of the domain tilt angle, θ, of the FVIII C2 (top) and FVIII C1 
(bottom) for the pooled subset of membrane-binding trajectories (#1-#5 for FVIII C2, and 
#2-#5 for FVIII C1). Domain tilt angles corresponding to the final converged 
configurations are indicated by arrows. 
 
FIGURE 5: (Top) Calculated amide (C-N vector) S2 order parameters (black circles) and 
membrane contact frequencies (brown shaded bars) for FVIII C2 in the membrane-bound 
state. The positions of the spikes (S1-S4) are indicated with blue colored bars above the 
panel. Hemophilic missense mutations are marked with crosses on the baseline. (Bottom) 
Calculated amide (C-N vector) S2 order parameters (black circles) and membrane contact 
frequencies (brown shaded bars) for FVIII C1 in the membrane-bound state. The positions 
of the spikes (S1-S4) are indicated with red colored bars above the panel. Hemophilic 
missense mutations are marked with crosses on the baseline. 
 
FIGURE 6: (A) Our constructed model of the FVIIIa:FIXa tenase complex. B-domain 
deleted FVIIIa (domains A1-A2-A3-C1-C2) is shown in wire representation (A1-A2 in 
blue, A3-C1-C2 in tan). FIXa is shown as surface (HC: Heavy Chain in gray, LC: Light 
Chain in green). (B) The tenase complex model structurally aligned and overlaid the final 
converged membrane-bound individual C2-like domains (top: C2/HMMM trajectories #1-
#5 from left to right, bottom: C1/HMMM trajectories #2-#5 from left to right).  
 
TABLE 1: Detailed overview and component count of the simulated systems. 
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Tables 
 
System Lipid 
type 
Area / 
lipid 
[Å
2
] 
No. of 
trajector
ies 
Spontaneous 
binding in 
Simulation 
time per 
trajectory 
[ns] 
No. of 
water 
molecules 
No. of 
atoms  
C1/HMMM PS 88.5 5 All except #1 50-55 ~7,800 ~37,000 
C2/HMMM PS 85.0 5 All ~37 ~7,700 ~37,000 
C2/Soln - - 1 - 50 ~4,600 ~16,400 
TABLE 1: System configurations 
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Figure S1: Non-bonded interactions energies between the HMMM membrane and specific 
portions of C2 domain: R2220 (Top panel), R2320 (Center), or the complementary 
selection (i.e., C2 domain excluding R2220 and R2320; Bottom) for a FVIII C2 on 
HMMM trajectory (C2/HMMM #5). The energies are decomposed into electrostatic (blue) 
and van der Waals (green) terms; the total (shown in black) is the sum of the two terms. 
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Figure S2: Calculated amide (C-N vector) S2 order parameters for human FVIII C2 in bulk 
water (C2/Soln trajectory). 
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Figure S3: Structural change in C1 upon the release of the main chain leading to spike 1 
from the body of the β-barrel. The C1 domain is shown in wire representation (pink) with 
the spikes 1-4 highlighted (red). Positions of residues Q2036 and K2072 which restrain the 
loopy segment in the X-ray crystallographic structure are indicated in blue and backbone 
atoms are shown as sticks. (Left) X-ray crystallographic reference structure. (Right) Snap-
shot from C1/HMMM trajectory #2 at t = ~32 ns.  
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Figure S4: (Top) Observed frequency of close interaction (cutoff = 3 Å) between basic 
residues and negatively charged functional groups (PO4
-
 along the x-axis; COO
-
 along the 
y-axis) of the PS head groups. Each point in the plot corresponds to the interaction 
frequency between single residue averaged over a single membrane-binding trajectory of 
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the individual C2-like domains (Top Left: FVIII C1; Top Right: FVIII C2.) (Bottom) Front-
side and back-side view of FVIII C1 and C2 shown as surface (PDB entry code 3cdz) with 
basic residues (K or R) highlighted (blue). Front view corresponds to the orientation of Fig. 
6A with FVIII C1 positioned to the right and FVIII C2 to the left. 
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4.2 Clearance of FVIIIa by LRP1 
4.2.1 Prelude 
The final manuscript of this dissertation, manuscript 5, describes a detailed biochemical 
and biophysical characterization of the binding between LRP1 of the LDL receptor family 
and (one of) its natural ligands, coagulation factor VIII. LRP1 is known to clear the FVIII 
molecule from circulation in vivo(Bovenschen et al., 2003) and lysines in the ligand well-
established as being critical for the interaction with the receptor.(Dolmer, Campos, & 
Gettins, 2013; Fisher, Beglova, & Blacklow, 2006) Other physiological clearance receptors 
of FVIII include proteoglycans and carbohydrate receptors.(Lenting, VAN Schooten, & 
Denis, 2007) The typical half-life of FVIII in the bloodstream is ~10 hours, although 
numbers vary significantly among patients with haemoplilia A.(Dijk et al., 2005) 
 
The LRP receptor contains cytoplasmic tail, a transmembrane-spanning segment, auxiliary 
domains, and the ligand-binding complement-type cysteine-rich repeasts (CRs). The 
principal binding cluster (cluster II) has 8 of these CR repeats numbered 3 through 10 (of 
31 in the full-length receptor). This modular composition where many repeats can interact 
with different regions of the ligand enables LRP to be a promiscuous receptor and achieve 
affinity through avidity.  
 
Based on selected anchor-point lysine residues identified in the mutagenesis study, an 
illustrative model of the canonical interaction between a LRP1 cluster II CR-triplet(Dolmer 
& Gettins, 2006)(Meijer et al., 2007) and an extended surface patch also covering regions 
with reduced deuterium-incorporations in hydrogen-deuterium exchange mass 
spectrometry experiments on FVIII was constructed.  
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Low-Density Lipoprotein Receptor-Related Protein 1 Interacts with its Ligand Blood Coagulation 
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Background: Lysine residues mediate the 
interaction between ligands and members of the 
LDL receptor family.  
Results: Regions on FVIII and specific lysine 
residues that contribute to the interaction of 
FVIII and LRP1 are identified.  
Conclusion: LRP1 interacts with FVIII via an 
extended surface comprising multiple lysine 
residues. Significance: Our study sheds light on 
ligand interaction with the LDL receptor family.  
 
ABSTRACT 
Lysine residues are implicated in driving the 
ligand binding to the LDL receptor family. 
However, it has remained unclear how 
specificity is regulated. Using coagulation 
factor VIII as a model ligand, we now study 
the contribution of individual lysine residues 
in the interaction with the largest member of 
the LDL receptor family, low-density 
lipoprotein receptor-related protein (LRP1). 
Using hydrogen-deuterium exchange mass 
spectrometry (HDX-MS) and surface plasmon 
resonance (SPR) interaction analysis on a 
library of lysine replacement variants as two 
independent approaches, we demonstrate that 
the interaction between Factor (F)VIII and 
LRP1 occurs over an extended surface 
containing multiple lysine residues. None of 
the individual lysine residues account 
completely for LRP1 binding, suggesting a 
cooperative binding model. Together with 
structural docking studies, our data suggest 
that LRP1 interacts with FVIII via an 
extended surface of multiple lysine residues 
that starts at the bottom of the C1 domain and 
winds around the FVIII molecule.  
The low-density lipoprotein receptor family 
is an ancient family of transmembrane receptors 
regulating diverse biological processes ranging 
from lipoprotein metabolism to blood 
coagulation(1-3). Members of the LDL receptor 
family are able to interact with an unusual 
number of ligands; e.g. more than 30 ligands 
have been reported for the largest member LRP1, 
including lipoproteins, viruses, bacteria toxins, 
proteinase-inhibitor complexes and coagulation 
proteins(4,5). Given the importance of the LDL 
receptor family in human physiology, much 
research has been focused on the questions how 
the various members of the LDL receptor family 
can interact with such a large variety of 
structurally unrelated ligands and which 
molecular mechanisms regulate specificity of the 
interaction.  
The LDL receptor family is characterized by 
the presence of a varying number of distinct 
domains; the YWTD β-propeller and EGF 
domains, a transmembrane region, an 
intracellular cytoplasmic tail and ligand-binding 
domains or complement-type repeats (CR 
domains). Ligand binding is mediated by clusters 
of structured CR domains that consist of 
approximately 40 amino acids folding into a 
compact structure. Each CR domain contains 
three disulfide bonds, a highly conserved 
octahedral calcium binding cage and a short β-
hairpin near the N-terminal end(6). The calcium 
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cage is required both for structural integrity of 
the CR domain as well as for direct ligand 
binding and is formed by 6 oxygen atoms derived 
from four conserved acidic residues and two 
backbone carbonyl groups(6-9). The CR domains 
are connected by flexible linker sequences, 
thereby enabling the receptor family to bind to a 
wide range of proteins.  
Most of our knowledge on ligand-receptor 
interaction is based on the intracellular chaperone 
receptor-associated protein (RAP) which binds 
with high affinity to members of the LDL 
receptor family(10,11). Based on a co-
crystallization study of two CR domains from the 
LDL receptor with the third domain of RAP 
(RAP-D3), a general mode for ligand recognition 
by lipoprotein receptors has been proposed(12). 
In this ‘acidic necklace’ model, each CR domain 
encircles an ε-amino group of a lysine residue in 
a tripartite salt bridge (K256 and K270 in RAP-
D3) via the three remaining oxygen atoms from 
the acidic residues forming the octahedral 
calcium cage(12). This model was supported by a 
previous study in which K256 and K270 were 
identified as being critical for the interaction of 
RAP-D3 to complete LRP1 using random 
mutagenesis(13). Further support for the lysine-
binding model was provided by the NMR 
structure of the complex of complement type 
repeat 5 and 6 of LRP1 and the first domain of 
RAP (RAP-D1)(14), although the models differ 
in terms of the additional contribution of 
hydrophobic interactions. Recently, we further 
experimentally demonstrated that positively 
charged arginines cannot substitute for the two 
dominant lysine residues (K256 and K270) in the 
interaction with the RAP-D3 domain and 
LRP1(15). In agreement with these data, arginine 
residues do also not take over lysine residues in 
the high-affinity interactions of RAP-D1 (K143 
and K146) with the LDL receptor(16). In a recent 
elegant study, Dolmer et al. established that 
lysine residues are the sole contributors to 
binding of RAP-D3 to a LRP1 fragment 
containing 2 CR domains and that pairs of lysine 
residues ensure high-affinity interaction in an 
additive rather than synergistic manner(17).  
RAP prevents premature ligand-binding 
during biosynthesis of the LDL receptor family 
members by efficiently competing with other 
ligands(18-20). It therefore seems well possible 
that the affinity and molecular mechanism of 
interaction have been optimized during 
evolution. While the acidic necklace model is 
consistent with previous observations that lysine 
residues are implicated in the binding of ligands 
other than RAP to the LDL receptor family(21-
28), it has remained unclear how large ligands 
containing multiple lysine residues interact with 
the LDL receptor family members. This is 
particularly relevant since experiments using 
single CR domains and simple (modified) amino 
acids have shown that also arginine and 
protonated histidine, especially pairs of proximal 
charges, can interact well with CR domains(29). 
Taken together, it has remained unclear whether 
lysine residues make a dominant contribution to 
the interaction with the LDL receptor family, 
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also for low-affinity ligands. Another important 
question is how specificity of the interaction is 
attained. It has been suggested that high-affinity 
interaction requires the engagement of at least 
two separate lysine residues located at an 
appropriate distance from each other(12,30). In 
addition, it has been proposed that there are 
modest requirements for being a coordinating 
lysine residue and that specificity may be 
regulated by a second, immediately adjacent 
positive charge(17,29). We therefore set out to 
study in detail the interaction of LRP1 with its 
low-affinity ligand FVIII using two independent 
approaches with particular emphasis on lysine 
residues. Using hydrogen-deuterium mass 
spectrometry we studied the interaction of B-
domain deleted FVIII with LRP1 cluster II. 
Subsequently, we used a lysine mutagenesis 
approach to study the role of lysine residues in 
the FVIII light chain in the interaction with full 
length LRP1 and LRP1 cluster II. These 
combined studies revealed important novel 
aspects of the interaction between FVIII and 
LRP1.    
 
EXPERIMENTAL PROCEDURES 
Plasmid mutagenesis -FVIII light chain in 
pcDNA3.1 was created from wild type FVIII-
GFP in pcDNA3.1(31) by fusing the signal 
peptide to the acidic a3 domain (glutamic acid at 
position 1649) by Quick Change mutagenesis
TM
 
(Stratagene, La Jolla, CA, USA) using forward 
primer 5’-
TTGCGATTCTGCTTTAGTGAAATAACTCG
TACTACT-3’ and reverse primer 5’-
AGTAGTACGAGTTATTTCACTAAAGCAGA
ATCGCAA-3’. B domain deleted (del 746-1639) 
factor VIII (FVIIIdB) in pcDNA3.1 has been 
described before(32). Point mutations in the 
FVIII light chain and FVIIIdB were introduced 
by Quick Change mutagenesis
TM
 (Stratagene, La 
Jolla, CA, USA) using appropriate primers. The 
coding regions of all constructs were verified by 
sequence analysis. Sequence reactions were 
performed with BigDye Terminator Sequencing 
kit (Applied Biosystems, Foster City, CA, USA). 
Expression of recombinant proteins -
Recombinant factor VIII (FVIII) Turoctocog alfa 
(previously named N8) was produced in Chinese 
hamster ovary (CHO) cells as previously 
described(33). The molecule consists of a heavy 
chain of 88 kDa including a 21 amino acid 
residue truncated B-domain and a light chain of 
79 kDa, it contains four N-glycosylation sites of 
which two are complex bi-antennary glycans and 
two are high mannose structures. FVIII light 
chain variants were expressed under serum-free 
conditions using 293-F cells (Invitrogen, 
Carlsbad, CA, USA #R790-07) and Freestyle 293 
Expression Medium (Invitrogen). 293Freestyle 
cells were transfected using 293fectin 
(Invitrogen) according to the manufacturer’s 
instructions for small scale expression and using 
linear polyethylenimine (PEI) Mw  25000 
(Polysciences Inc, PA, USA) for large scale 
expression. Cells were harvested 4-5 days after 
transfection. Cells were centrifuged for 8 min at 
4600 × g and the supernatant was collected. The 
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cell pellet was subsequently washed with 0.55 M 
NaCl in Freestyle 293 Expression Medium and 
centrifuged for 8 min at 4600 × g. The 
conditioned medium was combined with the 0.55 
M NaCl wash and filtered using a 0.22 µm 
disposable filter unit. FVIII light chain variants 
were purified using CLB-CAg117 coupled to 
CNBr-Sepharose 4B as an affinity matrix 
followed by concentration using Q-sepharose(31) 
(Amersham Pharmacia Biotech, Roosendaal, The 
Netherlands). HEK293 cell-lines stably 
expressing FVIIIdB variants were produced as 
described(34) and grown in DMEM-F12 medium 
supplemented with 10% FCS. Recombinant 
FVIIIdB variants were purified and analyzed as 
described using CLB VK34 IgG1 coupled to 
CNBr-Sepharose 4B as an affinity matrix 
followed by concentration using Q-
sepharose(21). LRP1 cluster II was expressed in 
Baby Hamster Kidney (BHK) cells and purified 
as described(35) using glutathione S-transferase 
fused receptor-associated protein (RAP) coupled 
to CNBr-Sepharose 4B as an affinity matrix. 
Subsequently, purified LRP1 cluster II was 
concentrated using Q-sepharose.  
HDX-MS experiments -189 μM FVIII and 
256 μM LRP1 cluster II were dialyzed to a buffer 
comprising 20 mM imidazole pH 7.3, 10 mM 
CaCl2, 500 mM NaCl and complex formation 
was allowed for 30 minutes at room temperature. 
In-exchange of deuterium was initiated by a 10-
fold dilution into either 20 mM imidazole pH 7.3, 
10 mM CaCl2, 111 mM NaCl in 100% H2O for 
the undeuterated experiments, or 20 mM 
imidazole pD 7.3, 10 mM CaCl2, 111 mM NaCl 
in 100% D2O for the deuterated experiments. All 
sample deuterium labeling, quenching, injection 
to MS and timing of samples were handled by an 
automated set-up (Leap Technologies Inc.) as 
described(36) with minor adjustments. Minor 
modifications included exchange times ranging 
from 10 seconds to 256 minutes, the use of a 7 
min linear acetonitrile gradient of 8−45% 
containing 0.1% formic acid and the use of a 
SYNAPT G2 HDMS mass spectrometer 
(Waters). Four undeuterated and two complete 
HDX experiments were performed for FVIII and 
FVIII in complex with LRP1 cluster II within 
two consecutive days. Blank injections were 
performed between each sample injection to 
confirm the absence of peptide carryover from 
previous runs. Peptic peptides were identified in 
separate experiments using MS
E
 methods. MS
E
 
data were processed using ProteinLynx Global 
Server software (Waters version 2.4). Searches of 
MS
E
 data were conducted as non-specific digest 
with N-terminal acetylation of FVIII as 
modification. The sequence coverage map of 
FVIII was plotted using the online tool 
MSTools(37). The relative deuterium 
incorporation levels for each peptic peptide were 
automatically calculated using DynamX software 
(Waters) as described(36). The data were 
expressed in either mass units (Da) or relative 
fractional exchange, which was calculated by 
dividing the deuterium level (in Da) by the total 
number of backbone amide hydrogens that could 
have become deuterated (equal to the number of 
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amino acids, minus proline residues minus 1 for 
the N-terminal amide). The experimental 
uncertainty of measuring a deuterium level was 
found to be ±0.15 Da. Using this value of 
experimental uncertainty and a 98% confidence 
interval, a significant difference value of 0.5 Da 
was calculated for individual time points and a 
value of 1.5 kDa for summed HDX differences 
across all time points. 
 
Surface Plasmon Resonance analysis-
Association and dissociation of LRP1 cluster II to 
FVIII light chain and FVIIIdB variants was 
assessed by Surface Plasmon Resonance (SPR) 
analysis employing a BIAcore 3000 biosensor 
(Biacore AB, Uppsala, Sweden). The anti-C2 
antibody CLB-EL14 IgG4(38) (26 fmol/mm
-2 
for 
FVIII light chain variants and 39 fmol/mm
-2 
for 
FVIIIdB variants) was immobilized onto a CM5 
sensor chip using the amine coupling method 
according to the manufacturer’s instructions. 
Subsequently, FVIII light chain variants were 
bound directly from medium to the anti-C2 
antibody at a density of 17 fmol/mm
-2
 and 
purified FVIIIdB variants were bound at a 
density of 9 fmol/mm
-2
. LRP1 cluster II (0.2-200 
nM) was passed over the FVIII light chain or 
FVIIIdB variants in a buffer containing 150 mM 
NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 and 
20 mM Hepes (pH 7.4) at 25 °C with a flow rate 
of 20 L/min. The sensor chip surface was 
regenerated three times after each concentration 
of LRP1 cluster II using the same buffer 
containing 1 M NaCl. Binding to FVIII light 
chain or FVIIIdB variants was corrected for 
binding in absence of FVIII. Binding data during 
the association phase were fitted in a one-phase 
exponential association model. Responses at 
equilibrium were plotted as a function of the 
LRP1 cluster II concentration. The responses at 
equilibrium were fitted by non-linear regression 
using a standard hyperbola to generate KD values 
assuming similar Bmax values (GraphPad Prism 4 
software, San Diego, CA, USA). To study the 
contribution of lysine residues on the interaction 
between LRP1 cluster II and the FVIII light 
chain, lysine residues were modified by passing 
over 50 mM of sulfo-NHS acetate or sulfo-NHS 
biotin (ThermoFisher Scientific, Rockford, IL, 
USA) for 10 min at 25 °C with a flow rate of 20 
L/min prior to passing over LRP1 cluster II 
(0.2-200 nM) and anti-a3 antibody CLB-
CAg69(39) (0.1-100 nM). Binding of purified 
FVIII light chain and FVIIIdB variants to full 
length LRP1 was studied by coupling LRP1 
(Biomac, Leipzig, Germany) directly on a CM5 
chip according to the manufacturer’s instructions 
at three different densities (15 fmol/mm
-2
, 18 
fmol/mm
-2
 and 21 fmol/mm
-2
). FVIII light chain 
variants (1-25 μg/ml based on Bradford analysis) 
and FVIIIdB variants (5-1000U/ml based on 
chromogenic activity) were passed over the 
immobilized LRP1 in a buffer containing 150 
mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 
and 20 mM Hepes (pH 7.4) at 25 °C with a flow 
rate of 20 L/min. The sensor chip surface was 
regenerated three times after each concentration 
of FVIII using the same buffer containing 1 M 
NaCl. Binding to LRP1 was corrected for 
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binding in absence of LRP1. The response units 
at time point 235 seconds were plotted as a 
function of the concentration.  
Structural modeling -The illustrative model 
of the triplet canonical binding mode of LRP to 
the light chain of FVIII is constructed using the 
Rosetta Modeling Suite(40) and the NAMD 
molecular dynamics software package(41). The 
basic preparation procedure was as follows, a 
detailed description can found in the 
Supplementary Materials section. Based on 
structural alignment with the x-ray 
crystallographic structure of the LDLR-RAP 
complex (PDB: 2FCW)(12), a homology model 
of the calcium-loaded LRP double 
complementary repeat (CR) 56 was created and 
aligned with the FVIII light chain (PDB: 4BDV, 
chain B)(42). Lysine residues (K2065 and 
K2092) were aligned to reconstruct the LDL 
family ligand receptor binding motif. A further 
CR5 module was positioned to interact with 
lysine K2136 of the FVIII light chain and was 
connected to its adjacent CR56 module by loop 
modeling. The resulting model was energy 
minimized prior to being equilibrated using 
molecular dynamics simulations for a short 
period of time, giving the structural model of the 
proposed canonical interaction between LRP and 
the FVIII light chain, as seen in Figure 6 (right).  
 
RESULTS 
HDX-MS of LRP1 interaction with cofactor 
FVIII -HDX mass spectrometry was employed to 
structurally elucidate the LRP1 binding surface 
of the FVIII light chain. HDX of FVIII in the 
presence and absence of LRP1 cluster II was 
followed at various time intervals ranging from 
10 seconds to 256 minutes. Inline pepsin protein 
digest conditions were established that afforded 
peptides of reasonably small length (typically 5-
20 amino acids). These conditions enabled 
detection of a total of 127 peptides covering 89% 
of the primary sequence of the FVIII light chain, 
with redundant coverage of all subunits, i.e., A3, 
C1, and C2 (Figure 1). The small areas of the N-
terminus of a3, and of A3 contributed to 5% of 
the 11% gap in resolution. The majority of the 
peptides displayed an exchange pattern that is 
unaffected by the binding of LRP1 cluster II 
(Figure 1, blue color). However, several 
overlapping peptic peptide fragments 
encompassing residues 1671-1689, 1737-1746, 
1804-1835, 2057-2069, 2078-2099, 2213-2235, 
2266-2271, and 2293-2296 showed reduced 
HDX in the presence of LRP1 cluster II (Figure 
1, red color). The raw data of representative 
HDX profiles for these peptides are shown in 
Figure 2. The unaffected peptide fragments 
(blue) and the peptides showing reduced HDX 
(red) were color coded in the crystal structure of 
FVIII (pdb code 4BDV) (Figure 2). This analysis 
revealed that the regions that demonstrate 
reduced HDX are scattered throughout the a3, 
A3, C1 and C2 domains of the FVIII light chain.  
Chemical modification of lysine residues in 
the FVIII light chain abolishes the interaction 
with LRP1 cluster II -To address the role of 
lysine residues in the interaction between LRP1 
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cluster II and the FVIII light chain, we 
chemically modified lysine residues of the FVIII 
light chain on a SPR sensor chip using the 
compounds sulfo-NHS-acetate and sulfo-NHS-
biotin. Both these compounds form stable, 
covalent amide bonds with primary amines, 
resulting in the replacement of the positively 
charged ε-amino group of the lysine residue by 
an uncharged acetate group (sulfo-NHS-acetate) 
or biotin group (sulfo-NHS-biotin). 
Subsequently, LRP1 cluster II and a control 
antibody CLB-CAg69 directed against the a3 
domain of FVIII, were passed over the 
unmodified and chemically modified FVIII light 
chain. While LRP1 cluster II readily bound to the 
unmodified FVIII light chain, no detectable 
binding was observed for the FVIII light chain in 
which the lysine residues were chemically 
modified (Figure 3). As a control, the CLB-
CAg69 antibody bound to a similar extent to the 
unmodified as well as to the chemically modified 
FVIII light chain (Figure 3). These data suggest 
that lysine-containing surface patches mediate 
the interaction between LRP1 cluster II and the 
FVIII light chain. 
Multiple lysine residues in the FVIII light chain 
contribute to the interaction with LRP1 cluster II 
-To systematically address which lysine residues 
in the FVIII light chain contribute to LRP1 
cluster II interaction, we constructed a library of 
FVIII variants carrying lysine to arginine (KR) 
replacements. All of these variants were tested 
for LRP1 cluster II interaction using SPR 
analysis. On each SPR sensor chip we included a 
control channel (only CLB-EL14 IgG4), wild 
type FVIII light chain and two FVIII light chain 
variants. Therefore, wild type FVIII light chain 
was analyzed multiple times (n=14). For each 
channel, binding data during the association 
phase were fitted in a one-phase exponential 
association model. A typical example of the 
binding curves and the fit of the one-phase 
exponential association model (dotted line) for 
wild type FVIII light chain are represented in 
Figure 4A. Responses at equilibrium were plotted 
as a function of the LRP1 cluster II concentration 
and fitted by non-linear regression using a 
standard hyperbola to generate KD values 
(Supplemental Figure 1). The KD value for wild 
type FVIII light chain was 30 ± 4 nM (Figure 
4B). Initially, we constructed FVIII light chain 
variants based on the domain structure of FVIII 
carrying 2 (a3), 17 (A3), 8 (C1) or 9 (C2) 
replacements. However, KR variants of the A3 
domain (17 replacements) and the C1 domain (8 
replacements) were poorly expressed. We 
therefore constructed KR variants carrying 
single, double or triple lysine to arginine 
replacements in the A3 and C1 domain. 
Unfortunately, the K1732R FVIII light chain 
variant was poorly expressed and could not be 
assessed using SPR analysis. For all of the other 
variants, binding to LRP1 cluster II was analyzed 
and the KD was calculated as described above 
(Figure 4C). The KD for LRP1 cluster II for these 
variants was compared to the KD of wild type (30 
± 4 nM) using a two-tailed students t-test. Our 
SPR analysis showed that lysine residues in the 
  
193 
 
C2 domain of the FVIII light chain do not 
contribute to the interaction with LRP1 cluster II. 
In contrast, multiple lysine residues in the 
a3A3C1 domains contributed to the interaction 
of FVIII to LRP1, although none of the 
individual substitutions completely abolished 
LRP1 cluster II binding. Lysine residues 
contributing to the interaction included 
K1673/1674, K1693, K1813/K1818, K1827, 
K1967, K1972, K2065, K2092 and K2136. Of 
these, K1693, K1827 and K1967 ranked the 
highest in the A3 domain, and K2065 and K2092 
in the C1 domain. These residues were selected 
for further studies.   
Single and multiple replacements of selected 
lysine residues in the A3 domain K1693, K1827, 
K1967 and in the C1 domain K2065 and K2092 
by arginine, alanine or glutamic acid -From the 
SPR data of our library of FVIII light chain 
variants, we concluded that multiple lysine 
residues contribute to the interaction with LRP1 
cluster II. However, there are some lysine 
residues in the A3 domain (K1693, K1827 and 
K1967) and in the C1 domain (K2065 and 
K2092) that contribute most to the interaction. 
To study the effect of charge, these lysine 
residues were replaced by positively charged 
arginine, uncharged alanine or negatively 
charged glutamic acid. The variant carrying a 
K1967E replacement was poorly expressed and 
could not be analyzed. All other FVIII light chain 
variants demonstrated a reduced interaction with 
LRP cluster II (Supplemental Figure 1 and Table 
1), confirming the contribution of lysine residues 
at positions 1693, 1827, 1967, 2065 and 2092 to 
the interaction with LRP1 cluster II. There were 
no major differences in the interaction with LRP1 
cluster II for FVIII light chain variants carrying 
lysine to arginine or lysine to alanine 
replacements for the positions 1967, 2065 and 
2092. This confirms our previous observation 
that, despite their positive charge, arginine 
cannot replace lysine in the interaction with 
LRP1. However, for lysine residues at positions 
1693 and 1827, alanine replacements 
demonstrated a higher KD as compared to 
arginine replacements (Table 1), suggesting that 
although for these specific residues a lysine 
residue is preferred, the charge of the arginine 
can maintain some interaction with LRP1. In 
addition, we have reversed the positive charge of 
the lysine residue by replacing the lysine with a 
negatively charged glutamic acid residue. 
Alanine and glutamic acid variants demonstrated 
a similar KD, indicating that there was no 
additive effect of neutralizing the charge (Table 
1). To study the additive effect of combining 
lysine replacements, we constructed FVIII 
variants carrying 3 (K1693, K1827 and K1967), 
2 (K2065 and K2092) and 5 lysine replacements. 
All FVIII light chain variants carrying the 
K1967E replacement were poorly expressed and 
could not be analyzed. All the other variants 
demonstrated a reduced interaction with LRP1 
cluster II (Supplemental Figure 3 and Table 2). 
FVIII light chain variants containing 3 lysine 
replacements in the A3 domain demonstrated a 
slightly increased KD as compared to the variants 
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containing only 1 lysine replacement in the A3 
domain. There was no major difference between 
the lysine to arginine and lysine to alanine 
variants (Table 2). For the C1 domain, the KD for 
variants in which both K2065 and K2092 were 
replaced was increased as compared to the C1 
variants carrying only 1 lysine replacement. For 
the C1 domain, alanine or glutamic acid 
replacements did result in a higher KD as 
compared to arginine replacements (Table 2). 
The combined variants in which the 5 lysine 
residues in the A3 and C1 were replaced by 
arginine or alanine demonstrated a KD which was 
approximately 20-fold (arginine) or 40-fold 
(alanine) reduced as compared to wild type FVIII 
light chain (Table 2). In addition to interaction 
studies by capturing FVIII light chain variants 
directly from medium via the C2-domain on a 
SPR chip, interaction studies were performed 
using purified FVIII light chain variants and full 
length LRP1 (Supplemental Figure 4). These 
studies showed that, although the FVIII light 
chain variant carrying 5 lysine to arginine 
replacements demonstrated a 20-fold reduced 
interaction with LRP1 cluster II, binding to full 
length LRP1 was not affected. However, 
replacements at the same position by alanine or 
glutamic acid did result in a reduced interaction 
with full length LRP1 (Supplemental Figure 4).  
From light chain to heterodimer: Binding of 
FVIIIdB variants to LRP1 cluster II and full 
length LRP1 -So far, we performed our binding 
assays using FVIII light chain variants. The 
FVIII light chain may have a different 
conformation as compared to the FVIII cofactor. 
To verify the contribution of the 5 lysine residues 
in the FVIII cofactor, we purified FVIIIdB 
variants carrying 5 lysine to arginine, alanine or 
glutamic acid replacements. FVIII variants were 
bound via the C2 domain to antibody CLB EL14 
IgG4 and a concentration range of LRP1 cluster 
II was passed over the immobilized FVIII 
variants. These SPR binding studies indicated 
that all FVIIIdB variants showed a dramatically 
reduced interaction with LRP1 cluster II in the 
order wild type>>>5xKR>5xKA>>5xKE (Figure 
5). While for individual lysine residues, there 
was only a minor difference between KR, KA 
and KE variants, the combined KE replacements 
proved to be more detrimental for the interaction 
with LRP1 cluster II than KA and KR 
replacements. In addition, we studied the 
contribution of the 5 lysine residues in the 
interaction with full length LRP1. Therefore, we 
directly coupled full length LRP1 on the CM5 
chip and passed over the FVIIIdB variants. 
Binding studies indicated that the binding was 
reduced in the order 5xKR>5xKA>5xKE. The 
binding defect of the 5xKR variant was 
remarkably minor while the binding defects of 
the 5xKA and 5xKE were more severe 
(Supplemental Figure 5).   
 
DISCUSSION 
This study demonstrates that lysine residues 
indeed make a dominant contribution to the 
LRP1-FVIII interaction. When we chemically 
modify all surface exposed lysine residues of 
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FVIII using NHS-biotin or NHS-sulfo acetate, 
the binding to LRP1 cluster II is completely 
abrogated. Our combined experimental approach 
using HDX-MS and site-directed mutagenesis 
further suggests that the interaction of LRP1 with 
FVIII occurs over an extended surface containing 
multiple lysine residues in FVIII. Hydrogen 
deuterium exchange-mass spectrometry (HDX-
MS) experiments identified regions 1671-1689, 
1737-1746, 1804-1835, 2057-2069, 2078-2099, 
2213-2235, 2266-2271, and 2293-2296 to be 
involved in the binding of FVIII to LRP1 cluster 
II. Intriguingly, these regions are scattered 
throughout the a3, A3, C1 and C2 domains of 
FVIII. Subsequent SPR analysis of a library of 
FVIII light chain variants carrying lysine to 
arginine (KR), alanine (KA) or glutamic acid 
(KE) revealed that multiple (11) lysine residues 
within the FVIII light chain including 1673/1674, 
1693, 1813/1818, 1827, 1967, 1972, 2065, 2092 
and 2136 contribute to the interaction with LRP1 
cluster II. However, none of the individual lysine 
residues accounts completely for LRP1 cluster II 
binding. We did observe an additive effect of 
combining multiple lysine replacements and 
further mutagenesis studies using positively 
charged arginine, uncharged alanine or 
negatively charged glutamic acid residues 
indicated that reversing the positive charge had 
the strongest effect on the interaction.  
The majority of the lysine residues that were 
identified in the mutagenesis study are located 
within those regions that were also identified 
using the HDX-MS study and are therefore 
considered ‘hot spots’. These include 1673/1674, 
1813/1818, 1827, 2065 and 2092 in FVIII. These 
data are in good agreement with previously 
described interactive sites on FVIII that mediate 
the binding to LRP1(21,35) and are fully 
compatible with our previous observation that the 
A3C1 domains of FVIII harbor important 
interaction sites for LRP1(43). Taken together, 
the pattern that emerges suggests that ligand 
binding to LRP1 is supported by a variety of 
target binding sites that most likely interact 
simultaneously with multiple CR repeats. The 
interaction of each individual site may be weak, 
however, when many interaction sites are in play 
at the same time dissociation of a single site will 
not allow abrogation of the complex. Hence, the 
combination of many weak binding sites results 
in an overall strong interaction, suggesting a 
cooperative model of interaction. This may 
explain our observations that the binding defects 
of both FVIII light chain and FVIIIdB variants 
containing 5xR replacements for full length 
LRP1 cluster II were remarkably minor 
compared to LRP1 cluster II. In contrast, the 
binding defects of the FVIII light chain and 
FVIIIdB variants containing 5xA and 5xE 
replacements were comparable between LRP1 
cluster II and LRP1.   
The question remains why certain lysine 
residues contribute more to the interaction than 
others. Based on a study on the specificity of 
binding of the serpins PAI-1 and PN-1 to 
LRP1(30), Jensen et al. have suggested that there 
may be modest requirements to be a coordinating 
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lysine residue. However, inspection of the x-ray 
structure of the LDLR-RAP complex suggests 
that members of the LDL receptor family interact 
with clusters of lysines being 18-20 Å apart(12). 
In addition, it has been suggested that 
hydrophobic interactions may play an additional 
role in the binding of ligands to the complement-
type repeats(14). While the acidic necklace 
model as proposed by Fisher et al. suggests that 
hydrophobic interactions are mediated by the 
side chain of the lysine residue of the ligand(12), 
Jensen et al. propose that an additional 
hydrophobic residue of the ligand, typically a 
leucine or an isoleucine, is important for the 
interaction(14). Therefore, hydrophobic residues 
located in the vicinity of the lysine residue may 
determine whether a lysine residue is a ‘hot-spot’ 
or not. Alternatively, the presence of a second 
proximal charge near the lysine residue, or 
perhaps even repulsive charges from amino acid 
residues surrounding the lysine residue, may 
determine specificity(17,29).  
We therefore took a close look at the spatial 
distribution of the identified interactive regions 
and lysine residues within FVIII. Crystal 
structure analysis revealed that all ‘hot spot’ 
lysine residues that we identified may spatially 
align with the acidic binding pockets of the 
extracellular part of the LDL receptor. The 
distance from the bottom of the C1 domain to the 
top of the A3 domain spans 69 Å, a distance that 
LRP1 cluster II can easily encompass using just 
3-4 complement type repeats. We therefore 
propose that LRP1 cluster II interacts with the 
FVIII light chain via an extended surface that 
starts at the bottom of the C1 domain and extends 
to the top of the A3 domain. This prompted us to 
perform structural modeling with the goal to both 
exemplify and substantiate likely interactions 
between LRP1 cluster II and the FVIII light 
chain. Initially, we focused on the FVIII C1 
domain in which both HDX-MS and mutagenesis 
studies indicated the contribution of 2 lysine 
residues in the C1 domain, K2065 and K2092. 
Homology modeling was performed in consensus 
with the canonical binding mode for members of 
the LDL receptor family using the X-ray 
crystallographic structure of the LDLR-RAP 
complex as a template(12). Hence, each CR 
module contains three acidic aspartic acid 
residues placed in a concave surface region 
which interacts with lysine clusters. The 
proposed canonical interaction mode between 
LRP1 triple module and the FVIII light chain 
allows two principal binding modes oppositely 
oriented relative to each other, i.e. LRP1 N-
terminus to C-terminus aligns along the K2065-
K2092-K2136 as opposed to K2136-K2092-
K2065 surface patch. Two key features 
contribute to a favorable interaction between 
lysine regions and the LRP triple module. Shape 
complementarity is eminently achievable due to 
flexible nature of the chain of complementary 
repeats allowing the receptor to adapt to the 
ligands surface topology and exploit hydrophobic 
interaction in between repeats. Also, the ionic 
interactions between the positively charged 
lysine residues and the negatively charged 
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aspartic acid residues resulted in close packing of 
the partners suggesting that these features are the 
driving forces behind the interaction. The wide 
spread imprint of LRP1 binding on FVIII 
identified by HDX-MS analysis points to the 
notion that during LRP1 binding CR repeats 
switch between different lysine clusters. This is 
reflected in the designed LRP1 model where 
several interacting modes are equally likely.  
In addition to the overlap of HDX and the 
lysine mutagenesis study, there were also some 
differences. Residues 1693, 1967, 1972 and 2136 
were identified only in the lysine mutagenesis 
study, while regions 1737-1746, 2213-2235, 
2266-2271 and 2293-2296 were only identified 
using the HDX-MS approach. We therefore 
consider these regions and lysine residues ‘soft-
spots’. The effect of the ‘soft-spot’ lysine 
residues may be explained by conformational 
changes; lysine residue 1693 is directly facing 
the ‘hot-spot’ lysine at position 1818 and the 
soft-spot lysine residue 1967 has been shown to 
interact with the A2 domain of FVIII(44). As for 
the ‘soft-spot’ regions identified by HDX-MS: 
region 1737-1746 is located within the A3 region 
and consists of the amino acids EFTDGSFTQP. 
The remaining 3 peptides are located within the 
C2 domain. The C2 domain has previously been 
reported to bind to LRP1 with low affinity (KD  
3.6 µM)(43). The peptide 2293-2296 (VVNS) 
contains no positively charged residues, the 
peptide 2266-2271 (QDGHQW) contains 1 
histidine residue and peptide 2213-2235 
(QGRSNAWRPQVNNPKEWLQVDFQ) 
contains 2 arginine residues and 1 lysine residue. 
We did not observe any contribution of lysine 
residues in the C2 domain of FVIII to the 
interaction with LRP1 in our mutagenesis study 
(Figure 4C), suggesting that the reported low 
affinity of the C2 domain may be mediated by 
residues other than lysine.  
In recent years the importance of the C 
domains in the life cycle of FVIII has been 
appreciated since they are involved in lipid 
binding, VWF interaction and cellular uptake(45-
50). The C2 domain is loosely attached to the C1 
and A1 domains and it is likely that the domain 
has a high degree of rotational freedom. We 
believe that the positioning of the FVIII C 
domains relative to each other may therefore be 
an important aspect in the biology of FVIII. The 
regions in the C2 domain that were identified by 
HDX-MS may reflect conformational changes 
within these areas as opposed to a direct 
interaction with LRP1 cluster II. It would 
therefore be highly interesting to study the 
dynamics of the FVIII C domains in response to 
interaction with various ligands and lipids using 
HDX-MS technology.  
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FIGURE LEGENDS 
 
Table 1. Effect of replacement of lysine residues by positively charged arginine, uncharged 
alanine or negatively charged glutamic acid on the interaction between the FVIII light chain 
and LRP1 cluster II. 
Association and dissociation of LRP1 cluster II to FVIII light chain variants K1693, K1827, 
K1967, K2065 and K2092 was assessed by Surface Plasmon Resonance (SPR) analysis employing 
a BIAcore 3000 biosensor (Biacore AB, Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 
(26 fmol/mm
-2
) was immobilized onto a CM5 sensor chip using the amine coupling method 
according to the manufacturer’s instructions. Subsequently, FVIII light chain variants were bound 
to the anti-C2 antibody at a density of 17 fmol/mm
-2
. LRP1 cluster II (0.2-200 nM) was passed over 
the FVIII light chain variants in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) 
Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The sensor chip 
surface was regenerated three times after each concentration of LRP1 cluster II using the same 
buffer containing 1 M NaCl. Binding to FVIII light chain variants was corrected for binding in 
absence of FVIII. Binding data during the association phase were fitted in a one-phase exponential 
association model.  
 
Table 2. Effect of combining lysine replacements on the interaction between the FVIII light 
chain and LRP1 cluster II. 
Association and dissociation of LRP1 cluster II to FVIII light chain variants carrying replacements 
at positions K1693, K1827 and K1967 (A3), K2065 and K2092 (C1) and K1693, K1827, K1967, 
K2065 and K2092 (A3C1) was assessed by Surface Plasmon Resonance (SPR) analysis employing 
a BIAcore 3000 biosensor (Biacore AB, Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 
(26 fmol/mm
-2
) was immobilized onto a CM5 sensor chip using the amine coupling method 
according to the manufacturer’s instructions. Subsequently, FVIII light chain variants were bound 
to the anti-C2 antibody at a density of 17 fmol/mm
-2
. LRP1 cluster II (0.2-200 nM) was passed over 
the FVIII light chain variants in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) 
Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The sensor chip 
surface was regenerated three times after each concentration of LRP1 cluster II using the same 
buffer containing 1 M NaCl. Binding to FVIII light chain variants was corrected for binding in 
absence of FVIII. Binding data during the association phase were fitted in a one-phase exponential 
association model.  
 
Figure 1. HDX of FVIII and FVIII in complex with LRP1 monitored by mass spectrometry.  
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Sequence coverage of peptide fragments of LC FVIII. Peptides that display reduced deuterium 
incorporation (>2 S:D.) following complex formation with LRP1 are colored in red peptides that 
displayed no changes are colored in blue. Localization of exchanging amides in both N- and C-
terminally overlapping peptides was performed by substraction, assuming complete back exchange 
of the two N-terminal hydrogen in each peptide. Domains of LC FVIII are shown schematically.  
 
Figure 2. HDX of FVIII and FVIII incubated with LRP1 monitored by mass spectrometry. 
Surface plot of FVIII based on the crystal structure of FVIII (Protein Data Bank code 4BDV). 
Peptides that display reduced deuterium incorporation (>2 S:D.) following complex formation with 
LRP1 are colored in red peptides that displayed no changes are colored in blue. Areas uncovered 
by the peptide fragment are grey colored. Insert fitted HDX curves of the representative peptides of 
FVIII (blue colored) and FVIII incubated with LRP1 (red colored) are shown, with raw data 
indicated by solid squares and open circles.  
Figure 3. Chemical modification of lysine residues in the FVIII light chain abolishes the 
interaction with LRP1 cluster II. 
Association and dissociation of LRP1 cluster II to FVIII light chain was assessed by Surface 
Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, Uppsala, 
Sweden). The anti-C2 antibody CLB-EL14 IgG4 (26 fmol/mm
-2
) was immobilized onto a CM5 
sensor chip using the amine coupling method according to the manufacturer’s instructions. 
Subsequently, FVIII light chain was bound to the anti-C2 antibody at a density of 17 fmol/mm
-2
. 
To study the contribution of lysine residues on the interaction between LRP1 cluster II and the 
FVIII light chain, lysine residues were modified by passing over 50 mM of sulfo-NHS acetate or 
sulfo-NHS biotin (ThermoFisher Scientific, Rockford, IL, USA) for 10 min at 25 °C with a flow 
rate of 20 L/min. A. LRP1 cluster II (0.2-200 nM) and B. anti-a3 antibody CLB-CAg69 (0.1-100 
nM) were passed over the FVIII light chain in a buffer containing 150 mM NaCl, 5 mM CaCl2, 
0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The 
sensor chip surface was regenerated three times after each concentration of LRP1 cluster II using 
the same buffer containing 1 M NaCl. Binding to FVIII light chain was corrected for binding in 
absence of FVIII. The response at 235 seconds after association is plotted as a function of the 
concentration. 
 
Figure 4. Library of lysine to arginine replacements in the FVIII light chain identifies the 
contribution of multiple lysine residues in the interaction with LRP1 cluster II.  
Association and dissociation of LRP1 cluster II to FVIII light chain variants was assessed by 
Surface Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, 
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Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 (26 fmol/mm
-2
) was immobilized onto a 
CM5 sensor chip using the amine coupling method according to the manufacturer’s instructions. 
Subsequently, FVIII light chain variants were bound to the anti-C2 antibody at a density of 17 
fmol/mm
-2
. LRP1 cluster II (0.2-200 nM) was passed over the FVIII light chain variants in a buffer 
containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) at 25 
°C with a flow rate of 20 L/min. The sensor chip surface was regenerated three times after each 
concentration of LRP1 cluster II using the same buffer containing 1 M NaCl. Binding to FVIII light 
chain variants was corrected for binding in absence of FVIII. The sensor chip surface was 
regenerated three times after each concentration of LRP1 cluster II using the same buffer 
containing 1 M NaCl. Binding to FVIII light chain variants was corrected for binding in absence of 
FVIII. Binding data during the association phase were fitted in a one-phase exponential association 
model. A. Representative experiment for the interaction between LRP1 cluster II and wild type 
FVIII light chain. B. On each SPR sensor chip we included a control channel (only CLB-EL14 
IgG4), wild type FVIII light chain and two FVIII light chain variants. Therefore, wild type FVIII 
light chain was analyzed multiple times (n=14) C. The KD for LRP1 cluster II for the FVIII light 
chain variants was compared to the KD of wild type FVIII light chain (n=14 degrees of freedom=13 
p<
*
0.10 t-value=2.16, p
**
<0.05 t-value=3.012, p
***
<0.001 t-value=4.22) using a two-tailed students 
t-test. 
 
Figure 5. Binding of FVIIIdB variants to LRP1 cluster II. 
A. Association and dissociation of LRP1 cluster II to FVIIIdB variants was assessed by Surface 
Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, Uppsala, 
Sweden). The anti-C2 antibody CLB-EL14 IgG4 (39 fmol/mm
-2 
for FVIIIdB variants) was 
immobilized onto a CM5 sensor chip using the amine coupling method according to the 
manufacturer’s instructions. Subsequently, FVIIIdB variants were bound to the anti-C2 antibody at 
a density of 9 fmol/mm
-2
. LRP1 cluster II (0-200 nM) was passed over the FVIIIdB variants in a 
buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) 
at 25 °C with a flow rate of 20 L/min. The sensor chip surface was regenerated three times after 
each concentration of LRP1 cluster II using the same buffer containing 1 M NaCl. Binding to 
FVIIIdB variants was corrected for binding in absence of FVIII. Binding data during the 
association phase were fitted in a one-phase exponential association model. B. The responses at 
equilibrium were fitted by non-linear regression using a standard hyperbola to generate KD values 
(GraphPad Prism 4 software, San Diego, CA, USA).  
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Figure 6. Left: Schematic depiction of the suggested LRP1 cluster II interaction with the FVIII 
light chain with the canonical (triplet) mode emphasized. Right: Cartoon representation of the 
binding motif between the calcium-loaded LRP triple module (green) and FVIII C1 (gray). 
Aspartic acid residues of LRP and the “hot spot” lysine residues of FVIII are shown in sticks.  
 
Supplemental Figure 1.  
Association and dissociation of LRP1 cluster II to FVIII light chain variants was assessed by 
Surface Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, 
Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 (26 fmol/mm
-2
) was immobilized onto a 
CM5 sensor chip using the amine coupling method according to the manufacturer’s instructions. 
Subsequently, FVIII light chain variants were bound to the anti-C2 antibody at a density of 17 
fmol/mm
-2
.LRP1 cluster II (0.2-200 nM) was passed over the FVIII light chain variants in a buffer 
containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) at 25 
°C with a flow rate of 20 L/min. The sensor chip surface was regenerated three times after each 
concentration of LRP1 cluster II using the same buffer containing 1 M NaCl. Binding to FVIII light 
chain variants was corrected for binding in absence of FVIII. Binding data during the association 
phase were fitted in a one-phase exponential association model.  
 
Supplemental Figure 2. 
Association and dissociation of LRP1 cluster II to FVIII light chain variants K1693, K1827, 
K1967, K2065 and K2092 was assessed by Surface Plasmon Resonance (SPR) analysis employing 
a BIAcore 3000 biosensor (Biacore AB, Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 
(26 fmol/mm
-2
) was immobilized onto a CM5 sensor chip using the amine coupling method 
according to the manufacturer’s instructions. Subsequently, FVIII light chain variants were bound 
to the anti-C2 antibody at a density of 17 fmol/mm
-2
. LRP1 cluster II (0.2-200 nM) was passed over 
the FVIII light chain variants in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) 
Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The sensor chip 
surface was regenerated three times after each concentration of LRP1 cluster II using the same 
buffer containing 1 M NaCl. Binding to FVIII light chain variants was corrected for binding in 
absence of FVIII. Binding data during the association phase were fitted in a one-phase exponential 
association model.  
 
Supplemental Figure 3. 
Association and dissociation of LRP1 cluster II to FVIII light chain variants carrying replacements 
at positions K1693, K1827 and K1967 (A3), K2065 and K2092 (C1) and K1693, K1827, K1967, 
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K2065 and K2092 (A3C1) was assessed by Surface Plasmon Resonance (SPR) analysis employing 
a BIAcore 3000 biosensor (Biacore AB, Uppsala, Sweden). The anti-C2 antibody CLB-EL14 IgG4 
(26 fmol/mm
-2
) was immobilized onto a CM5 sensor chip using the amine coupling method 
according to the manufacturer’s instructions. Subsequently, FVIII light chain variants were bound 
to the anti-C2 antibody at a density of 17 fmol/mm
-2
. LRP1 cluster II (0.2-200 nM) was passed over 
the FVIII light chain variants in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) 
Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The sensor chip 
surface was regenerated three times after each concentration of LRP1 cluster II using the same 
buffer containing 1 M NaCl. Binding to FVIII light chain variants was corrected for binding in 
absence of FVIII. Binding data during the association phase were fitted in a one-phase exponential 
association model.  
 
Supplemental Figure 4. Binding of FVIII light chain variants to full length LRP1. 
A. Association and dissociation of FVIII light chain variants to full length LRP1 was assessed by 
Surface Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, 
Uppsala, Sweden). LRP1 (Biomac, Leipzig, Germany) was coupled directly on a CM5 chip 
according to the manufacturer’s instructions at three different densities (15 fmol/mm-2, 18 
fmol/mm
-2
 and 21 fmol/mm
-2
). FVIII light chain variants (1-25 μg/ml based on Bradford analysis) 
were passed over the immobilized LRP1 in a buffer containing 150 mM NaCl, 5 mM CaCl2, 
0.005% (v/v) Tween 20 and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The 
sensor chip surface was regenerated three times after each concentration of FVIII using the same 
buffer containing 1 M NaCl. Binding to LRP1 was corrected for binding in absence of LRP1. 
Shown are the SPR curves for the channel on which 21 fmol/mm
-2
 LRP1 was coupled. B. The 
response units at time point 235 seconds were plotted as a function of the concentration. 
 
Supplemental Figure 5. Binding of FVIIIdB variants to full length LRP1. 
A. Association and dissociation of FVIIIdB variants to full length LRP1 was assessed by Surface 
Plasmon Resonance (SPR) analysis employing a BIAcore 3000 biosensor (Biacore AB, Uppsala, 
Sweden). LRP1 (Biomac, Leipzig, Germany) was coupled directly on a CM5 chip according to the 
manufacturer’s instructions at three different densities (15 fmol/mm-2, 18 fmol/mm-2 and 21 
fmol/mm
-2
). FVIIIdB variants (5-1000U/ml based on chromogenic activity) were passed over the 
immobilized LRP1 in a buffer containing 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) Tween 20 
and 20 mM Hepes (pH 7.4) at 25 °C with a flow rate of 20 L/min. The sensor chip surface was 
regenerated three times after each concentration of FVIII using the same buffer containing 1 M 
NaCl. Binding to LRP1 was corrected for binding in absence of LRP1. Shown are the SPR curves 
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for the channel on which 21 fmol/mm
-2
 LRP1 was coupled. B. The response units at time point 235 
seconds were plotted as a function of the concentration. 
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Table 1. 
  arginine alanine glutamic acid 
1693 63 ± 5 170 ± 19 154 ± 17 
1827 80 ± 7 157 ± 16 130 ± 13 
1967 73 ± 6 91 ± 5 - 
2065 168 ±14 202 ± 17 210 ± 22 
2092 72 ± 6 45 ± 4 98 ± 10 
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Table 2. 
  arginine alanine glutamic acid 
A3 201 ± 18 222 ± 20 - 
C1 220 ± 21 620 ± 59 534 ± 52 
A3C1 567 ± 48 1339 ± 144 - 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Supplemental Figure 1. 
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Supplemental Figure 2.  
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Supplemental Figure 3.  
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Supplemental Figure 4.  
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Supplemental Figure 5.  
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Supplemental methods 
Structural Modeling 
To construct a LRP model in consensus with the receptor ligand family binding motif however, we 
chose to create a homology model of LRP based on the LDLR-RAP complex as a template. This 
was done using the Rosetta Comparative Modeling protocol(51) by generating 30,000 decoys of 
the LRP1 CR56 double module. Calcium-ions, one per complementary repeat, were inserted based 
on the structural alignments and adjusted slightly by hand to remove atomistic overlap. The 
resulting calcium-loaded LRP double complementary repeat 56 (LRP1 CR56) model was 
positioned relative to the light chain of FVIII as to reconstruct the interaction motif of the LDLR-
RAP complex in which CR5 interacts with K2065 and CR6 with K2092. The lysine residues of the 
FVIII light chain, K2065 and K2092 were overlaid with the NZ atoms of the two interacting lysine 
residues (K256 and K270) of RAP. To complete the triplet binding mode, a further CR5 module 
was positioned to interact with K2136 and connected to its adjacent CR56 module by the 
loopmodeling application in Rosetta, making 1,000 loop decoys. The specific sequence to be 
remodeled in each fragment was identified using the domain linker predictor DLP-SVM(52). The 
sequence for a CR56-CR56 chain was analyzed using their SVM-Joint consolidated predictor 
which identified region “CSH-SARTCPPNQFSCASGRCIPI” (residues 80-102 according to LRP 
alignment numbering) as a possible inter-domain linker. Since the natural chain break is after 
position 82 and both Cys 80 and Cys 87 are involved in forming intra-module disulfide bonds, we 
chose to limit the remodel region to residues 80-87. The resulting LRP1 CR565:FVIII light chain 
model in which the interaction pattern is CR565 against K2065-K2092-K2136 is truncated to 
remove the a3A3 and C2 domains of the FVIII light chain, leaving only the C1 domain (chain B 
residues 2020 to 2171). This system was solvated with ~10,000 TIP3P water molecules and ionized 
to salt concentration of 0.15. Following an energy minimization for 5,000 steps by a steepest decent 
method, the system was equilibrated using molecular dynamics simulations with constant number 
of atoms (N), constant pressure (P = 1 atm), and constant temperature (T = 310 K) for 5 ns, 
allowing it to settle. 
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5. Concluding remarks and perspectives 
Molecular dynamics simulations have been performed to elaborate in atomistic detail 
intricate structural and functional relationships of constituting components of the two 
principal factor X-activating protein complexes in the blood coagulation cascade.  
 
The coagulation cascade, though extensively studied, still has many un-explained subtleties 
and poorly understood concepts. Some of these are addressed using theoretical methods in 
this dissertation. In particular, the crystal structure of the un-inihibited FVII zymogen 
(ms.1) reveals that TF does not induce the rigidification of the activation (SP) domain 
because major parts are missing (and assumed to be too flexible). This flexibility was 
supported by the performed simulations of the homology model complex. Hence, the 
stabilization of the active site domain (including the formation of the S1 pocket and the 
oxyanion hole) by rigidification of especially the activation loops (1, 2, and 3) is most 
likely induced by the substrate (or inhibitor). Furthermore, we showed that TF could 
preserve the productive conformation of the activation domain in FVIIa (ms.2). This 
decisive result, in combination with the observations regarding the trypsin 170-loop-
swapped variants, suggest for the first time an allosteric mechanism involving the E2 
strand-following segment (residues 364{c215}-368{c219}) and putatively W364{c215} 
acting as a gating-residue for the active site cleft. The last study involving the extrinsic 
tenase complex looked at EGF1-EGF2 linker-deleted FVIIa variants and their ability to 
productively interact with tissue factor (ms.3). While it is long established that FVIIa binds 
TF in an extended conformation, is has not previously been shown how this extension 
related to the flexibility of said linker. Very recently was the inter-kringle domain linker 
investigated in prothrombin with respect to its role in the activation process.(Pozzi, Chen, 
Pelc, Shropshire, & Di Cera, 2014) The membrane-bound state of the FVIIIa molecule is 
important for appropriate co-factor function. Using a membrane-mimetic model known to 
facilitate the insertion of proteins, we studied the resulting conformations of the 
membrane-anchoring (discoidin) domains from FVIII (ms.4). Surprisingly, FVIII C1 and 
FVIII C2 did not converge to similar distribution of membrane-bound states emphasizing 
the subtleties and different roles of each domain in the binding process. Lastly, we 
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constructed an illustrative canonical binding mode between the LRP receptor and FVIII as 
ligand (ms.5).  
 
The ideas and concepts explored in this dissertation have cousins in other areas of 
biochemistry due to the relative abundance of (serine) protease enzymatic systems. The 
fundamental functional construction of the coagulation system is a battery of serine 
proteases with auxiliary domains, regulators (cofactors and inhibitors), substrates, and 
receptors. This exact recipe is also adopted by the complement system (C1r, C1s and the 
C3 convertases e.g.) whereas the digestion system proteases (trypsin, chymotrypsin and 
elastase) are simpler molecules only consisting of the peptidase domain with activation 
peptides. Additionally, it is interesting to mention the subtilisin family of serine proteases. 
These share the exact same catalytic triad as serine proteases of the chymotrypsin family 
but have a completely different structural fold; a typical textbook example of a convergent 
result in evolution.  
 
Throughout this dissertation, conventional (or classical) all-atomic MD simulations have 
been used as the de facto tool to investigate the mentioned structure-function relationships. 
It is, in this context, worth noting that it, for certain classes of problems, might be more 
appropriate to study the systems of interest at a different level of theory than chosen here. 
For instance, to do justice to e.g. the coordination chemistry of ions, a more detailed 
description at the quantum level is required. Multimerization of biomolecular components, 
on the other hand, is best studied using a more coarse grained description of the system, 
allowing simulation of larger time scales for even bigger systems. Yet another issue to 
philosophize about is sampling strategy. Basically, two schools of thought exist: 1) 
equilibrium simulations could be as long as possible or 2) parallel (much shorter) 
simulations could be executed. The caveat for the second procedure is obviously that this 
tactic greatly reduces the accessible time scales and, in consequence, slower processes 
would remain uncharted.  
 
Pioneering work on the modelling of important haemostatic proteins and complexes has 
been performed by the group of Lee G. Pedersen. Using a combination of (sometimes 
incomplete) X-ray crystallographic structures, homology modelling, and experimentally 
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guided docking, Pedersen and co-workers have proposed models for the protein C 
zymogen(L Perera et al., 2000), the FIX zymogen(Lalith Perera, Darden, & Pedersen, 
2001), the ternary prothrombinase:prothrombin FVa:FXa:PT complex(C J Lee, Wu, & 
Pedersen, 2011), and the binary tenase TF:FVIIa complex with TF containing the 
transmembrane part(Chang Jun Lee et al., 2012). However, a major challenge still stands 
to adequately sample the dynamical ensemble of such models in order to explain 
accumulating and increasingly complex experimental observations.  
 
The studies presented in this thesis have added structural insight at the atomistic scale and 
a dynamical perspective on FVII activation and FVIII trafficking. Future challenges in the 
field include attempts to introduce the present findings into an ever more realistic physical 
and complex biological setting.  
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